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Abstract 
 
Foot-and mouth disease (FMD) is highly transmissible between all cloven-hoofed animals 
and is considered a livestock disease of great importance due to its impact upon 
productivity and the trade restrictions. The aetiological agent is an RNA virus classified 
into seven serotypes: A, O, C, Asia 1, SAT 1, SAT 2 and SAT 3. Despite considerable global 
research efforts, serological in-vitro tests, such as virus neutralisation test (VNT) and 
liquid phase blocking ELISA (LPBE), are still the only methods for vaccine selection. 
Although, these assays are relatively simple to perform, they are known to be highly 
variable and the accuracy of the resulting relationship coefficient (r1-values) is often 
questioned. The overall aim of the thesis was to identify the source of variability that 
impacts the relationship coefficient (r1-values) and understand the limitations of the in-
vitro vaccine-matching tests. Therefore, three main factors, thought to contribute to this 
variability, were investigated: (i) cellular, (ii) serological, and (iii) virus. The 
experimental design focused on the A/ASIA/Sea-97 lineage; a contemporary virus 
frequently detected in Southeast Asia that exhibits high antigenic variability in in-vitro 
vaccine matching tests. The impact of cell replication cycle on virus and neutralisation 
titres, reflect on the variability of vaccine-matching tests. Thus, it is recommended that 
fully confluent cells are used to reduce the variability. Further, the source of the 
variability in the vaccine-matching tests is also attributed to the low of day-to-day 
repeatability of the serological tests and the inherent differences between individual post 
vaccinal sera. Consequently, variability in in-vitro vaccine matching assays can be 
reduced by pooling sera from different animals and performing the tests for field and 
vaccine viruses simultaneously. Although, measuring different spectrum of antibodies, 
results obtained using VNT are more inconsistent than those of LPBE. The importance of 
FMDV antigen integrity on variability of in-vitro vaccine matching tests was shown to be 
multifactorial; even in related strains, viral capsid dissociates at different temperatures 
and the level of dissociated capsid particles varies in different viruses. Interestingly, the 
A-May-97 vaccine virus was found to be more unstable than the field strains. Field 
evaluation of post vaccination immune response in Peninsular Malaysia indicated that the 
vaccine used is effective and able to confer protection against the contemporary field 
virus, despite poor vaccine-matching results.  
In conclusion, the current serological tests can be useful indicators for vaccine selection; 
there are simple and affordable but the r1 values need further attention as well as 
improvement, and, ideally, should be linked to protection.  
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Chapter 1: 
 
General Introduction 
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2 
 
1.1 Introduction  
 
Antigenic variation of foot-and-mouth disease (FMD) virus impacts the performance of 
FMDV vaccines used to control outbreaks. Serological methods used to define antigenic 
relationships are relatively inexpensive and quick to perform and provide an indicator of 
the antibody cross-reactivity between vaccine and field strains. Although these tests are 
widely used, their reliability of the test have been questioned due to issues with 
variability of the results. This thesis investigates the inherent variability of the assay and 
possible impacts upon vaccine selection and FMD control in Malaysia. 
 
1.2 History and background: disease, virus and control 
 
In the year 1514 Girolamo Fracastoro made the first description of a disease that 
resembled FMD in cattle in Italy. Fracastoro also noted that this disease was able to be 
transmitted to other cattle in the herd (Blancou, 2002). A disease with similar clinical 
presentation was observed in the United Kingdom in 1839 (Henderson, 1978); whereas, 
the first occurrence of a disease with similar description in Peninsular Malaysia (P. 
Malaysia) was not observed until 1860 (Wallace, 1936). At that time, the impact of FMD 
was significant, indicated by the offer of a prize in 1893 amounting to 3000 Reichmarks 
by the Prussian Ministry. for the person who ‘identified and, if possible isolated the 
contagious matter causing the disease and demonstrated its effectiveness by means of 
decisive experiments on animals’ (Brown, 2003). Five years later, in 1987 after the 
establishment of an experimental institution in Germany for thorough investigation of the 
disease that for FMD was identified as filterable agent or a virus by Loeffler and Frosch 
providing the first knowledge of the aetiology of FMD. The highly infectious nature of FMD 
placed constraints on the early research work which lead to the relocation of the FMD 
research facilities from Greifswald Germany to an island in the Baltic Sea (Insel Reims) in 
1909. United States of America also built their FMD facility in 1954 on the Plum Island for 
the same reason.  
The aetiological agent of FMD discovered by Loeffler and Frosch in 1897 was the first virus 
recognised to cause animal or human disease. About 25 years after this first discovery, 
the antigenic diversity of FMD virus was defined by two French scientists named Valles 
and Carre. Initially, they described serotypes O (Oise) and A (Allemande), findings that 
were broadly confirmed and expanded (serotypes A, B, C) by two German scientists, 
Waldmann and Trautwein, in 1926. As a consequence of the work by these two groups, 
three serotypes of FMDV, now known as O, A and C were defined. Later in 1940’s three 
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additional FMDV serotypes from Southern Africa were described by Galloway, Brooksby 
and Henderson and named after the place “Southern African Territories” as SAT1, SAT2 
and SAT 3 (Brooksby and Rogers, 1957).  The seventh serotype, Asia 1, was discovered at 
the FMD World Reference Laboratory, Pirbright in a sample from Pakistan in 1954 
(Brooksby and Rogers, 1957).  
FMD is a transboundary animal disease recognised as the main sanitary barrier for the 
international trade of livestock and livestock products. Moreover, FMD is included on the 
OIE notifiable disease list. Unlike many other animal diseases where national free status 
can be achieved through self-declaration (and mutual agreement between countries in 
trade), FMD freedom needs to be declared by the Office Internationale des Epizooties  
(O.I.E, 2018). Countries with FMD free status prohibit importation of susceptible animals 
and their related products from non-FMD free countries. This restriction also relates to 
FMD free countries by vaccination, unless appropriate measures are taken to remove any 
parts of the carcases that may contain residual FMD virus. Thus, the economic 
consequences of FMD is high. Fear towards this highly infectious transboundary animal 
disease has motivated Food and Agriculture Organisation of the United Nations (FAO) and 
OIE to facilitate eradication programs within FMD endemic countries. The ultimate 
objective is to eliminate risk of FMD spread by eradication of the disease. Examples of 
these programs are: 
 The EuFMD Commission, which is involved in understanding risks to the European 
neighbourhood (such the work of the West Eurasia Roadmap).  
 In southeast Asia, the South East Asia FMD (SEAFMD) Campaign that started in 1997 
and its expansion to the 2020 Roadmap for Foot and Mouth Disease Control in South-
East Asia and China (SEACFMD)  
 The Plan Hemisférico de Erradicación de la Fiebre Aftosa (PHEFA) for South America 
 
1.3 Foot-and-mouth disease virus 
 
FMD virus (FMDV) belongs to the Aphthovirus genus within Picornaviridae family and, like 
other members of this family, FMDV is non-enveloped and small in size (approximately 
30nm in diameter). The family is currently divided into at least 40 proposed genera that 
cause both human and animal disease (Knowles, 2018). The classification of 
picornaviruses is currently defined by molecular techniques in combination with an 
assessment of virus sensitivity to pH.  Among the generas that belong to Picornaviridae 
family the Enterovirus genus has the largest number of member while, 23 of the defined 
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genera have only single member of virus (MacLachlan, 2017). A member of the Enterovirus 
genus, poliovirus that causes poliomyelitis in human, has been studied most extensively 
due to its severe negative impact upon human quality of life. The efforts in poliovirus 
vaccinology research have resulted in the development of an effective vaccine that has 
significantly combated the disease and eradicated two out of the three poliovirus types.  
Among the animal viruses classified under the umbrella of the Picornaviridae family is 
Equine rhinitis A virus (ERAV). ERAV shares physiochemical properties such as base 
composition and acid lability as well as buoyant density with FMDV (Newman et al., 1973; 
Newman et al., 1977). In addition, the nucleotide sequence of these two viruses (FMDV 
and ERAV) share a high degree of identity (Li et al., 1996; Studdert and Gleeson, 1978; 
Wutz et al., 1996). These two factors have placed ERAV and FMDV in the same Aphthovirus 
genus alongside two other bovine viruses (Bovine rhinitis A virus and Bovine rhinitis B 
virus) of the Picornaviridae family. FMDV like other RNA viruses, are prone to errors during 
replication which is thought to underpin the constant development of mutant strains 
resulting in antigenic variability within the different serotypes (Domingo et al., 2004). 
 
 The genome organisation of foot-and-mouth disease virus  
 
All viruses within Picornaviridae family have capsids with icosahedral symmetry. The 
capsid is constructed from 60 copies each of four capsid proteins to contain the positive-
sense single-stranded Ribonucleic acid (RNA) genome. As member of the Picornaviridae 
family, FMDV has similar overall capsid structural organisation as other picornaviruses but 
has several unique features that can be observed by X-ray diffraction techniques at a 
resolution of 2.9 Å (Acharya et al., 1990). At present, FMDV can be visualized in 
crystallographic structure representing serotype A, O and C (Fry et al., 2005). The 
dimensions of the virus are approximately 30 nm in diameter. The virus particle is non-
enveloped, spherical in shape with icosahedral symmetry made of major structural capsid 
VP1, VP2 and VP3 and a smaller peptide of VP4 in mature virus. Unlike other members of 
the Picornaviridae family such as enteroviruses and Mengovirus that have large depression 
or protrusions on the capsid surface, FMDV surface structures appeared smoother with no 
deep canyons in the capsid. The lack of the canyon-like structure revealed as important 
for FMDV to attach itself to the host cells and plays a part in its immunogenic function 
(Fry et al., 2005; Olson et al., 1993; Rossmann, 1989). FMDV has a single-stranded 
positive-sense RNA genome of about 8500nt in length that includes two untranslated 
regions (UTR) that flank a single open reading frame (ORF) at both ends (5’UTR and 
3’UTR). Similar to the other picornaviruses, the RNA of FMDV is uncapped and a small 
viral protein (VPg) is covalently attached to the 5´end of the genome. The ORF is divided 
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into four regions according to the presence of their cleavage sites namely Lpro, the P1, 
P2 and P3 (Figure 1.1). P1 encodes the proteins that comprise the viral capsid shell of the 
virus. The Lpro and the non-structural proteins are involved in RNA synthesis and create 
conditions within the host cell favourable for FMD virus replication (Mason et al., 2003). 
Both P2 and P3 are precursors that make up the additional non-structural protein of the 
virus that promote viral replication and assembly (Belsham, 2005).   
 
Figure 1.1: A schematic representation of FMDV genome organisation. The genome is 
covalently linked to the protein VPg at the 5’ end and is polyadenylated at the 3’ end. 
The FMD virus RNA coding regions are shown in the form of a single large open reading 
frame. The poly-proteins flanked both end by untranslated regions (5’ and 3’ UTR). 
The capsid coding (structural protein of VP 1-4) contained in the P1 region while the 
rest are the non-structural proteins. Figure adapted from (Belsham, 2005). 
 
 
 Diversity of FMDV  
 
At present there are seven FMDV serotypes that have been identified by serological 
differences; A, O, Asia 1, C, South African Territories (SAT) 1, SAT 2 and SAT 3. These 
seven serotypes were determined using serological method. These serotypes can also be 
discriminated on the bases of 30 - 50% nucleotide sequences difference within the VP1-
coding region between the different serotypes (Knowles and Samuel, 2003; Marquardt and 
Adam, 1990). Similar to other picornaviruses, FMDV undergoes constant mutation and 
evolution that leads to considerable sequence variability within a serotype. FMD viruses 
can also undergo genomic recombination within and between serotypes. These 
mechanisms enable the virus to rapidly adapt to changes in their environment (Duarte et 
al., 1994). Diversity in FMDV as the outcome of high mutation rate has direct impact on 
FMD control in endemic countries particularly when vaccination is used.  
Each FMDV serotype can be further classified on the basis of phylogenetic comparison of 
the VP1 coding sequences. These analyses, combined with geographical regional 
information of the disease occurrence has led to the sub-classification of FMDV sequences 
into topotypes, lineages and sub lineages (Knowles and Samuel, 2003). Serotype A is 
considered the most antigenically and genetically diverse (Pereira, 1976). There are three 
L
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major topotypes of the FMDV serotype A: EURO-SA, ASIA and AFRICA (Knowles and Samuel, 
2003).  
Generally it is understood that antibodies produced against one serotype either by 
vaccination or infection have no demonstrable cross-protection against other FMDV 
serotypes and in some cases antibodies do not cross-protect even within the same 
serotype (Kitching et al., 1988; Knowles and Samuel, 2003). However, multiple challenge 
with three different FMDV serotypes demonstrated to induce protection against further 
challenge with FMDV (Cottral and Gailiunas, 1972). Furthermore, sequential multiple 
vaccination with different heterologous FMD viruses of serotypes A, O and Asia-1 elicited 
humoral antibody responses that could recognise FMDV serotype SAT-1 and C detectable 
by ELISPOT (Grant et al., 2017). In addition, administration of bivalent vaccine containing 
serotype O and A has been demonstrated to elicit neutralization titre against FMDV 
serotype SAT 1 in naïve animals (Kalmar et al., 1972).  
 
 FMDV capsid assembly and dissociation 
 
Similar to the other Picornaviruses, FMDV has structural capsid proteins VP1, VP2, VP3, 
and VP4 also termed as 1D, 1B, 1C and 1A, respectively. During maturation, the 3C NSP 
protease processes the P1–2A precursor to produce VP1, VP3 and VP0 (that is subsequently 
cleaved into VP4 and VP2). The VP1, VP2 and VP3 form a trapezoid and are positioned 
externally on the viral capsid. VP4 is concealed internally and is predicted to be in contact 
with the viral RNA inside the capsid structure (Mateu, 2017). The VP4 protein is the 
smallest capsid protein and is myristoylated at the N-terminus (Acharya et al., 1990). The 
major capsid (VP1, VP2 and VP3) of FMDV are smaller as compared to capsid proteins of 
other picornaviruses.  
The mature FMDV capsid is made up of 60 copies each of the four structural proteins. 
These four proteins assemble in wedge-shaped to form a protein sub-unit known as 
protomer (Figure 1.2d) which later forms a pentamer (Figure 1.2c) when five of the 
protomer joint together. The whole capsid forms when twelve pentamers join up together 
(Figure1.2c) (Fry et al., 2005; Rueckert and Wimmer, 1984). The intact capsids are held 
together by non-covalent hydrogen bonds and weak hydrophobic interactions between 
the inter-pentameric subunits (Acharya et al., 1990; Ellard et al., 1999). 
Intact FMDV capsid has a sediment size of 146 based on its sediment rate in sucrose 
gradient centrifugation (sediment at coefficient 146S) in sucrose gradient and are hence 
also known as 146S particles (Figure 1.5a). Empty capsids, capsid shells without 
encapsidated viral RNA, can also form and are known as 75S particles (sediment at a 
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sucrose gradient coefficient of 75). These 75S particles are often referred to as “natural 
empties” as they are naturally produced in cells during FMDV infection. The virus 
neutralising antibody responses are elicited by antigenic sites on the viral capsid, known 
as epitopes. The majority of these epitopes are associated with the intact viral capsids 
rather than disassociated capsid components. Although the 75S particles resemble the 
146S in structure and antigenicity, they are inherently less stable (Basavappa, Syed et al. 
1994). Furthermore, a study has demonstrated that 75S particles of FMDV serotype A 
Cruzeiro are able to produce useful level of immunity but are less effective compared to 
the 146S (Doel and Chong, 1982). The intact capsid (146S particles) is vulnerable to low 
pH (below 6.8) (Brown and Cartwright, 1961) as well as to high temperatures (Bachrach 
et al., 1957). These conditions cause the 146S particle to split into pentamers (Figure 
1.2b) resulting in generation of another type of FMDV particle known as 12S to form 
(Figure 1.2c) (Cartwright et al., 1980).  
 
 
Figure 1.2: A schematic representation of FMDV capsid dissociation. The intact capsid 
(a) contains viral RNA is known as 146S. Dissociated capsids (b) contain 12 pentamers. 
The pentamers (c) are assembled from 60 copies of protomers (d). A capsid protomer 
comprise of VP1 (blue), VP2 (green) and VP3 (red) and VP4 which is concealed inside. 
Figure adapted from (Kotecha et al., 2015). 
 
Unlike the 146S, antibodies raised against the 12S particles have been demonstrated to 
have low neutralising activity (Cartwright et al., 1982; Rao et al., 1994). FMDV protein 
particles of various sizes exist in FMDV preparations (such as FMDV virus stocks and FMDV 
vaccine preparations) (Doel and Chong, 1982). Therefore, the proportion of 146S, 75S and 
12S will affect the efficiency of a vaccine. Stability of the FMDV capsid differs markedly 
between serotypes. The FMDV serotype A and Asia-1 are relatively more stable upon heat 
and pH change as compared to FMDV serotype O and SATs (Doel and Baccarini, 1981; 
Kotecha et al., 2016).  
 
a. b. c. d.
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 Survival of FMDV in the environment  
 
FMD virus is sensitive to heat and desiccation but is stable at a humidity above 55 to 60% 
(Bachrach, 1968). Survival of FMDV in fomites is influenced by the nature of the materials 
as a high concentration of organic material helps the survival of the virus (Donaldson and 
Ferris, 1975). Wool that is kept at 4ºC allows  FMDV to survive for an average period of 
two months, but survival of the virus decreases considerably by increasing the 
temperature to 18ºC (McColl et al., 1995). At a temperature greater than 20ºC, it was 
estimated that FMDV was able to survive for about three months in soil surface while at 
below 0ºC FMD virus can survive about six months beneath the soil surface, as reviewed 
by Bartley (Bartley et al., 2002). FMD virus can survive in bovine faeces and slurry (Haas 
et al., 1995; Parker, 1971). Study by Dowson indicated that transmission of FMD among 
dairy cattle during the FMD epidemic in the UK in 1967-1968 has been associated with 
bulk milk tanker during milk collection. FMD transmission via milk can occur through 
drinking contaminated milk, inhalation of droplet or aerosol as reviewed by Donaldson 
(Donaldson, 1975). In addition, FMDV can survive in milk and cream collected from FMD 
infected cows even after pasteurisation process at 72°C for 0.25 minutes (Blackwell and 
Hyde, 1976). 
 
1.4 Clinical signs of FMD 
 
FMD virus causes acute vesicular disease affecting livestock and wild cloven-hoofed 
animals with an average mortality of about 1%. However, the disease is highly infectious, 
and morbidity can be close to 100% in affected herds (Mahy, 2005). The disease has rapid 
onset causing acute fever with transmission primarily from this early febrile stage to 
susceptible animals (Alexandersen et al., 2003c).  
For livestock in the Bovidae family, fever can exceed 40ºC and is associated with 
depression and a decrease in milk production (Donaldson, 2004; Kitching, 2002). Fever is 
followed by the development of vesicular lesions in the epithelial tissues of the mouth 
(dental pad, tongue, lips, and gums), feet (coronary bands, interdigital and bulbs of the 
heals) and teats (Kitching, 2002). Occasionally vesicular lesion form in the nostrils or vulva 
(Kitching, 2002). In severe cases of FMD, large areas of the dorsal surface mucosa of the 
tongue may slough leaving red and raw painful lesions that leads to excessive salivation 
and a refusal to feed. At the same time, lesions in the feet can cause acute lameness and 
a reluctance to move. Rapid loss of body weight is often observed mainly associated with 
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the painful lesions in the mouth and the feet. Mortality usually involves neonates 
associated with myocarditis (also known as tiger heart). Indigenous breeds of cattle or 
buffalo in endemic areas can often exhibit milder lesions than the high-productivity 
breeds that are derived from temperate countries (Geering et al., 1995; Kitching, 2002). 
In order to estimate the time of initial infection, the progress of vesicular lesions 
(commonly in the epithelial tissue of the mouth) can be aged in cattle. 
Early clinical signs of FMD in pigs include fever, depression and lameness (Donaldson, 
2004). Unlike cattle, the marked vesicular lesions are usually found on feet that cause 
acute lameness and recumbence particularly when pigs are housed on a hard floor 
surface. Vesicular lesions that occur around the coronets can cause the keratinised layer 
of the hoof to detach from the corium. Complete detachment of the hoof can sometimes 
occur in severe cases. Vesicular lesions can also be seen on the snout, but these can be 
difficult to see if a lesion forms at the base of their tongue. Lesions on the teat as well 
as abortion is often a consequence of FMD infection in pregnant sow. Sudden death in 
suckling pigs may also occur (Donaldson, 2004). The aging of FMD lesion in pigs often 
estimated by the lesion of the keratinised layer detachment of hoof (Donaldson, 2004). 
Clinical signs and lesions are usually not obvious in small ruminants such as sheep and 
goats. For these species, foot lesions are on commonly confuse with foot-rot (Donaldson, 
2004) and mouth lesions can be hard to distinguish (Grubman and Baxt, 2004; Kitching, 
2002).   
 
1.5 Transmission of FMD 
 
FMD disease transmission pathways can be divided broadly into two distinct mechanisms; 
(i) direct and (ii) indirect transmission via fomites. The direct transmission occurs through 
direct contact between infected and susceptible animals. This is the most common route 
of transmission in pigs, goats and sheep (Aggarwal et al., 2002). Although FMDV is 
considered acid labile, the virus can survive outside the host and become air borne. The 
main source for the air borne FMDV transmission include excretions and secretions of 
infected livestock, such as breath, saliva, semen, milk, faeces, urine, and vaginal 
secretions (Bedson and Maitland, 1927; Brown, 2004; Paton et al., 2018). A limited 
number of FMDV infective particles are required for FMD infection in susceptible animals 
particularly cattle (Sellers, 1971). Therefore, airborne transmission through inhalation is 
considered a common route in cattle transmission, unlike pigs which are relatively 
resistant to infection via the airborne route and need higher virus dose to get infected  
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(Donaldson, 1987). Although air borne/aerosol transmission is not an efficient route of 
infection in pigs, in an acute infection, pigs excrete more FMD virus particles per day than 
cattle and other ruminants (Donaldson et al., 1970; Kitching et al., 2005; Sellers and 
Parker, 1969) As a consequence, while infection in pigs is more difficult to initiate, FMD 
in pigs has a greater potential to seed the disease on other susceptible animals. Spread 
of FMDV from goats and sheep to other susceptible animals can commonly occur via 
clinical or sub-clinically infected animals (Barnett and Cox, 1999). Furthermore, the virus 
may be excreted intermittently during recovery and thereafter (Donaldson, 1987). The 
typical spread of FMDV within a herd or flock takes 2 to 6 days for all species 
(Alexandersen et al., 2003a). 
FMD can also be transmitted indirectly by mechanical dissemination through 
contaminated clothing and other fomite routes such as contaminated vehicles, 
agricultural tools and many more (described in the section below). In addition to these 
“mechanical” transmission routes, FMDV can persist in the human nasal passages for up 
to 28 hours after exposure (Sellers et al., 1970) which may pose a risk of FMDV 
transmission (Amass 2003). However, a more recent study indicated low risk of FMDV 
survival in human nasal cavity at 16 to 22 hours after exposure to FMDV infected animals 
(Wright et al., 2010). In addition, ingestion of infected animal products by susceptible 
animals either through water or feed can spread the disease (Alexandersen et al., 2003b; 
Schijven et al., 2005). Even though FMDV has also been detected in the semen of boars, 
the risk of spread of the disease through sexual transmission is considered low (Guerin 
and Pozzi, 2005).  
 
1.6 Incubation Period of FMD 
 
The incubation period is important in the epidemiology of FMD due to the fact that FMDV 
can be excreted during this period particularly in pigs housed in groups (Stenfeldt et al., 
2016b). The incubation period of FMD is highly variable depending on agent factors 
particularly the dose and route of transmission, the host factors including the species and 
pre-existing immunity as well as environmental factors such as husbandry management 
(Alexandersen et al., 2003b; Hughes et al., 2002). For example, the incubation period 
within a farm is 2 to 14 days (Alexandersen et al., 2003c; Hugh-Jones and Tinline, 1976). 
However, the incubation period in experimental pig challenge with high dose can be as 
short as 24 hours (Alexandersen and Donaldson, 2002; Alexandersen et al., 2003c). 
Another study in non-vaccinated piglets and dairy cattle reported excretion of FMDV one 
to two days after challenge, whereas non-vaccinated lambs took three to three and a half 
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days (Orsel et al., 2009). However, a study based on paired calves (a one to one 
transmission system) showed that animals are less likely to be infectious before the 
appearance of clinical sign (Charleston et al., 2011).  
 
1.7 Subclinical infection versus persistent / carrier     stage 
 in FMD  
 
In addition to clinical disease, infection by FMDV can also be unapparent. Animals that 
transmit FMD virus but do not show clinical signs of FMD are said to have a subclinical 
FMDV infection. The other type of unapparent FMDV infection is known as a persistent or 
so-called carrier stage animal that was first defined by van Bekkum in 1959 (Bekkum 
1959). Persistent stage of FMD is common in ruminants, particularly in FMD endemic area 
but does not exist in pigs (Salt, 2004; Stenfeldt et al., 2016a). FMD Persistent state is 
defined as live FMDV being able to be recovered from the oropharyngeal fluid by the 
probang sampling method for more than 28 or more days after acute infection 
(Alexandersen et al., 2002; McVicar and Sutmoller, 1969; Woodbury, 1995). Using an 
experimental infection model, it was shown that similar numbers of vaccinated and naïve 
cattle develop persistent infection and that it is possible to define whether animals will 
become persistently infected before 28 days post infection (dpi) (at 21 dpi and 10 dpi for 
naïve and  vaccinated cattle, respectively) (Stenfeldt et al., 2016a). Persistently infected 
animals add to the complexity of FMD control and eradication processes, since the 
currently used serological tests are only useful at herd level, do not differentiate sub-
clinical from persistently infected animals. The complication occurred during post 
vaccination monitoring (PVM) for the FMD control where vaccine is used particularly to 
identify an uninfected herd. For FMD eradication process inability to discriminate 
subclinical from persistent animal may lead to unnecessary culling.   Furthermore, the 
existence of persistent stage in vaccinated animals impede livestock and livestock 
product trading rights of FMD free countries with vaccination.  
The duration of FMD persistence stage is variable in different species of ruminants. It can 
last for 3.5 years in cattle, nine months in sheep, four months in goat (Alexandersen et 
al., 2002) and five years in African buffalo (Syncerus caffer) (Bastos et al., 2000). African 
buffalos that are in persistent stage of FMD, have been reported to cause clinical FMDV 
infection in cattle in the field (Dawe et al., 1994a) and experimentally (Dawe et al., 
1994b). 
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1.8 Host immune response against FMD  
 
The host immune response against FMD involves both the cellular and humoral immune 
components. Unlike many other viruses that are typical monocytotropic, the agent (FMDV) 
does not use host immune cells such as monocytes (macrophages) and dendritic cells to 
propagate itself in the host (McCullough et al., 2009).  
Recruitment of immune cells during inflammation associated with the development of 
vesicular lesions together with cellular damage of the host provide a “danger signal” 
which can be recognised by the host innate immune response mechanism. Initiation of 
the local inflammatory reaction is self-amplifying and leads to the recruitment of blood 
monocytic, granulocytic cells and blood dendritic cells (DCs). The local immune response 
against FMD enhances the recruitment of lymphocytes resulting in a transient leucopenia 
in infected animal (Bautista et al., 2003). In response to FMDV infection, DCs in skin were 
shown to produce type 1 interferon (Bautista et al., 2005). The involvement of both B-
lymphocytes and T-lymphocyte in immune response against FMDV are dependent on these 
DCs (McCullough et al., 2017). DCs present the FMD antigen directly to B-lymphocytes 
through B-cell receptors (BCR) in the blood that stimulate differentiation of the B cells 
to plasma cells. Plasma cells produce FMDV-specific antibodies that can form complexes 
with the virus to activate the complement pathway to prevent FMDV infection 
(McCullough et al., 1992a). The interferon (IFNα) responses, stimulated by FMDV-antibody 
complexes, have been demonstrated to be produced by DCs (Guzylack-Piriou et al., 2006). 
On the other hand, monocyte-derived dendritic cells (moDCs) process FMDV proteins into 
peptides before they can be presented to T-lymphocytes (Banchereau et al., 2000). These 
cellular interactions of DCs with live virus or vaccine are vital functions for functional 
adaptive immune response. However, the antibody-FMDV complexes hinder the host 
immune response by attachment to the Fc receptor to enter and kill the cells (moDCs). It 
was reported that the antibody-FMDV complexes killed bovine moDCs six hours after 
entry, resulting in inability of moDCs to present the B-lymphocytes in the lymph nodes 
(Robinson et al., 2011).  
 
 Epitopes and antibody escape mutant of FMDV 
 
FMDV needs to be recognised as foreign body by the host’s receptor, in order to initiate 
the host immune responses. Structural analysis of FMDV, through the three-dimensional 
modelling of viral capsid proteins, has provided information that has helped uncover the 
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important antigenic properties of FMDV. The antigenic sites recognised to date are 
located at the surface of capsid proteins VP1, VP2 and VP3 (Kitson et al., 1990).  
Antibodies interact mainly with the loop located at the carboxy-termini of VP1, VP2 and 
VP3 proteins. The VP1 contains the main antigenic site, the G-H loop, which can elicit 
virus neutralising and non-neutralising antibodies (Bolwell et al., 1989; Ouldridge et al., 
1984; Thomas et al., 1988). The G-H loop is a flexible structure that protrudes out from 
the FMDV capsid making it exposed and highly accessible by the host immune responses. 
There are about 20 amino acids on the G-H loop that make several overlapping epitopes. 
These epitopes can be classified as continuous (linear epitopes) and discontinuous or 
conformational epitopes. Additionally, a conserved, trypsin-sensitive amino acid triplet 
Arg-Gly-Asp (RGD) that located at the surface of VP1, close to the G-H loop, is identified 
as the primary site for promoting cell attachment via integrin (Burman et al., 2006; 
Cavanagh et al., 1977; Fox et al., 1989; Jackson et al., 2004; Laporte et al., 1973).  
Antibody-escape mutants are often used to determine FMDV functional epitopes. Most of 
these escape mutant studies were conducted experimentally using monoclonal antibodies 
to generate resistant mutants. Many neutralisation antigenic sites were then determined 
by sequencing of the monoclonal antibody resistant mutants (Martinez-Salas and Belsham, 
2017; Reeve et al., 2010).  
Most of the escape-mutant data has been obtained for serotype O viruses with limited 
data also available for serotype A. However, it is thought that similarities between 
locations of antigenic sites exist among all FMDV serotypes. The five known neutralisation 
antigenic sites for serotype O are located within VP1–3 and are described as Sites 1 to 5. 
Site 1 is associated with the (G– H) loop of VP1 and the C terminus of VP1 at amino acid 
positions 144, 148, 154 and 208; these residues are linear and trypsin-sensitive. On the 
other hand, Sites 2 - 5 are conformation-dependent and trypsin-resistant. Site 2 involves 
VP2 at amino acids positions 70–73, 75, 77 and 131, whereas the Site 3 involves the B-C 
loop of VP1 at amino acids positions 43 and 44. Site 4 involves amino acids positions at 56 
and 58 of VP3. Finally, Site 5 involves VP1 at amino acids position 149, which is probably 
formed by interaction of the VP1 G–H loop region with other surface-located amino acids 
(Baxt et al., 1989; Crowther et al., 1993; Kitson et al., 1990; Mateu et al., 1990; Xie et 
al., 1987). More recent studies, using reverse genetics techniques, have identified an 
additional new neutralising epitope for FMDV serotype O, at the threefold axis of VP2 
(Asfor et al., 2014). Structural analysis and antigenic escape mutant studies have 
determined significant antigenic variability between and within FMDV serotypes. 
However, application of this information to improve the design of FMD vaccines in order 
to provide wider antigenic coverage, is yet to be achieved. 
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1.9 Diagnosis for FMD 
 
Rapid spread of the disease after introduction of FMD virus to susceptible animals 
highlight the need for a rapid and accurate diagnostic method. Besides, initiatives to 
understand the epidemiology of FMD and to control the disease rely on accurate reporting. 
FMD is often initially diagnosed clinically in the field. Suitable samples are collected for 
confirmatory diagnosis according to the recommendations of the OIE Manual of Diagnostic 
Test and Vaccine for Terrestrial Animals (OIE, 2017). In some instances, confirmatory 
tests can be performed at the field using portable devises, providing rapid results. 
However, in order to confirm FMD, series of laboratory diagnostic tests need be performed 
in designated laboratory premises (Figure 1.3).  
 
Figure 1.3: The workflow of FMD laboratory diagnostics. Blue lines with arrow indicate 
standard diagnostic procedures. Blue dashed lines with arrow indicate optional 
diagnostic procedures.    
 
These tests are commonly performed simultaneously even though virus isolation (VI) is 
considered as the gold standard. The tests include antigen detection methods (Antigen 
enzyme-linked immunosorbent assay (ELISA)) and real-time reverse transcription-
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polymerase chain reaction (rRT-PCR), a method to detect FMDV nucleic acid. Sequencing, 
particularly of VP1 coding region, can be performed for detail virus characterisation, 
often used in molecular epidemiology of FMDV. Occasionally, sequencing may also be 
carried out on a clinical specimen, without the need for prior virus propagation. 
Serological methods can be used to confirm the presence (or absence) of FMDV specific 
antibodies, either against structural proteins (SPs) or against non-structural proteins 
(NSPs). Currently, specific antibody tests against FMDV NSPs is only available as ELISA 
method. On the other hand, more serological methods have been developed to detect 
and measure specific antibody against FMDV SPs that include virus neutralisation test 
(VNT), liquid phase blocking ELISA (LPBE), solid phase blocking ELISA (SPBE) and 
complement fixation test (CFT), with VNT being recognised as the gold standard. These 
serological methods are perform routinely in FMD laboratories for various purposes, 
mainly (i) for certification of FMDV absence for animal import-export activities, (ii) 
determination of antigenic matching between the field isolates and vaccine virus, (iii) 
demonstration of previous FMD virus infection or post vaccination monitoring (PVM) 
particularly in endemic countries that use vaccination as part of FMD control measures, 
and (iv) determination of FMD serological prevalence for routine surveillance, particularly 
in endemic countries.     
  
1.10 Global distribution of FMD  
 
FMD distribution is broadly correlated with the geographical location of the countries with 
least developed economy. Resolution No 22 for the OIE General Assembly Session 
described four categories for official   FMD status for member countries is currently 
divided into four categories. These are (i) countries recognised as FMD free where 
vaccination is not practised, (ii) countries recognised as FMD free where vaccination is 
practised, (iii) countries having FMD free zones where vaccination is not practised and 
(iv) countries having FMD free zones where vaccination is practised. These four categories 
are defined within Chapter 8.8 of the Terrestrial Animal Health Code and are subject to 
annual revision. Out of the 182 member countries of the OIE, there are only 68 countries 
in category (i) and only two countries that belong to category (ii). A total of 11 countries 
have free zones where vaccination is not practised and eight countries have FMD free 
zones where vaccination is practised. Out of the eight countries that have FMD free zones 
where vaccination is practised, only three countries do not have zones in category (iii) 
(OIE, 2018) (Figure 1.4). The rest of the member countries are without OIE official status 
for FMD. 
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Figure 1.4: Map of OIE member countries with official FMD status for the year 2018. 
Marked in dark green, are the countries and zones that are recognised as FMD free 
where vaccination is not practised; in light green, are countries and zones that are 
recognised as FMD free where vaccination is practised; in red, are countries that were 
previously reconised as FMD free but this status is currently suspended due to recent 
or ongoing FMD outbreaks; in grey, are countries without OIE official status for FMD 
where FMD is endemic or causes sporadic outbreaks. Source: (OIE, 2018). 
 
 Endemic FMDV Pools  
 
FMD virus circulation in endemic countries is divided into seven ecological pools (Figure 
1.5); each containing defined FMD viruses. These pools share common FMDV genotypes 
that are circulating and evolving independently within respective geographical areas. The 
designation of the ecological pools facilitated more focused, regional FMD control 
strategies (as part of the OIE and FAO Global FMD Control Strategy) and selection of FMDV 
vaccine virus that are most appropriate for the respective regions. However, boundaries 
between pools can be fluid and some countries (e.g. Egypt and Libya) experience FMDV 
incursions from more than one pool (WRLFMD, 2018). The circulation of FMDV within each 
pool is dynamic and can be subject to incursion/migration of new FMDV genotypes. Prior 
to 2004, FMDV serotype A and O were the most prevalent (Kitching, 1998). Serotype C has 
not been reported since 2004 when outbreaks occurred in Kenya and Brazil (Rweyemamu 
et al., 2008). Viruses classified within the Asia-1 serotype are mostly detected within Asia 
(including the Middle East) but reported incidences are relatively low. Serotype SAT 1, 2 
and 3 are mostly confined within Africa with incidental outbreaks occurring in the Middle 
East. 
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Figure 1.5: The global distribution FMDV within seven of pools. Countries and regions 
where FMD is endemic are indicated in grey. Map adapted from OIE website (FMD 
official status). The (SAT) Southern African Territories. 
 
Long-distance, large-scale trance-pool movement of viruses occurs relatively rarely but 
can have severe consequences, also impacting upon FMDV vaccine selection. The recent 
spread of FMD viruses from Pool 2 (South Asia) is a good example of the dynamic patterns 
of global FMDV distribution (Bachanek-Bankowska et al., 2018a; Bachanek-Bankowska et 
al., 2018b). A recent study described a pandemic spread, including to mainland SEA, of 
two sub-lineages within the O/ME-SA/Ind-2001 lineage that normally circulates within the 
Indian subcontinent (Bachanek-Bankowska et al., 2018b). Another example of an FMDV 
moving out of Pool 2 is the spread of the A/ASIA/G-VII lineage into the Middle East region 
(Turkey, Iran, Saudi Arabia, Armenia and Northern Israel) (Figure 1.6) (Bachanek-
Bankowska et al., 2018a; WRLFMD, 2018). Within Pool 1, migration of the A/ASIA/Sea-97 
lineage from mainland SEA has caused outbreaks in the Republic of Korea in 2017 and 
2018 (Figure 1.7).  
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Figure 1.6: Recent movements of the A/ASIA/G-VII lineage. The A/ASIA/G-VII lineage 
normally exists in the Indian sub-continent (Pool 2), but it was introduced to the 
Middle East (Pool3) in 2013. Since the introduction, the lineage not only persists in 
the countries affected but also spreads into new territories, with outbreaks in 
Northern Israel recorded in 2017. Confirmed FMD reports due to the A/ASIA/G-VII 
lineage between 2010 and 2017 are indicated in shades of blue. Black arrows 
represent confirmed movements of the virus, while grey arrows indicate predictions 
of a possible spread. The map is adapted from the OIE/FAO FMD Laboratory Network 
annual report (WRLFMD, 2018). 
 
Figure 1.7: Recent movements of the A/ASIA/Sea-97 lineage. The A/ASIA/Sea-97 
lineage circulates within mainland SEA (Pool 1), but its normal distribution within the 
Pool has recently changed and outbreaks were recorded in South Korea in 2017 and 
2018. Confirmed FMD reports due to the A/ASIA/Sea-97 lineage between 2010 and 
2017 are indicated in shades of blue. Black arrows represent confirmed movements 
of the virus, while grey arrows indicate predictions of a possible spread. The map is 
adapted from the OIE/FAO FMD Laboratory Network annual report (WRLFMD, 2018). 
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 Regional distribution: FMDV in mainland Southeast Asia 
 
Countries within mainland SEA (Pool 1) are largely affected by common FMD viruses. These 
viruses belong predominantly to serotypes O (five different lineages), less commonly to 
serotype A (two different lineages) and, infrequently, to serotype Asia 1 (Table 1.1).  
 
Table 1.1 Summary of recent occurrences of FMDV individual lineages in Southeast 
Asia (Pool 1). The data was collated based on the World Reference Laboratory for FMD 
(WRLFMD) and the OIE/FAO FMD Laboratory Network reports, accessed from the 
WRLFMD webpage (WRLFMD, 2018). 
  Cambodia Laos Malaysia Myanmar Thailand Vietnam 
O/ME-SA/In-2001   2015 2018 2016 2016 2017 
O/SEA/Mya-98 2014 2016 2016 2016 2016 2017 
O/CATHAY         2012 2017 
O/ME-SA/PanAsia 2015 2012     2015 2017 
O/ME-
SA/PanAsia2 
    2006       
A/ASIA/May-97 2015 2015 2014 2015 2016 2017 
A/ASIA/unnamed       2010     
Asia 1       2017   2006 
 
 
However, there are subtle differences in the distribution of the FMDV lineages within the 
region. For example, the latest confirmed detection of serotype Asia 1 was in 1998 in 
Thailand and in P. Malaysia in 1999, while this serotype was detected recently, in 2017, 
in Myanmar. It is important to note, that the Asia 1 virus detected in Myanmar was 
genetically linked to the Asia 1 virus currently circulating in South Asian countries (Pool 
2) such as India and Bangladesh. These recent outbreaks in Myanmar might occurred after 
the withdrawal of serotype Asia 1 (Asia 1 Shamir) component from the FMD vaccine used 
in the country (Bo et al., submitted) and might linked to the reduced protection in 
animals. These events reinforce the importance of using vaccines that contain serotype 
Asia 1 virus particularly in parts of mainland SEA with trade connections to South Asia 
(Pool 2). Additionally, in 2005, the O/CATHAY lineage was last detected in P. Malaysia 
and Thailand. The same lineage was also reintroduced to Thailand in 2012 but it was not 
detected in Malaysia on that occasion. However, the O/CATHAY lineage was isolated in 
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Vietnam in 2012, 2016 and 2017 (Table 1.1). The difference in the occurrence of 
O/CATHAY in Vietnam as compared to P. Malaysia is believed to be due to the strict 
import regulation (ban of import) of live pigs from Vietnam into Malaysia introduced after 
the incidence in 2005. 
 
1.11 Economic impact of FMD 
 
The immediate negative impact of FMD is more dramatic when the disease occurs in 
countries that are free of the disease or where FMD has been previously eradicated. 
Outbreaks of FMD that occurred in Japan in 2010 had significant economic impacts with 
the direct cost of eradication estimated to be US$563 million (Hayama et al., 2017; 
Muroga et al., 2012). FMD costs to the UK national economy have been estimated at 
US$9.2 billion during the UK 2001 FMD epidemic (FAO, 2002). The estimated costs of an 
FMD outbreak, if it is to occur in Australia is US$12.5 billion (Buetre et al., 2013). 
Together, the global costs of FMD incursions into FMD free countries is estimated at 
US$1.5 billion per year (Knight-Jones and Rushton, 2013). These costs are mainly due to 
the implementation of control and eradication measures particularly through the culling 
of infected and susceptible livestock, in addition to the ban of livestock trade activities 
that arises due to the loss of FMD-free status. In contrast, the negative impacts of FMD 
on livestock and rural economy are more subtle in endemic countries. Here, the 
detrimental losses of FMD outbreaks are often under estimated and less-well defined. 
Most farmers in these countries are smallholders (Swanepoel et al., 2002). In mainland 
SEA, the agriculture system is closely linked and always related to animal husbandry of 
smallholders with mixed farming practices. In this region, livestock are traditionally 
reared in household backyards in a local system that is usually integrated with crops, and 
deeply rooted to the in their lifestyle of the people. It represents a complex relationship 
between the farmer’s family, their animals and their crops.  In this setting, FMD causes 
loses through neonatal mortality of livestock, lowered fertility of animals and loss of 
income due to the prohibition of selling animals and animal products. Also, smallholder 
dairy farmers face production losses through reduced milk yields and prohibition of selling 
milk. Other impacts of FMD include smallholders that keep cattle or buffalo to plough rice 
fields where the impacts can result from a loss of draught power. In mainland SEA the 
estimated losses due to FMD in smallholders varies among countries. For example, in Lao 
PDR FMD estimated costs per animal are between US$56 and US$66 (Nampanya et al., 
2016) whereas, in Cambodia these costs are higher and estimated to be between US$216 
to US$371 (Forman et al., 2009). Furthermore, these losses can differ within a country. 
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For instance, in the highland region of  Vietnam, an area with low livestock density, FMD 
related losses were estimated at US$84, in contrast to US$930 for the lowland areas, 
where livestock density is high (Forman et al., 2009). Unfortunately, no studies have been 
undertaken to estimate the losses due to FMD in P. Malaysia.   
 
1.12 FMD control 
 
Despite global attention and considerable effort in scientific research into the causative 
agent of FMD, the disease remains endemic in many regions of the world. These are 
predominantly less developed and poorer countries in Asia (including the Middle East), 
Africa, Middle East and South America (Gleeson, 2002; Kitching, 1998; OIE, 2018). Within 
the regions where FMD is endemic, there are also countries (such as Japan 2010) that are 
free from the disease where sporadic outbreaks have been recorded where it has been 
possible to control and regain FMD free status (without vaccination). On the other hand, 
there are countries that have struggled to eradicate FMD after these sporadic FMD 
episodes such as in the Republic of Korea where regular outbreaks have occurred since 
2010, and recovery of FMD-free status has not been possible to achieve. In order to assist 
in the process of FMD control and eradication, the Progressive Control Pathway for FMD 
(PCP-FMD) has been introduced by the FAO and OIE (Sumption et al., 2012) (Figure 1.8) 
and improved in new edition (FAO/OIE, 2018). The purpose of the framework is to assist 
endemic countries to develop a strategy to attain free status in a step-wise manner. Thus, 
the PCP-FMD framework identifies an endemic country’s risk and helps to develop a work 
plan to move progressively through development of FMD free zones in order to ultimately 
achieve the status of FMD free country without vaccination. The PCP-FMD framework 
includes vaccination as well as other FMD control measures. However, in order to 
implement this PCP-FMD framework, FMD endemic countries require affordable and 
reliable tools to carry out post-vaccination monitoring activity alongside affordable and 
reliable but more manageable vaccine. Therefore, improvements of the existing 
serological diagnostic and surveillance tools are needed to increase specificity and 
reliability of the in-vitro methods. 
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Figure 1.8: Principle, Stage Description and Standard of Progressive Control Program 
for FMD (PCP-FMD) framework. Adapted from Progressive control pathway for Foot-
and-Mouth Disease guideline 2nd Edition 2018. 
 
 Review of FMD control initiatives 
 
Developed countries deployed stringent policies in order to control FMD by culling of 
infected animals and animal movement restrictions. These methods were first applied in 
France in 1739, and later adopted by Great Britain in 1869. These stringent measures 
against FMD are still in place in developed countries.  
In contrast to these successful polices to control FMD in Europe, FMD control in the most 
developing countries (including P. Malaysia) has progressed more slowly. For example, in 
P. Malaysia, the first two disease resembled FMD records were in cattle in 1860 and in 
1909. Then, 26 years later, in 1936 an outbreak of a disease resembling FMD was recorded 
in 551 cattle in the states of Perak and Selangor (Wallace, 1936) and was followed by 
reports of similar nature, involving 238 cattle in Perak in 1938 (Wallace, 1939). The latest 
incidence was linked to the movement of animals from neighbouring countries. These 
events resulted in the development of policies to control livestock movement in four 
northern states of P. Malaysia (Perlis, Perak, Kedah and Kelantan).  
P. Malaysia changed its policy to slaughter coupled with strict sanitary procedures after 
an outbreak by FMDV subtype A22 in Perlis in 1973. These measures lead to effective 
control of FMD outbreaks, with no FMD cases recorded for next five years. However, in 
October 1978 another FMD case was recorded in the state of Kelantan which borders 
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Thailand. The disease was then spread through trading routes, to the district of Muar in 
Johor and to the district of Ipoh in Perak. Another FMD case was then reported in the 
district of Tumpat in Kelantan, which spread to the states of Perlis and Kedah in late 
1978. These FMD cases were identified as being caused by FMDV subtype O1. The extension 
of this spread lead to the adoption of a stamping out policy by Department of Veterinary 
Services (DVS) which was applied in the affected area. In total, 18,117 animals were 
slaughtered of which 7,511 (41.5%) were cattle (Chong, 1979; Thuraisingham, 1977). 
However, this stamping out policy was unpopular and strongly objected by the people. 
Therefore, in January 1979 the policy was changed to prophylactic vaccination (Chong, 
1979). However, the vaccination policy was found not to be effective since more FMD 
cases  were identified (due to serotype Asia 1) which were linked to importation of cattle 
to P. Malaysia for slaughter (Babjee, 1994). 
Realising the complexity of FMD control across countries that share common borders 
(Ozawa, 1994), SEAFMD Campaign was proposed and established in 1994, with the first 
meeting being held in 1995. Subsequently, a Regional Coordination Unit (RCU) was also 
established in Bangkok in 1997 to supervise the FMD control program in the SEA region 
(Abila and Foreman, 2006; Edwards, 2004). In 2001 an area was identified by OIE that 
could as the potentially gain FMD free status in the SEA region by the OIE. This area, 
include the northern P. Malaysia and isthmus of Kra involving three countries: Malaysia, 
Thailand and Myanmar. The five-year program, named Malaysia-Thailand-Myanmar (MTM) 
Campaign for FMD Freedom, was officially established (Edwards, 2004; Suseno and 
Wongsathapornchai, 2004; Wongsathapornchai et al., 2008). In Malaysia, the MTM FMD 
free zone involved the entire states of Perlis and Kedah and selected districts located in 
additional four states in the northern part of the country. In Thailand two regions, 8 and 
9, were selected in addition to a buffer zone involving Prachuapkirikhan province that 
located in region 7. In Myanmar, Kawthung district of Tanintharyi division was involved in 
addition to the buffer zone in Myeik district (Turton, 2004) (Figure 1.9). 
In 2010, the SEAFMD Campaign was expanded to involve China and renamed as SEACFMD 
Campaign. Guided by the SEACFMD Roadmap, the implementation of the eradication 
campaign is divided into five phases that will run up to 2020 (OIE, 2016). Now, with only 
about two years left before the end of the campaign, the number of FMD cases in mainland 
SEA countries are still increasing adversely affecting the livelihoods of the local 
populations. Furthermore, incursions of new, previously unreported in mainland SEA 
lineages of FMDV, such like the O/ME-SA/Ind-2001 lineage, are reported (WRLFMD, 2018). 
Despite the efforts, out of the six FMD endemic countries in mainland SEA and China 
(People’s Rep of), only Thailand and China currently have an official national control 
program for FMD that is endorsed by resolution no. 23 of the general assembly of OIE.  
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Figure 1.9: The geographical area of the Malaysia-Thailand-Myanmar (MTM) Campaign 
for FMD Freedom. Map is courtesy of Dr Di Nadro. 
 
 Challenges of FMD control 
 
The Food and Agricultural Organization of the United Nations (FAO) and OIE has 
recognised FMD as a threat to world food security, and has therefore made FMD control a 
global priority (Sumption et al., 2012). Although there are various different control 
measures that can be adopted there is no standard FMD control and eradication program 
that is suitable for all FMD endemic countries. The epidemiology of FMD involves a 
complex and dynamic interaction of the aetiological agent, susceptible hosts, and 
environment (including livestock trade). Unlike other animal diseases, the environmental 
factor in the epidemiological triad of FMD is wider and more complex. It is not only limited 
to the direct interaction of the agent or host with the environment but it includes 
economic status, trade, cultural and political situation of the society that manage the 
host (non-direct environmental factors). In fact, the success of FMD control and 
eradication program of a country is almost solely dependent on these non-direct 
environmental factors. The current global distribution of FMD mirrors the geographical 
location of countries with low economic status. In these countries, FMD cases are often 
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under-reported and animal health services are generally under-resourced. Therefore, it 
is almost impossible for these countries to adopt the stringent FMD control measures.  
In mainland SEA, control measures adopted include mainly vaccination and restrictions in 
animal movements (Gleeson, 2002). The development of the PCP-FMD control framework 
through vaccination and free zoning by the FAO and OIE can be used to facilitate FMD 
control program. This approach has worked in some countries in SEA such as Indonesia 
and the Philippines. However, these countries comprise of islands with the sea/ocean 
acting as natural barriers. Countries that share common land borders face more 
challenges. It is established that the most effective way for the spread of FMD is through 
direct contact of the susceptible animals with either clinically or sub clinically infected 
animals, or with animals incubating the disease (Alexandersen and Donaldson, 2002; 
Brown, 2004; Donaldson, 1987; Orsel et al., 2009).  
Movement of animals, either via legal or illegal trade, has been demonstrated to be an 
effective mechanism of FMD spread (Mansley et al., 2003; Rweyemamu et al., 2008). For 
example, the 1990s spread of FMDV serotype Asia 1 was shown to follow the movement 
of livestock from India, to Myanmar via Bangladesh and then, following the route of 
livestock movement, down to P. Malaysia (Rweyemamu et al., 2008). Another example is 
the introduction of the O/ME-SA/PanAsia-2 lineage to P. Malaysia, a virus linked with 
previous outbreaks in India and Bangladesh (Knowles et al., 2005). Cultural practices pose 
great challenges to the deployment of restrictions on animal movements to control FMD 
in Malaysia (Sasaki, 1994), particularly when imports of livestock and meat products from 
FMD free countries more expensive than from adjacent countries.  
Another hurdle faced by FMD endemic countries is that livestock are mainly reared by 
smallholder farmers. For example, in P. Malaysia, even though pigs and poultry are 
generally reared on farms with good husbandry and zoo sanitary practices, ruminants are 
reared differently. For beef cattle 23% are reared under the oil palm plantations and beef 
cattle reared traditional system contributes 57% of the ruminant population. This 
indicates the majority of ruminants in the country are reared by smallholders in their 
backyards. The livestock husbandry practices are not very different in other countries in 
mainland SEA. In these settings, animals are free to roam and co-mingle with other 
animals within the village and, to some extent, with other villages. Under these 
conditions, the probability of effective FMD spread is very high, while implementation of 
effective control measures, such as vaccination, can be difficult. For instance, to perform 
vaccination in these traditional and integration systems, which do not have basic facilities 
to restrain the animals, the vaccinator’s team often has to build temporary corrals before 
the actual vaccination can be performed (Figure 1.10 and 1.11).  
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The existence of persistent/carrier state of FMDV infection in naïve and vaccinated 
ruminants adds to the complication of FMD control. The problem occurs especially during 
post vaccination monitoring (PVM) and manifests itself in the lack of the ability of the 
currently available serological tests to discriminate a subclinical infection from a 
persistent infection at an individual animal level. In addition, FMDV serotype cannot be 
distinguished based on clinical manifestation of the disease. This results in the need for 
regular PVM to determine whether the vaccine virus currently in use is appropriate against 
the serotype that is causing contemporary outbreaks. Furthermore, a spectrum of viruses 
with their own antigenic and epidemiological characteristic can also exist within a 
serotype making the FMD control measures and preparedness even more complicated 
requiring regular in-depth laboratory characterisation of the currently circulating FMD 
viruses.  
 
 
Figure 1.10: Vaccination of cattle reared in integration system in P. Malaysia. Pictures 
are courtesy of Pn Salamiah Binti Sarif. 
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Figure 1.11: Vaccination of buffalo reared in traditional system in P. Malaysia. 
Pictures are courtesy of Pn Salamiah Binti Sarif. 
 
 FMD vaccines 
 
In countries where FMD is endemic, vaccination is commonly used as a primary tool to 
suppress clinical signs of the disease. Vaccines can be applied to induce herd immunity, 
reduce clinical infection and viral transmission (Orsel et al., 2007). In addition, systematic 
vaccination in combination with movement controls and culling of FMD infected animals, 
has been implemented to effectively control and eradicate FMD from endemic regions, 
such as Western Europe and most courtiers of South America (Clavijo et al., 2017; 
Leforban and Gerbier, 2002; Saraiva, 2004). For countries with FMD free status, the use 
of vaccine as a “vaccinate-to-kill policy” has reduced the spread of the disease, and 
subsequently led to the reinstatement of the FMD free status (such as in The Netherlands 
[2001] and Japan [2010]). However, FMD control by vaccination has challenges and to 
date there are no countries that have achieved an FMD freedom status by using 
vaccination alone.  
There are many factors associated with the success of FMD control by vaccination such as 
vaccine quality, potency and cross-reactivity between a vaccine virus and field isolate 
(Barnett and Carabin, 2002). The fact that diverse FMDV field isolates needs to be 
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matched to the homologous vaccine virus, highlights the importance of a sound and 
reliable vaccine matching test (Paton et al., 2005). In addition to antigenic match, the 
type of adjuvant used in the vaccine formulation also contributes to the performance of 
a vaccine (Jamal et al., 2008). Besides these points, there are two more main factor that 
influence the successfulness of FMD vaccination. One is host related factor such as the 
impact of maternally derived immunity and interference with other vaccine if it were to 
be given at the same time. The second point relates to human factors, such as the 
maintenance of a cold chain from the vaccine plant to the field and correct vaccine 
administration (the dose, route, frequency and time) (Heininger et al., 2012; Lyons et 
al., 2016). 
 
 Vaccine potency for FMD 
 
In order to quantitatively measure the specific ability of the vaccine to confer protection 
(vaccine immunogenicity), a vaccine potency test is usually performed. There are 
currently two different methods that are described to measure vaccine potency. 
Following the standard set by the European Pharmacopeia that FMD vaccine potency is 
expressed in half of protective dose (PD) more frequently called PD50 (Goris et al.). In 
South-America FMD vaccine potency testing is guided by Argentine Animal Health Service 
(SENASA). The SENASA expressed FMD vaccine potency by Protection against Podal 
Generalisation (PPG) (Goris and De Clercq, 2008). Both of these methods involve 
vaccination and experimental challenge of animals (usually cattle). According to the OIE 
terrestrial manual chapter 2.1.8 section C requirement for vaccine, FMD vaccines can be 
classified into two classes: (i) standard and (ii) higher potency vaccines (OIE, 2017). The 
standard potency vaccine for FMD should have minimum of 3PD50 or 75% PPG (protection 
against generalised foot infection) whereas, the higher potency vaccine should have > 
6PD50.  
 
In order to achieve 75% PPG (which is broadly an equivalent of >3PD50), a minimum of 16 
animals need to be vaccinated with a full dose of the test vaccine. The animals are 
challenged at four weeks or more with 104 bovine infectious doses (BID50) after which 12 
animals have to be protected, without clinical lesions, on the feet for 7 days. The PD50 
test is generally performed by dividing a group of animals into three; (i) a group of animals 
that receives full vaccine dose, (ii) a group of animals that receives quarter vaccine dose 
and (iii) a group of animals that receives sixteenth vaccine dose. This method allows usage 
of fewer animals in total. However, comparison of the two vaccine potency methods, 
using large number (>60) of animals tested, showed that PPG was more reliable as 
compared to PD50 (Filho et al., 1993; Goris et al., 2008). Additionally, the PD50 method 
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requires a higher number of animals per vaccine dose; a group up to 25 animals is needed 
in order to distinguish between 3, 6 or 10 PD50 in a single trial (Goris et al.). Therefore, 
alternative in-vitro method has also been suggested. The alternative for PD50 using the 
indirect potency test, for example, the use of neutralisation or total antibody titre and 
protection against challenge (Robiolo et al., 1995).  
 
 The current FMD vaccines 
 
Conventional FMD vaccines used worldwide are derived from in-vitro passaged FMDV 
isolates that are chemically inactivated and purified. These “killed” vaccines use binary 
ethyleneimine (BEI) to inactivate the FMDV and are often processed to deplete non-
structural proteins (NSPs). These are produced as purified monovalent or polyvalent FMDV 
products that are formulated as oil or aqueous based vaccines with adjuvants. Vaccines 
can be stored as concentrated antigens that are suitable for long term preservation (~5 
years) when kept in liquid nitrogen, but can have a shorter shelf life when kept at 4°C. 
Furthermore, once prepared into a formulated product the shelf life of the vaccine is 
usually about 12 twelve months. The potency of the vaccine varies depending on the 
supplier and purpose of vaccination and ranges from those standard vaccines that provide 
half protective dose of least three (3PD50) to high (6PD50) suitable for emergency 
vaccination. Vaccines that contain at least 3PD50 are reported to confer protection against 
homologous virus challenge in cattle within seven days (Golde et al., 2005). Further 
research has shown that very high potency vaccines of at least 30PD50 confer good 
protection against heterologous virus (Brehm et al., 2008) irrespective of a poor antigenic 
match.  
The current inactivated FMD vaccines have many limitations. Among them are that these 
vaccines typically elicit only short-lasting serological immunity and therefore frequent 
vaccination are usually needed (Doel, 2003; Doel and Chong, 1982). Furthermore, these 
vaccines are vulnerable to degradation at elevated temperatures. At about 30°C, FMDV 
antigen in the vaccine rapidly converts into irreversible immunogenically incompetent 
12S (Doel and Baccarini, 1981; Doel and Chong, 1982). As consequence, the FMD virus 
capsid’s integrity requires maintenance of a cold chain from the vaccine plant to the 
point that the vaccine is given to individual animals. These limitations are troublesome 
since most of livestock in the endemic countries are kept by smallholders that have 
limited facilities. Another disadvantage of these vaccines is that high-containment 
facilities are required for their manufacture, which are expensive to build and maintain, 
and handling live FMDV in these facilities can increase risks of virus escapes to cause field 
outbreaks.   
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 Other types of FMDV vaccines 
 
Due to the limitation of inactivated vaccines, alternative vaccines have been developed. 
Among them are viral vectored vaccines, recombinant virus like particle (VLP) vaccines, 
peptide vaccines, DNA vaccines, live attenuated vaccines and attenuated DIVA-marked 
FMDV for inactivated vaccine production. 
In principle, viral vectors can be used to deliver FMDV structural proteins in virus-like 
particles (VLPs) to induce an immune response in the host. There are different vectors 
systems that have been researched and, to date, the recombinant replication defective 
human adenovirus was shown to be protective against O1 Manisa in swine (Fernandez-
Sainz et al., 2017). The recombinant VLP vaccines uses baculovirus (insect cell) culture 
system to produce stabilised FMDV empty capsid (75S). These recombinant VLP vaccines 
were shown to confer protection against serotype A in challenge study in cattle (Li et al., 
2012; Porta et al., 2013).  
Peptide vaccines were developed using selected linear epitopes of the virus and do not 
involve infectious virus. This type of FMD vaccine is currently being used in pigs in China, 
as reviewed by Cao and colleague (Cao et al., 2016). Protection to selected linear peptide 
is usually limited and escape mutant can arise in FMDV.  
DNA vaccine are generally safe but the technology requires large amount of DNA and 
multiple inoculation. Furthermore, DNA vaccines have not been tested in natural host.  
Live attenuated vaccines of FMD can provide rapid long-lasting immunity against FMDV. 
However, the technology has not shown to be protective in the natural host such as swine 
and cattle (Chinsangaram et al., 1998; Mason et al., 1997). Furthermore, the fear of the 
virus reversing to infectious virus is one of the main factors as to why it has not been used 
in the field. As a consequence, attenuated DIVA-marked FMDV for inactivated vaccine 
production is suggested (de Los Santos et al., 2018). The principle of this approach is 
replacement of the wild type inactivated whole FMDV with attenuated derivatives that 
can be easily propagated in a cell culture system.   
Despite extensive research in FMD vaccinology, the only other type of FMD vaccine 
currently available on the market is the peptide vaccine that only use in China and limited 
in pigs.  
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 Control measures, to complement vaccination 
 
It is established that FMD control programs in countries where the disease is endemic is 
complicated. For example, in mainland SEA, many different suggestions have been made 
in order to develop and implement an effective FMD control program. It has been 
suggested that systematic quarantine procedures coupled with vaccination (minimum 21 
days prior the quarantine procedure) and the establishment of FMD free zones is the 
appropriate approach to eradicate the disease in mainland SEA (Sasaki, 1994). This study 
argues that, due to cultural constrains and lifestyle of the people, movement restriction 
on live animals should not be implemented if the disease would to occur in the exporting 
country. However, others argue that the introduction of animal movement restriction 
from FMD affected country is necessary for prevention of spread of the disease (Edwards, 
2004). However, in both of these scenarios, vaccination is paramount.  
There are other methods that are well established and proven to be effective in FMD 
control, including the application of stamping out policies. However, due to economic as 
well as cultural reasons, it would be difficult to include stamping out policy in mainland 
SEA and/or in other FMD endemic countries. FMD control in endemic countries needs to 
extend beyond the current policy of vaccination and systematic quarantine practices. 
Thus, despite the socio-economic and cultural restrictions in the region, the 
implementation of animal movement restriction from FMD affected regions needs to be 
considered. In addition, an application of simulation models to aid the choice of control 
policies during an outbreak might be useful (Morris et al., 2002). However, in order to 
develop reliable models suited for supporting FMD control in mainland SEA, good 
epidemiological data is required. 
 
1.13 Vaccine matching  
 
In order to have an effective FMD vaccine, the vaccine virus has to be matched with the 
circulating field isolate through a vaccine matching method. This method needs to be 
reliable, affordable and relatively easy to perform. FMD reference laboratories undertake 
vaccine matching tests for the selection of vaccines.  
 
According to the OIE terresterial manual section chapter 2.1.8 secion D, there are four 
main options for the vaccine matching test:  
i. Two dimensional (chequerboard) VNT method. 
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ii. Expected precentage of protection (EPP), determination using one-dimensional 
VNT; the method is widely used in South America and correlation tables between 
serological responses and protection are developed  
iii. ELISA 
iv. CFT (only used for screening purpose), although this method is not widely 
practiced. 
 
The antigenic relationship between the vaccine virus and field virus is determined by a 
mathematical formula that determines a relationship coefficient (r1-value). The r1 values 
generated by serological methods (most commonly either VNT or ELISA) are used as a 
guide to predict whether or not the vaccine virus will confer protection against the field 
virus (Rweyemamu and Hingley, 1984; Rweyemamu et al., 1977). The formula used to 
determine the relationship coefficient is expressed as follows (OIE, 2017): 
 
r1 value = reciprocal arithmetic titre of reference serum against field virus  
                reciprocal arithmetic titre of reference serum against vaccine virus 
 
Determination of fitness for purpose of a vaccine using EPP method (ii) is only possible 
when correlation studies have been carried out for the particular vaccine viruses tested. 
Post-vaccination antibody titres (primary or booster) measured by VNT or ELISA are 
related to the probability of protection using the established correlation tables for the 
vaccine viruses available. For primary vaccination, protection level of vaccinated cattle 
is established at more than 75%, whereas for post booster vaccination, the protection 
level of vaccinated cattle at more than 50% (OIE, 2017).  
   
 In-vitro vaccine matching methods 
 
Direct in-vitro vaccine matching methods using susceptible animal species that are 
vaccinated and challenged is ideal, however this is expensive, time consuming and creates 
animal welfare concerns. As an alternative, serological relationship between field and 
vaccine viruses can be adopted as indirect methods: such as liquid phase blocking ELISA 
(LBPE)(Crowther and Abuelzein, 1979), complement fixation test (CFT) and VNT (Booth 
et al., 1978). However, CFT was found to be less specific than VNT (Rweyemamu et al., 
1978) and is not widely used by FMD Reference laboratories.   
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Sequence analysis as well as antigenic profiling using monoclonal antibodies (mAbs) may 
also be useful to indicate whether an FMDV isolate is a match with a vaccine virus (Paton 
et al., 2005). However sequencing analysis techniques are expensive and complicated; 
more detail information is needed for analysis using mAbs (Mahapatra et al., 2008). 
Furthermore, current modelling techniques such as antigenic cartography cannot yet 
accurately predict vaccine matching, although future discovery may allow for this (Ludi 
et al., 2014). 
 
Virus neutralisation tests utilise susceptible cell culture to measure the ability of serum 
to neutralise a virus dose of a 100 TCID50. Cytopathic effect (CPE) is used as the indicator 
for neutralisation. The 100TCID50 is chosen for the standard protocol of the test because 
at this value that the linear part of the sigmoid curve is located in the chart that described 
the relationship between neutralization titre on the Y axis and the virus dose on the X 
axis (Booth et al., 1978). This is the preferred method (gold standard) for vaccine 
matching of FMDV field isolates since it is a better predictor of protection (Mattion et al., 
2009; O.I.E, 2012; Robiolo et al., 2010). However, the test is laborious and time 
consuming and requires high-containment facilities to handle live FMDV.   
 
An alternative test is the liquid phase blocking ELISA where, guinea pig polyclonal 
antibody raised to serotype specific FMDV is used to bind a fixed dose of virus. It is the 
detector antibody and that it can’t bind if the FMD antigen-antibody complexes get 
formed. The binding form antigen-antibodies complexes, preventing the colour 
appearance, produce by the substrate/chromogen solution in LPBE testing. Enzyme-linked 
immunosorbent assay (ELISA) produces more reproducible results than VNT 
(Tekleghiorghis et al., 2014; Van Maanen and Terpstra, 1989). Both VNT and LPBE tests 
measure antigen-antibody complexes using serial dilutions. However, there are 
remarkable differences between these two methods. VNT measures only neutralising 
antibodies whereas LPBE measures binding of the antigen antibody complexes which 
include neutralising and non-neutralising antibodies. The fact that it is not able to 
differentiate neutralising from the non-neutralising antibody makes ELISA less preferred 
compared to VNT. Neutralising antibodies are more closely related to protection alongside 
interaction with the complex immune response and cell reactions (McCullough et al., 
1992b; Reading and Dimmock, 2007). In addition to indirect serological test, ELISA 
measuring bovine serum immunoglobulin subtype ELISA particularly IgG1/IgG2 ratio and 
avidity ELISA have also been explored as approaches that may better predict protection 
(Capozzo et al., 1997; Lavoria et al., 2012).  
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 Review of retrospective r1 values generated from VNT 
 
Vaccine matching tests measures the relationship between a vaccine virus (homologous 
virus) and the virus isolated from the field (heterologous virus) using hyper-immunised 
bovine vaccinal sera that is homologous to the vaccine virus. Vaccine matching is being 
carried out routinely at the World Reference Laboratory for FMD (WRLFMD) to determine 
the most suitable vaccine for a field FMD virus. The serological test used is the virus 
neutralisation test (VNT). The ratio of the neutralisation titre determined against the 
homologous virus and the heterologous virus are used to generate the quantitative 
relationship coefficient (r1 value) as a predictor of potential coverage. Traditionally r1 
value with minimum acceptable cut-off of 0.3 are accepted as a match, as recommended 
by OIE (OIE, 2017). It is assumed that the closer the r1 value is to 1 the more antigenically 
similar the two viruses are. However some researchers find the use of r1-values 
questionable (Brito et al., 2014), while others have suggested to improve r1-values 
calculation by using statistical models (linear mixed effects models) that utilised 
sequencing data (Reeve et al., 2010). During the early part of this study a preliminary 
analysis of retrospective r1 values for ten years (2006 - 2017) of serotype A linage 
A/ASIA/Sea-97 generated at WRLFMD for mainland SEA were analysed to assess the 
repeatability of the r1 values generated. The preliminary analysis shows that the r1 values 
generated from the neutralisation titres for A/ASIA/Sea-97 vaccine virus were 
uncorrelated above and below the protective cut-off point at 0.3 (OIE, 2017) (Figure 
1.12). The proportion of the r1 values of A/ASIA/Sea-97 viruses showed majority (62%) 
were below the cut-off point (no-match), while 38% of field virus tested matched the 
vaccine virus (Figure 1.13). 
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Figure 1.12: The r1 values generated from neutralisation titres of FMD viruses 
belonging to the A/ASIA/Sea-97 lineage collected in mainland SEA from the year 2006 
- 2017. The orange dots represent the individual r1 values and the black dashed line 
indicate the suggested protective cut-off (0.3) defined by the OIE. 
 
 
 
Figure 1.13: The proportion of r1 values generated at WRLFMD that are matched and 
not matched for viruses collected in mainland SEA from the year 2006 - 2017 for the 
A/ASIA/Sea-97 lineage. Data represents testing done using neutralisation titres of 
collected for viruses collected from mainland SEA against the A/May-97 vaccine virus 
over a 10-year period (2006 to 2017). A cut-off of r1 ≥0.3 defines matched and not-
matched field viruses (OIE, 2017). 
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1.14 Thesis hypothesis and aims 
 
Current vaccines used in P. Malaysia to control FMD include the A/MAY-97 virus. Vaccine 
matching tests, using virus neutralisation, suggests that this vaccine virus poorly protects 
against contemporary FMD isolates in the region. In SEA only 32% of field isolates have 
been shown by in-vitro testing to be covered by the A/MAY-97 vaccine virus. However, 
poor robustness in the current in-vitro vaccine matching methods combined with a lack 
of properly designed field studies of vaccine effectiveness make it difficult to identify the 
contribution of factors affecting vaccination, including vaccine matching, to incomplete 
FMD control. It has been widely recognized that the serologically derived relationship 
coefficients used to determine vaccine matching (r1-values) can produce conflicting 
results. The high costs of performing cross-virus challenge potency tests has made it 
difficult to address this problem. This work will help to better characterise the antigenic 
epidemiology of Malaysian FMD viruses and explore the ability of the current vaccine virus 
to protect against the contemporary field isolate. This additional knowledge will lead to 
improved control measures within the region and elsewhere. 
The overall hypothesis of this study is that lack of reproducibility in serological vaccine 
matching methods, particularly the results generated by the virus neutralisation test 
(VNT) and liquid phase blocking ELISA (LPBE), is caused by intrinsic factors. This is based 
on the preliminary study (analysis of the retrospective r1 value 10 years data) and 
situation observed at the field in Peninsular Malaysia. In addition to inherent day-to-day 
variability, the three main determinants that are proposed to affect the reliability of 
results are; (i). the variability of FMD virus growth in the cells used in the VNT. Utilising 
information acquired from the variability of FMD virus growth in the cells used in VNT, 
(ii) the variability of reference sera used by producing bovine sera (BVS) as standardised 
sera to assess antigenic relationships between vaccine and field FMD viruses, and (iii) the 
instability of the FMD virus antigens used in both of these tests. In addition, (iv) results 
generated after vaccination in a field experiment are used to help understand the 
relationship of in-vitro test limitations and FMD control in endemic settings.  
Therefore, the overall objectives of this thesis are to describe the limitations of the in-
vitro vaccine matching methods, to identify the source of variability that is observed 
when using these tests and to assess the importance and relevance of these findings to 
FMD control in endemic settings. 
  Chapter 2 
37 
 
: 
 
Influence of cellular factors on in-vitro vaccine 
matching: impact of IB-RS-2 cell division cycle, 
and the presence of CSFV within the cells.  
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2.1 Abstract  
 
Foot-and-mouth disease virus (FMDV) causes an economically important disease that 
threatens international trade of livestock and livestock production. Virus neutralization 
test (VNT) is the accepted “gold standard” method used to define serological responses 
to vaccines and FMDV infection. However, one of the cell lines (IB-RS-2) that is widely 
used to detect and measure FMDV-specific antibodies is persistently infected with 
classical swine fever virus (CSFV), which restricts the use of these cells to high-
containment laboratories. The aim of this study was to define whether the presence of 
this virus in these cells impacts upon their ability to propagate FMDV. For ten cell cultures 
with different passage histories, confluent CSFV positive IB-RS-2 cells supported FMDV 
replication of field isolates and vaccine virus to higher titres (p=0.015) compared to non-
confluent cells (in 7/10 and 8/10 cell cultures, respectively). Moreover, confluent cells 
yielded lower neutralisation titres in six individual sera tested with significant different 
in titres, at 100TCID50. The presence of CSFV was confirmed using real-time RT-PCR. Data 
showed that confluent cells generated significantly (p=0.005) higher levels of CSFV 
genome copies compared to the non-confluent cells. However, no significant correlation 
was observed between the amount of CSFV and FMDV titres obtained with the respective 
cell cultures. Further evidence to indicate that CSFV does not influence FMDV replication 
was obtained using CSFV negative IB-RS-2 cells, where equivalent analytical sensitivity to 
CSFV positive cells was observed for 25 FMDV isolates. These data reinforce the 
importance of standardising the cell cycle of cells used for VNT, and indicate that CSFV 
negative IB-RS-2 cells may provide an alternative to existing cell lines. 
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2.2 Introduction 
 
Foot-and-mouth disease (FMD) is a highly contagious livestock disease that has negative 
impacts on a country’s economy via effects on livestock productivity and reduced 
opportunities for trade. The global cost of FMD outbreaks in countries where the disease 
has been eradicated such as United Kingdom, Netherland, France, Japan and others as 
listed in OIE FMD status is estimated at US$1.5 billion per year (Knight-Jones and Rushton, 
2013), while countries with FMD endemic status face annual loss from livestock production 
and vaccination alone at an estimated of US$ 6.5 to 21 billion (Knight-Jones and Rushton, 
2013; Knight-Jones et al., 2017). Therefore, tools such as vaccination are extremely 
important to control the disease. One of the steps to achieve an effective vaccination 
program is to select an appropriate vaccine virus, which antigenically matches the 
circulating field isolates. FMD is caused by foot-and-mouth disease virus (FMDV) that has 
seven serotypes; O, A, C, Asia 1, SAT 1, SAT 2 and SAT 3 (Knowles and Samuel, 2003). The 
FMDV capsid is composed of four structural proteins: VP1, VP2, VP3 and VP4: VP1 contains 
many of the important epitopes able to elicit virus neutralising and non-neutralising 
antibodies (Bolwell et al., 1989; Ouldridge et al., 1984; Thomas et al., 1988). FMDV 
antibodies produced against one FMDV serotype have no cross protection with other 
serotypes, or in some cases even within serotype (Kitching et al., 1988; Knowles and 
Samuel, 2003; Robiolo et al., 2010).  
The virus neutralisation test (VNT) is the preferred in-vitro vaccine-matching method 
(OIE, 2017) used in FMD Reference Laboratories. This method relies on the use of 
susceptible cell cultures to measure the ability of bovine reference serum to neutralise 
standardized doses of vaccines and field viruses. A number of different cells culture 
systems, such as IB-RS-2 cells, baby hamster kidney cells (BHK 21), and bovine, lamb or 
pig kidney primary cells have been used for FMDV in-vitro VNT methods (OIE, 2017). Of 
these cells, IB-RS-2 cells are widely used due to their high analytical and diagnostic 
sensitivity and ease of maintaining the cultures. Despite the fact that the IB-RS-2 cell line 
was established from primary kidney cells of a physically normal three months old piglet, 
there was an early indication of the presence of classical swine fever virus (CSFV) in these 
cells (De Castro, 1964; De Castro, 1970; De Castro, 1973). CSFV is an enveloped, non-
segmented, positive strand RNA virus and a member of pestivirus genus within the 
Flaviviridae family. As outbreaks of CSF in pigs can cause major epidemics and are linked 
with significant economic losses, the virus is classified as the highest tier risk level by the 
United States Department of Agriculture (USDA) Animal and Plant Health Inspection 
Service (APHIS) and classified as a SAPO 3 pathogen by the UK Advisory Committee on 
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Dangerous Pathogens (ACDP). Thus, the presence of CSFV in IB-RS-2 cells is undesirable 
as the CSFV positive cell lines can only be maintained in high containment laboratories, 
limiting their application.  
The objectives of this study were to (i) determine cellular factors that influence the in-
vitro replication of FMDV in IB-RS-2 cells at different cell stages using non-confluent and 
confluent cultures, (ii) to determine presence and effect of CSFV in IB-RS-2 cells stocks 
routinely use for in-vitro vaccine matching test at The Pirbright Institute. (iii) to explore 
whether the CSFV negative IB-RS-2 cells have equivalent analytical sensitivity for FMDV 
replication.  
 
2.3 Materials and methods 
 
 Cell lines 
 
Ten vials of frozen CSFV positive IB-RS-2 cells with different passage history were obtained 
from the cell repository held at The Pirbright Institute (TPI) and the CSFV negative IB-RS-
2 cells were received from Friedrich-Loeffler-Institut (FLI), Germany. All the cells were 
propagated in Glasgow minimum essential media (GMEM) supplemented with 10% adult 
bovine serum, 1% antibiotics (100 U/ml penicillin and 100 µg/ml streptomycin) and 1% L-
Glutamine. Before use, the IB-RS-2 cells were revived, washed and propagated until a 
fully confluent monolayer was achieved. These were then split on the same day but at 
different ratio in order to obtain the non-confluent (<60%) and confluent (100%) cells 
ready to be used 2 days later. The harvested cells were prepared for flow cytometry 
analysis and for the cell suspension used in VNT. For flow cytometry analysis, the cells 
were kept on ice prior to fixation. For VNT, a cell suspension was prepared at 1 × 106 cell 
count per ml for the CSFV positive IB-RS-2 cells.  
A preliminary study to determine the optimum cell count of the negative IB-RS-2 cell to 
be used in the 96 well plates was carried out prior to the FMDV limit of detection 
experiment. In this preliminary study, four cell concentrations (per ml) of the negative 
CSFV IB-RS-2 cell were tested; 0.25 x 106, 0.5 x 106, 0.75 x 106 and 1.0 x 106. The result 
from this experiment showed that 0.5 x 106 cells per ml of the negative CSFV IB-RS-2 cells 
was the optimum conditions. Therefore, to directly compare the FMDV limit of detection 
of both the CSFV positive and negative IB-RS-2 cells, the cell cultures were prepared at 
0.5 × 106 cells per ml, although this is lower than the cell seeding density used for VNT 
(described above).  
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 Flow cytometric analysis  
 
The flow cytometric analysis was performed to determine the relationship between the 
cell division cycle and the cell confluency. 
A suspension of 2 × 106 CSFV positive IB-RS-2 cells was prepared in two individual wells of 
a 96 well u-bottom plate before washed twice with 100µl cold PBS buffer. The cells were 
re-suspended in 100µl per well of 4% paraformaldehyde (PFA) and incubated on ice for 15 
minutes for fixation followed by washing with 100µl of PBS and twice with 100µl per well 
cold flow cytometry (FACS) buffer (PBS with 1% BSA). The fixed cells were permeabilised 
with 0.1% Triton X100 incubated for 30 minutes at room temperature as the cells were 
labelled with 1µg/ml 4',6-diamidino-2-phenylindole, dihydrochloride (DAPI) 
(Darzynkiewicz and Huang, 2004). DAPI is a fluorescent dye that binds selectively to DNA 
of the cells nuclei to form DNA-DAPI complex to enable the cell cycle analysis. The cell 
cycle data were collected using a BD LSR Fortessa (Fortessa instrument, BD Biosciences) 
and analysed in FCS express 5. Debris was excluded based on forward scatter (FSC) and 
side scatter (SSC) (P1), then gated on singlets based on DAPI Area vs width (P2). Finally, 
a histogram showing DAPI-(area) FCS multicycle was used to calculate the G1, S phase 
and G2 values.  
 
 FMDV isolates  
 
A vaccine virus (A/May-97, provided by Boehringer Ingelheim, Germany) and 25 different 
FMDV field isolates and were selected from the repository held at the FAO World 
Reference Laboratory for FMD (WRLFMD) at TPI (Table 2.1). All the field viruses were 
treated with stabilised di-ethyl ether to destroy any adventitious lipid-containing 
organisms before propagation. The FMDV field isolates were previously characterized by 
phylogenetic analyses based on VP1 coding sequences (Knowles et al., 2016). In order to 
eliminate the potential influence of adventitious CSFV that might have been carried over 
with the FMD virus isolates, all viruses in this panel originated from a CSFV negative cell 
culture (either primary bovine thyroid cells (BTy) or baby hamster kidney cells (BHK).  
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 FMDV titration  
 
Quantification of FMDV was determined by titration of each FMD test virus 
 
Table 2.1 List of FMDV isolates used in the study 
Viruses Serotype/topotype1/ 
lineage 
Country of Origin Passage history 
(prior to study) 
MAY/2/2011 A/ASIA/Sea-97 Malaysia BTy1 
VIT/10/2015 A/ASIA/Sea-97 Vietnam BTy1 
VIT/13/2015 A/ASIA/Sea-97 Vietnam BTy1 
May-97 A/ASIA/Sea-97 Boehringer 
Ingelheim 
BHK(BI) 
VIT/9/2015 A/ASIA/Sea-97 Vietnam BTy1 
MOG/2/2016 A/ASIA/Sea-97 Mongolia BTy1 
AFG/6/2017 A/ASIA/Iran-05 Afghanistan BTy1 
MAY/9/2016 O/SEA/Mya-98 Malaysia BTy1 
VIT/4/2016 O/SEA/Mya-98 Vietnam BTy1 
SRL/3/2017 O/ME-SA/Ind-2001 Sri Lanka BTy1 
MOG/1/2017 O/ME-SA/PanAsia Mongolia BTy1 
NEP/37/2017 Asia1/ASIA Nepal BTy1 
NEP/45/2017 Asia1/ASIA Nepal BTy1 
AFG/6/2016 Asia1/ASIA/Sindh-08 Afghanistan BTy1 
ZIM/14/2015 SAT1/II (SEZ) Zimbabwe BTy1 
MAL/1/2016 SAT1/I Mali BTy1 
BOT/5/2015 SAT1/III Botswana BTy1 
ZIM/1/2017 SAT2/II Zimbabwe BTy1 
BOT/1/2017 SAT2/II Botswana BTy1 
ZIM/5/2015 SAT2/II Zimbabwe BTy1 
ZAM/3/2015 SAT3/II Zambia BTy1 
ZAM/1/2017 SAT3/II Zambia BTy1 
SAR/1/2006 SAT3/I (SEZ) South Africa BTy2 
KEN/1/2004 C/ None defined Kenya BTy3 
NEP/35/1996 C/None defined Nepal BTy3 
BHU/10/1991 C/None defined Bhutan BTy2 
1 Where topotype has been defined       
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In order to assess the impact of cell cycle on FMDV replication, a titration series of the 
FMD vaccine virus (A/May-97) and A/MAY/2/2011 FMD field isolate was performed using 
CSFV positive IB-RS-2 cell cultures derived from different passage histories that each were 
synchronised (prepared in parallel as confluent and non-confluent cells). These 
experiments consisted of a four-fold titration carried out in flat-bottom 96 well micro-
titration plates using a pre-diluted antigen. Briefly, glycerinated antigen (virus) diluted 
serially with HEPES Modified Eagles Medium supplemented with 0.2% field antibiotic and 
0.4% NaOH (diluent) by making a 10-1 step. Dilution were performed in bijou bottles with 
enough volume needed for titration. Four-fold virus titrations were carried out (in 
duplicate) in flat-bottom 96 well micro-titration plates (Fisher Scientific) as illustrated in 
figure 2.1. A total of 50µl of an IB-RS-2 cell suspension at a cell count of 1 X 106 cells/ml 
was dispensed into all wells. The plates were incubated at 37oC for three days before 
being examined using microscope for cytopathic effect (CPE) indicative of FMD virus 
replication. The TCID50 endpoint titre was calculated as described in figure 2.2 following 
the Spearman-Kärber method 1931 (Kärber, 1931; Spearman, 1908). The FMDV titres 
produced by the confluent and non-confluent IB-RS-2 cells were analysed using analysis 
of variance (ANOVA). A General linear model was built with a random effect for the cells 
factor (nine different IB-RS-2 cell passages) and a fixed effect for the cell confluency 
(either confluent or non-confluent cells) and virus (vaccine virus; A/May-97 or field virus; 
A/MAY/2/2011) factors. Subsequently the data were compared to determine whether 
different confluency of the IB-RS-2 cells give different FMDV virus titres in both the 
vaccine and field viruses. (MiniTab 17). 
 
Figure 2.1: Plate layout for virus neutralisation test. Column 1 to 9 of row A to H were 
for virus titration of one virus. Column 10 to 12 were for control of diluent and cell 
suspension used.  
A
H
B
C
D
E
F
G
1 32 4 5 6 7 8 9 10 11 12
Add 100µl diluent then 
50µl cell suspension
Add 100µl serum free 
diluent then 50µl cell 
suspension
Add 150µl diluent
Add 150µl serum free 
diluent 
Add 50µl 
diluent 
to all well
row A-H, 1-9
Add 50µl highest virus dilution to 
column 9, second highest to column 8 
and so on to column 1
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Virus dilution (log10 0.6 dilution steps) 
Virus doses  106.7 106.1 105.5 104.9 104.3 103.7 103.1 102.5 101.9 
NO CPE (V1+V2) 16 16 11 8 2 0 0 0 0 
CPE (V1+V2) 0 0 5 8 14 16 16 16 16 
Σ(z x d)            = 49.6 
TCID50/ml = Dm + Σ(z x d)/50µl 
TCID50/ml = Dm + Σ(49.6)/16 
5.0 = 1.9 + (3.1)  
 
Recorded as 105.0 TCID50/50µl 
Dm = highest dilution with 100% CPE in all wells  
z = ½ of sums of reacting animals of two consecutive sums  
d = dilution interval   
m = number of wells per dilution  
 
Figure 2.2: Representation of virus titration plates and example of calculation to 
determine the TCID50. Two plates were used as duplicate (V1 and V2). In each plate, 
the virus was diluted in four-fold dilution from left to right. The control for cell and 
media is located in column 10, 11 and 12. Pink wells indicate cytopathic effect (CPE) 
and white wells represent cell monolayer. Virus end point titration (TCID50) is 
calculated following the Spearman-Kärber equation. The example of the stock virus 
titration is 105.0 TCID50 (50% of the well have CPE and 50% of the wells contain a 
monolayer of the cells).  
 
A
H
B
C
D
E
F
G
1 32 4 5 6 7 8 9 10 11 12
A
H
B
C
D
E
F
G
1 32 4 5 6 7 8 9 10 11 123 4 5 6 7 8 9 10 1 12
A
H
B
C
D
E
F
G
1 32 4 5 6 7 8 9 10 11 12
A
H
B
C
D
E
F
G
1 32 4 5 6 7 8 9 10 11 12
A
H
B
C
D
E
F
G
1 32 4 5 6 7 8 9 10 11 12
H
B
C
D
E
F
G
32 4 5 6 7 8 9 10 11 12
A
H
B
C
D
E
F
G
1 32 4 5 6 7 8 9 10 11 12
V1: virus plate 1
Cell control
Media control
101.9 101.9 106.7106.7
V2: virus plate 2
z 0 2.5 6.5 11 15 16 16 16 
d 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 
(z x d) 0 1.5 3.9 6.6 9 9.6 9.6 9.6 
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 Sera  
 
Inactivated sera collected from six individual animals as described in the next chapter 
(Chapter 3) material and method section; production of bovine sera (BVS) were used in 
the virus neutralization (VNT). 
 
 Virus neutralisation test (VNT)  
 
Virus neutralisation tests (VNTs) were carried out following the principles outlined in 
Chapter 2.1.8 Section D for vaccine matching test (OIE, 2017) and according to the 
WRLFMD protocol. In these VNT experiments both field and vaccine virus were tested 
simultaneously. The 50 % end-point serum neutralization titres at a virus dose of 100TCID50 
were calculated using linear regression at three virus doses. Inactivated and pre-diluted 
vaccine antiserum was dispensed on to the plate in two-fold dilutions. Cells were added 
to all wells and the plates were incubated at 37°C for 72 hours before examination by 
microscope for cytopathic effect (CPE). VNT assays were carried out using a field isolate 
(A/MAY/2/2011) and a vaccine virus (A/May-97) with six different vaccine antisera 
obtained from individual animals collected on 56 days post vaccination (dpv). For the 
confluent and non-confluent IB-RS-2 cell work, the same dilution of virus was used in all 
comparison tests, and these tests were carried out on the same day. Virus neutralisation 
titre data collected for the confluent and non-confluent cells were analysed using analysis 
of variance; a General linear model with random effect for the serum factor and fixed 
effect on the cell confluency factor, subsequently tested using Tukey pairwise 
comparison. 
 
 CSFV detection and quantification 
 
CSFV RNA was extracted from a cell suspension containing 1 x 106 cells/ml using the 
RNeasy Mini kit (QIAGEN Ltd.) according to the manufacturer’s protocol. The nucleic acid 
containing the viral RNA was eluted in 50 µl nuclease free water and stored at -80oC until 
used. The CSFV RNA was detected and quantified in a real-time RT-PCR assay targets the 
5’ NTR fragment of the virus using previously described probes (Everett et al., 2010). The 
reaction mix (One-step SuperScriptTM III/Platinum Taq enzyme mix, Life Technologies) 
was composed of 5 µl nucleic acid extract, 0.5 µl ROX (1:10), 12.5 µl 2x reaction mix, 2 
µl forward and reverse primers (at 10 µM) (CSF100F: 5’-ATG CCC AYA GTA GGA CTA GCA-
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3’ and CSF192-R: 5’- CTA CTG ACG ACT GTC CTG TAC-3’ and 1.5 µl probe (at 5 µM) (5’-
TGG CGA GCT CCC TGG GTG GTC TAA GT-3’) labelled with BHQ-1 (Black Hole Quencher). 
All oligonucleotides were synthesized by Sigma-Aldrich (USA). The amplification was 
carried out using the following cycling conditions: 60oC for 30 min followed by 95oC for 10 
min and 40 cycles of 95oC for 15 sec and 60oC for 60 sec (using an ABI model real-time 
PCR machine).  
The CSFV copy number was quantified using a 10-fold dilution of a CSFV RNA standard 
prepared using the pCRXLv324-6 plasmid containing the CSFV 5’UTR region of the strain 
Alfort 187 obtained from Animal and Plant Health Agency, Weybridge, UK. Briefly, after 
plasmid linearization with Hind III restriction enzyme (New England Biolabs), the RNA was 
transcribed using the MEGAscript™ T7 Transcription Kit (Ambion) according to the 
manufacturer’s instruction. The quality of the RNA was verified by electrophoresis and 
quantified using a nanodrop (Thermo Scientific). The RNA was purified using the QIA quick 
PCR Purification Kit (Qiagen) according to the manufacturer’s instructions. Serial dilution 
of the CSFV RNA standards (ranging from 101 to 108 copies) were prepared based on the 
Avogadro’s constant (number of entities in a mole of substance). One set consist of 
duplicate of the standard was used for experiment. The CSFV genome copy number was 
calculated based on the standard curve determined from the ten-fold serial dilution of 
the standard included in each PCR. Statistical analyses of CSFV genome copy number were 
performed in MiniTab 17 using the Spearman Rho non-parametric correlation test. 
 
 Detection for CSFV positive and negative IB-RS-2 cells 
 
The limit of detection was investigated for all the 26 different field viruses and a vaccine 
virus (Table 2.1). A virus titration was performed for each virus in a confluent monolayer 
of CSFV positive IB-RS-2 cells and CSFV negative IB-RS-2 cells at 0.5 × 106 cells/ml. A 
dilution for all individual viruses were prepared at the same time for tests in CSFV positive 
IB-RS-2 cells and CSFV negative IB-RS-2 cells in eight replicates on one plate and 
duplicated on a different plate. Correlation of all the 26 different FMDV strains limit of 
detection (virus titres) tested with monolayers of the CSFV positive and negative IB-RS-2 
cells were assessed with Pearson correlation (r) using MS-Excel. 
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2.4 Results 
 
 The effect of confluent and non-confluent cells on virus titres and 
serum neutralization titres 
 
Flow cytometric analysis of DNA content was used to assess the stage of the cell cycle on 
IB-RS-2 cell suspensions obtained from confluent and non-confluent monolayers (Figure 
2.3). The cell population of the confluent monolayer was shown to be predominantly at 
the non-dividing (G1) phase (83.90%) with 11.20% cells entering the DNA replication (S) 
phase and 4.85% at the division (G2) phase (Figure 2.3a). In contrast for the non-confluent 
cells, a higher percentage were shown to be entering the DNA replication (S) phase 
(41.64%) while 10.74% of the cell population was found to be at the division (G2) phase 
and 47.62% at the non-dividing (G1) phase (Figure 2.3b). 
To determine whether the FMDV titre was related to confluency of the IB-RS-2 cells, ten 
different IB-RS-2 cells passage preparations were tested with FMDV field isolate 
(A/MAY/2/2011) and FMD vaccine virus (A/May-97). In these experiments, confluent CSFV 
positive IB-RS-2 cells supported FMDV replication to higher titres compared to non-
confluent cells. For the vaccine virus, eight out of ten cell preparations were higher for 
the confluent cells, while for the field virus this was seven out of ten. The difference of 
FMDV titres in both field isolate and vaccine virus with confluent and non-confluent cells 
were statistically significant (p=0.015) with Tukey method at 95% confidence with mean 
values 4.43 for the confluent cells and 4.23 for the non-confluent cells. (Figure 2.4). 
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Figure 2.3: Histograms showing the DNA content of confluent and non-confluent 
IB-RS-2 cell populations.  
 
 
Cells were trypsinsed, labelled with DAPI and then analysed by flow cytometry. (a) 
Analyses of cells obtained from the confluent monolayer shows the majority of cells 
at the non-dividing (G1) phase (83.9%). (b) Analyses of cells obtained from the non-
confluent monolayer shows an increased number of cells entering the DNA 
replication (S) phase (41.6%).  Right-hand images are microscope camera-shots 
showing the status of the cell cultures.  
Furthermore, VNT was performed using synchronised cells, under the same 
experimental conditions. Confluent and non-confluent IB-RS-2 cells with (the same 
passage history) were used. One FMDV field isolate, A/MAY/2/2011, and six different 
individual cattle sera were tested. Consistently lower neutralisation titres were 
obtained for all of the six sera using confluent cells compared with the non-confluent 
cells (Figure 2.5). 
 
(intensity of the colour)  
(intensity of the colour)  
G1(83.9%) 
G1(47.62%) 
G2(4.85%) 
G2(10.74%) 
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Figure 2.4: FMD virus titres of a vaccine virus (A/May-97) and a field isolate 
(A/MAY/2/2011) using confluent and non-confluent IB-RS-2 cells. Results for confluent 
cells are indicated in green and non-confluent cells in grey. The ten IB-RS-2 cell 
preparations used for each of the FMD viruses are shown on the x-axis (with passage 
(p) histories indicated. For each pair, the viruses were tested on the same day with 
the same IB-RS-2 cell preparation for both confluent and non-confluent cells.  
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Figure 2.5: VNT of six different individual cattle sera using confluent and non-
confluent IB-RS-2 cells. Results for confluent cells are shown in green and non-
confluent cells are highlighted in grey. Individual animal numbers from which sera 
were collected at 56dpv are indicated on the x-axis. The same IB-RS-2 cell preparation 
were used. VNT was carried out on the field isolate (A/MAY/2/2011) on the same day 
with the same IB-RS-2 cell preparation for both confluent and non-confluent cells.  
 
2.5 The effect of CSFV on FMDV titres 
 
 CSFV positive IB-RS-2 cells verses CSFV negative IB-RS-2 cells 
 
Comparison between the CSFV positive and CSFV negative IB-RS-2 cells seeded at 0.5 X 
106 cells/ml revealed similar overall morphology after 72 hours incubation (Figure 2.6). 
However, the confluent monolayer of the CSFV positive IB-RS-2 cells (Figure 2.6c) showed 
less dense healthy cells compared to the monolayer of the CSFV negative IB-RS-2 cells 
(Figure 2.6a). Nonetheless, both the CSFV positive and CSFV negative IB-RS-2 cells were 
sensitive to FMDV infection and showed clear CPE (Figure 2.6b and d), where for both the 
CSFV positive and negative IB-RS-2 cells, the FMDV infected cells could be clearly 
distinguished from the negative control. 
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Figure 2.6: Microscopic images of FMDV infection in IB-IB-RS 2 cells. Cell count of 0.5 
X 106 cells/ml at magnification of 20X was used in all experiments. Panel (a) negative 
control: CSFV negative IB-RS-2, panel (b) FMDV infected CSFV negative IB-RS-2, panel 
(c) negative control: CSFV positive IB-RS-2, panel (d) FMDV infected CSFV positive IB-
RS-2. 
 
2.6 Relationship of the CSFV negative and CSFV positive IB-
RS-2 cells in FMDV detection. 
 
Twenty-five FMDV field viruses and one FMDV vaccine virus were tested to determine the 
limit of detection using the CSFV negative and CSFV positive IB-RS-2 cells. Pearson 
correlation analysis of all the 26 FMDV’s limit of detection using CSFV positive and CSFV 
negative IB-RS-2 cells showed moderate positive relationship with the r square value of 
0.56 (Figure 2.7). 
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Figure 2.7: Relationship of FMD viruses limit of detection in CSFV positive and 
negative IB-RS-2 cells. All experiments were performed in duplicates for both the 
CSFV positive and negative IB-RS-2 cells. The number of infected wells with cytopathic 
effect (CPE) was used to calculate virus titre. On the y-axis are the FMDV titre with 
CSFV positive IB-RS-2 cells in log10. On the x-axis are the same FMDV titre with CSFV 
negative IB-RS-2 cells in log10.  
 
2.7 CSFV genome copies contained in different confluency of 
 CSFV positive IB-RS-2 cells 
 
The CSFV genome copies contained in the confluent and non-confluent CSFV positive IB-
RS-2 cells was determined and compared. 
When using eight different passages of the CSFV positive IB-RS-2 cells at the same cell 
count (1 X 106 cells/ml), there were different number of CSFV genome copies determined 
in the confluent and non-confluent cultures (Figure 2.8). The actively dividing, non-
confluent cells contained significantly higher CSFV genome copy numbers/cell as 
compared to the confluent cells which were at stationary state (Uconfluent IB-RS-2 cell = 1.803, 
Unon-confluent IB-RS-2 cells = 4.379; p = 0.0054). In non-confluent cells the highest number of CSFV 
genome copies was determined as 16.39 copies per cell while the lowest as 2.22 copies 
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per cell. Whereas, in confluent cells, the highest and lowest number of CSFV genome 
copies was determined as 3.22 and 0.19 copies per cell, respectively.  
 
 
Figure 2.8: CSFV genome copy numbers per cell determined in the confluent and non-
confluent IB-RS-2 cell preparations by real-time RT-PCR. Results for confluent cells 
are indicated in green and non-confluent cells are indicated in grey. The x-axis shows 
the results for eight different IB-RS-2 cell preparations with different passage 
histories. The y-axis shows the CSFV genome copy number per cell.  
 
The relationship between FMDV titre and the CSFV genome copies was determined for the 
A/May-97 vaccine virus, as well as for the A/MAY/2/2011 field isolate in eight different 
confluent and non-confluent CSFV positive IB-RS-2 cell preparations at the cell count of 
1 x 106 cells per millilitre. As shown in Figure 2.9, no correlation was observed between 
the amount of CSFV genome copies in all the confluent and non-confluent eight CSFV 
positive IB-RS-2 cells and FMDV titre for both vaccine and field isolate (R2 = -0.171; P = 
0.320). This indicates that there is no significant influence of the amount of CSFV genome 
copies on the growth of field and vaccine FMD viruses. 
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Figure 2.9: Relationship between FMDV titre and the quantity of CSFV genome copies 
present in cells. The relationship between the A/May-97 vaccine virus and the 
A/MAY/2/2011 field isolate with the number of CSFV genome copies was plotted. 
Results for confluent cells are shown in green while non-confluent cells are shown in 
grey. The data for the FMDV field isolate is marked by the circular (○) symbol while 
the FMD vaccine virus is represented by the rectangular (□) symbol. The x-axis shows 
the CSFV genome copy number detected in a real-time RT-PCR reaction. The y-axis 
shows the log10 FMDV titres of field isolate and vaccine virus using confluent and non-
confluent cells. The viruses were tested on the same day with the same IB-RS-2 cell 
preparation for both confluent and non-confluent cells. 
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2.8 Discussion 
 
Virus neutralisation test (VNT) is an important laboratory method used to measure FMD 
serological responses. The OIE terrestrial animal manual (OIE, 2017) defines 4 main 
purposes for this test: (1) to certify animals prior to import or export, (2) to confirm 
suspect cases of FMD, (3) to substantiate freedom from infection and (4) to assess post-
vaccination performance including the use of vaccines in endemic countries.  
The method is also recommended for use in FMD vaccine matching tests in order to select 
the most suitable FMD virus for the production of a new FMD vaccine. This chapter studied 
the impact of IB-RS-2 cells at different stages of the cell cycle on the FMDV virus titres 
and virus neutralization titres that are measured. Since the routinely used cultures 
contain CSFV, further experiments explored the possibility to use the CSFV negative IB-
RS-2 cells as alternative cell culture systems in FMD virus titration.  
Many FMD Reference Laboratories use IB-RS-2 cells for routine VNT work to measure 
antibody responses. However, there is no existing knowledge on about how IB-RS-2 cell 
growth affects the neutralisation titres that are generated with this system, while it has 
been reported that IB-RS-2 cells used in different FMD Reference laboratories have 
different sensitivity to propagate FMD virus from clinical samples (Ferris et al., 2006). 
Therefore, here the effect of different extremes in the cell cycle (indicated by the use 
of confluent and non-confluent monolayers) of IB-RS-2 cells in FMD virus titre and VNT 
was studied. In FMD virus propagation studies, the viral titres were consistently lower in 
the non-confluent IB-RS-2 cells compared to FMD virus titres generated from the confluent 
IB-RS-2 cells. Consistently lower serum neutralisation titres were also obtained with the 
confluent cells compared to the results in VNT with the same sera and FMD viruses with 
non-confluent cells. This information highlights the variability that might be introduced 
into in-vitro serological methods when cells are not standardized prior to use in VNTs. 
This factor needs to be carefully considered by FMD diagnostic laboratories and the results 
from this study suggest that the same confluency of cells should be used in FMD virus 
titrations and VNT methods to reduce the inherent variability of the test. 
Despite the widespread use of the IB-RS-2 cell line, earlier extensive chromosome analysis 
by karyotype homogeneity of IB-RS-2 cell clones reported the manifestation of certain 
chromosome pattern (‘spontaneous’ degeneration) that at the time were thought to 
underlie the increased the cell sensitivity to FMD virus (De Castro, 1970). Subsequent 
studies undertaken at TPI (and elsewhere) have shown that these cells are persistently 
infected with CSFV. Earlier findings showed the presence of CSFV in IB-RS-2 cells by direct 
fluorescent antibody staining (House et al., 1988). The open reading frame of the CSFV 
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genome contains a protein known as Npro which plays a role in limiting the IFN-α induction 
(Ruggli et al., 2003), and it has even been suggested that the presence of CSFV in these 
cells may contribute to the high sensitivity to FMD virus due to innate antivirus effects. 
This present study confirmed the earlier finding and quantified the genome copy numbers 
present in the cell by quantitative real time RT-PCR.  
The quantitation of CSFV copy numbers of the CSFV present in the IB-RS-2 cultures in this 
study revealed that the IB-RS-2 cultures maintained the CSFV even though the number of 
copies/cells appears to be relatively low (on average, close to 1 or 10 virus copies/cell). 
Further tests demonstrated that the actively dividing, non-confluent IB-RS-2 cells 
contained significantly higher copy numbers of CSFV genome compared to the confluent 
cells, which were at stationary stage. In addition, this study also shows that there was no 
relationship between the CSFV genome copy number and the FMD virus titre.   
The potential use of the CSFV negative IB-RS-2 cells for FMD virus serological testing was 
also explored. In this study when the sensitivity to FMDV infection was measured using 
CSFV positive IB-RS-2 and CSFV negative IB-RS-2 cells, no significant difference was 
observed. This supports an earlier study by House who claimed that the CSFV free clone 
of IB-RS-2 cells (IB-RS-2D10), showed similar sensitivity to FMD virus as the parent CSFV 
positive IB-RS-2 cells (House et al., 1988). Furthermore, this present study also shows no 
physical difference between CSFV positive and CSFV negative IB-RS-2 cells, which 
indicates the suitability of CSFV negative IB-RS-2 cells for FMD virus titration and VNT. 
The current VNT standard method requires 50 µl of CSFV positive IB-RS-2 cells 1 X 106 cell 
count per ml. This study revealed that these tests performed with the CSFV negative IB-
RS-2 cells require only 50 µl of 0.5 X 106 cells count per ml. The reduction in the number 
of cells is likely because the CSFV negative IB-RS-2 cells achieve higher growth rate than 
the CSFV positive IB-RS-2 cells, however, this hypothesis needs to be further explored. 
The 50% reduction of cell count per ml needed in the in-vitro methods leads to cost, time 
and resources reduction. Another significant advantage of the CSFV negative IB-RS-2 cells 
is the ability of handling outside high containment facility. This subsequently widens the 
application of the usage of these cells such as potential use for FMD virus amplification 
during vaccine production where the use of “clean” cells without adventitious viruses is 
essential. The results in this study emphasize the importance of IB-RS-2 cell stage 
(confluent cell) to be utilised in serological methods of FMD. Furthermore, the study 
indicated that CSFV present in the IB-RS-2 cultures does not have any significant impact 
upon their sensitivity to FMD virus, findings that are supported by the use of the CSFV 
negative IB-RS-2 cells for the propagation of FMD virus. 
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In-vitro vaccine-matching for foot-and-mouth 
disease virus: does bovine vaccinal sera (BVS) 
impact upon the reliability of serological 
immune responses? 
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3.1 Abstract  
 
Systematic vaccination is a proven tool to control foot-and-mouth disease (FMD) 
particularly in endemic areas. Effective vaccination programmes are usually reliant upon 
selecting a vaccine that is antigenically matched to the circulating FMDV field strains. In-
vitro vaccine matching tests provide important evidence for the selection of these 
vaccines; however, the virus neutralisation test (VNT) which is considered to be the gold 
standard method lacks in reproducibility which sometimes causes uncertainty in the 
vaccine virus selection process. This uncertainty becomes apparent when repeated 
testing for the same virus strains and the same vaccine sera generates relationship 
coefficient (r1 values) that are above and below the suggested antigenic-match cut-off 
(0.3).  Therefore, the aim of this study was to investigate the impact of using different 
bovine vaccinal sera (BVS) on the test results. In this study, BVS was produced in six cattle 
vaccinated and boosted with a high potency (at least 6PD50) A/May-97 monovalent 
vaccine. Serological testing used the vaccine virus A/May-97 (homologous) and a 
representative Malaysian field isolate (A/MAY/2/2011; heterologous) from a viral lineage 
with a history of low r1 values. VNT and liquid phase blocking ELISA (LPBE) were 
performed on individual and pooled BVS at different time points to determine antibody 
titres which were then used to calculate the relationship coefficient (r1 values). 
Generally, sera from all six animals showed a similar pattern of increased antibody titres 
measured by VNT and LPBE after vaccination against both homologous and heterologous 
viruses. For the LPBE, antibody titres for individual sera were repeatable when measured 
within the same day and between different days. For this assay, only animal-to-animal 
variability was significant, with this contributing 49.5% and 57.2% of the variance in titres 
for sera collected at 21 dpv and 56 dpv, respectively. However, the data for the VNT were 
more variable, and the day-to-day variability contributed 47.4% of the variance for sera 
at 21dpv whereas, sera at 56dpv contributed 17.7% of the variance of the day-to-day 
variability. There was also significant animal-to-animal variability for sera tested by VNT. 
Pooling sera from different animals helped reduce the between-day variability of VNT. 
The inherent variability of these two assays was reflected in the r1 values that were 
measured, where the LPBE showed consistent values for individual and pooled sera. In 
contrast, r1 values determined using VNT were more variable above and below the 
suggested antigenic-match cut-off. This study revealed the inherent variability of the in-
vitro vaccine matching methods, the effect of sera collected at different sampling times, 
booster vaccination and pooling on serological immune response and the r1 values 
calculated. These findings highlight the importance of using standardised BVS to reduce 
some of this variation.   
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3.2 Introduction 
 
Foot-and-mouth disease virus (FMDV) serotype A is often considered to be the most 
antigenically variable among the seven FMDV serotypes (Knowles and Samuel, 2003). This 
high antigenic variability contributes to the complexity of FMD control, since antibodies 
induced by vaccination with one serotype A vaccine virus may have little or no cross-
protection against unrelated serotype A field isolates (Kitching et al., 1988; Knowles and 
Samuel, 2003). Therefore, in order for an FMD vaccine to be effective, the vaccine strain 
selected must be antigenically matched with the current field virus (Paton et al., 2005).  
Vaccine performance is ideally assessed using in-vivo methods in susceptible animal 
species that are vaccinated and challenged according to the European Pharmacopeia and 
OIE guidelines, but this approach is expensive, time consuming and also raises animal 
welfare concerns. Other approaches such as modelling techniques utilising FMDV capsid 
genetic sequence data along with antigenic cartography cannot yet accurately predict 
the suitability of a vaccine virus for a specific field isolate (Ludi et al., 2014). However, 
other studies have shown that phylogenetic distance between serotypes correlates 
reasonably well with antigenic distance measured by cross-reactivity to polyclonal 
antisera (Mateu, 1995). These insights have led to the development of in silico 
mathematical modelling tools that combine structural information to the amino acid 
sequence data, but these are not yet used for routine vaccine-matching (Reeve et al., 
2010).  
Virus neutralisation test (VNT) and the liquid phase blocking ELISA (LPBE) are in-vitro tests 
used to measure FMDV-specific antibodies that work in different ways. VNT utilises 
susceptible cell cultures to measure the ability of a serum to neutralise a virus dose of a 
100TCID50, where cytopathic effect (CPE) is used as the indicator for neutralisation. On 
the other hand, for the LPBE, rabbit polyclonal antibody raised to strain specific FMDV is 
used as trapping antibody to bind a fixed dose of virus. A detector antibody (guinea pig 
polyclonal antibody raised to strain specific FMDV) is unable to bind if an FMDV antigen 
complexes with the test bovine antisera. The inhibition due to the formation of antigen-
bovine antibodies complexes can be measured to calculate a percent of inhibition (PI) 
value for the test. In summary, VNT only measures neutralising antibodies, whereas LPBE 
measures all antibodies (neutralising and non-neutralising) that bind to external epitopes 
on the virus capsid. It is thought that neutralising antibodies are more closely related to 
protection (McCullough et al., 1992; Reading and Dimmock, 2007), and are a better 
predictor of protection (Mattion et al., 2009; Robiolo et al., 2010).  
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For vaccine-matching using both the VNT and LPBE, the serological relationship is 
expressed as a relationship coefficient (r1 value) of the vaccine virus and field isolate.  
The r1 value indicating antigenic cross-reactivity between the two FMD viruses can be 
calculated by looking at the ratio of the heterologous and homologous virus neutralisation 
titres (Ferris and Donaldson, 1992; Rweyemamu, 1984). It is assumed that the closer the 
r1 value is to 1 the more antigenically similar the two FMD viruses are.  
There are reports indicated that r1 values suffer from high variability and do not always 
reflect the performance of a vaccine in host species. For example, high-potency vaccines 
were able to induce protection even though low r1 values were observed (Brehm et al., 
2008). Conversely, other studies concluded that only partial protection of the animals 
occurred despite high r1 value (European Commission, 2013). It has also been noted that 
r1 values generated from VNT are not reproducible (Tekleghiorghis et al., 2014). Variation 
between batches of sera can also lead to inconsistent results (Kitching et al., 1988). 
In this study, a pair of serotype A (lineage A/ASIA/Sea-97) FMD viruses were used; A/May-
97 vaccine virus (homologous) and A/MAY/2/2011 field isolate (heterologous). Focus was 
given on these viruses because retrospective vaccine matching data (2006-2017) from 
mainland Southeast Asia indicated that only 38% of A/ASIA/Sea-97 field isolates were 
antigenically matched to the Sea-97 vaccine virus A/May-97 (as described in Chapter 1 
section 1.13.2 of this study). However, in contrast to these poor r1 values from the 
laboratory tests, field observations on a dairy cattle farm in Malaysia showed no clinical 
FMD after vaccination with A/May-97, with antibody responses in individual animals that 
were indicative of protection (as described in Chapter 5 of this study); observations that 
indicate that the vaccine is effective. Therefore, the objectives of the work in this 
chapter were (i) to identify the inherent variability of the in-vitro vaccine matching 
methods, (ii) to investigate the effect of different sampling time on the serological 
immune response and r1 values, (iii) to determine the effect of booster vaccination on r1 
values and (iv) to determine the effect of pooling sera on r1 value. 
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3.3 Materials and methods 
 
 Selection and propagation of viruses (in addition, see Appendix i 
Phylogenetic tree for lineage A/ASIA/Sea-97 viruses) 
 
The FMDV serotype A vaccine strain (A/May-97) was provided by Boehringer Ingelheim. A 
representative serotype field isolate from Malaysia; A/MAY/2/2011, from the A/ASIA/Sea-
97 lineage with a history of poor vaccine matching (r1 value), was selected as the 
heterologous virus from the WRLFMD archive. This virus was collected in Kg Sawah, Port 
Dickson, Negeri Sembilan, Malaysia from Cattle on 3rd May 2011 and has been previously 
characterised by phylogenetic analyses based on the VP1 coding sequence (Knowles NJ, 
2016). In preparation for VNT, both viruses were passaged twice in the IB-RS-2 cell line 
(De Castro, 1964) to achieve virus titres of more than 3.0 log10. HEPES Modified Eagles 
Medium supplemented with 0.2% field antibiotic; mixture of penicillin (10MU), neomycin 
(25,000µg/ml), polymyxin B (100,000U/ml) and amphotericin B (field antibiotic) from 
central services unit (CSU), TPI and 0.4% sodium hydroxide solution (NaOH) from Sigma-
Aldrich was used for passaging cells. Viruses were propagated in 175mls flasks (Greiner 
Bio-One, Greiner Bio-One International GmbH) on a 100% confluent monolayer of IB-RS-2 
cells. For long term storage, glycerol was added to the viruses at ratio of 1:1 after the 
viruses were harvested. The viruses were titrated, aliquoted and stored at -80oC until 
used for the VNT or LPBE that is compared with cut-off values of Barnett et al (Barnett 
et al, 2003). 
 
 Production of bovine vaccinal sera (BVS)  
 
Six Holstein-Friesian calves aged 6 months were kept in a disease-free isolation 
experimental unit (Greenfields) at The Pirbright Institute, Compton Campus, UK. The 
calves were acclimatised for one week prior to the start of the experiment. At day 0, two 
millilitres (ml) of inactivated monovalent FMDV A/MAY-97 vaccine, with a minimum 
protective dose of 6PD50, was administered intramuscularly (kindly provided by 
MERIAL/Boehringer Ingelheim). Booster vaccination was carried out using the same dose 
and route of the vaccine at 21 days post vaccination (dpv). Fifty ml blood samples were 
collected at 0, 7, 14, 21, 28, 35, 42, 49 and 56 dpv from coccygeal vein of each calf into 
five plain (red top) 10ml vacutainers. These samples included collections on the day of 
initial vaccination and booster (days 0 and 21). After collection the tubes were brought  
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in a cool box to The Pirbright Institute, Pirbright, UK, and placed in a refrigerator at 4°C 
overnight. The tubes were then centrifuged at 2000g for 5 minutes using a bench 
centrifuge (model: Hettich Rotanta 460R) after which the sera were decanted. The sera 
were placed in a water bath at 56°C for 30 minutes to inactivate any viruses and 
complement factor that might have been present (according to Pirbright Institute 
biosecurity regulations) before aliquoted in 4 ml cryo-vials and stored at -20°C until use. 
 
 
Figure 3.1: An outline of the animal experiment designed to evaluate the effect of 
sampling interval and booster vaccination on vaccine-matching r1 values. Bovine 
vaccinal sera (BVS) was collected from six calves at regular intervals (0, 7, 14, 21, 28, 
35, 42, 49 and 56dpv) pre and post-vaccination, to evaluate the effect of sampling 
interval and booster vaccination on r1 values. 
 
 Production of pooled post-vaccination bovine sera  
 
Inactivated sera were tested individually and as pools. Three types of pooled sera were 
prepared by mixing an equal amount of individual animal sera (500μl) based on the initial 
neutralisation titre results: (i) two pools of sera from two animals; comprising either two 
individual animal sera with similar neutralisation titres or two individual animal sera with 
different neutralisation titres, (ii) three pools containing five individual animal sera: with  
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highest neutralisation titres, lowest neutralization titres and a mixture of low and high 
neutralisation titres and (ii) pools of all six individual animal sera collected at the same 
time-point after vaccination (Figure 3.2). 
 
 
 
Figure 3.2: Summary of different types of sera (individual and pools) used for the 
study. The approaches to prepare individual and pooled sera are highlighted. 
 
 Virus titration 
 
Dilutions of the stock virus were performed in bijou bottles containing HEPES Modified 
Eagles Medium supplemented with 0.2% field antibiotic and 0.4% NaOH. Four-fold virus 
titrations were carried out (in duplicate) in flat-bottom 96 well micro-titration plates 
(Fisher Scientific). A total of 50µl of an IB-RS-2 cell suspension at a cell count of 1 X 106 
cells/ml was dispensed into all wells. The plates were incubated at 37oC for three days 
before being examined by microscope for cytopathic effect (CPE) indicative of FMD virus 
replication. The TCID50 endpoint titre was calculated following the Spearman-Kärber 
method 1931 (Kärber, 1931; Spearman, 1908). The virus titre information was then used 
to determine the correct virus dilutions to generate 100TCID50 used for the VNT (described 
below). This study used a method similar to the WRLFMD protocol where titrations carried 
out must be within 0.3 log10 (two-fold) of the running mean for that virus. A virus titration 
plate was also run every time a neutralization test was carried out. 
 
 
Animal ID: 
284 & 279 
Animal ID: 
281 & 279 
Animal ID: 
279, 280, 
282, 283,284 
2284284 
Animal ID: 
280, 281, 
282, 283,284 
284 
Animal ID: 
279, 280, 
281, 283, 284 
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 Virus neutralisation test (VNT)  
 
All VNTs were performed in 96 well plates (Fisher Scientific). Both the vaccine and field 
viruses were tested simultaneously under the same conditions following the principles 
outlined in Chapter 2.1.8 Section D for vaccine matching test (OIE, 2017) and according 
to the WRLFMD protocol (SAU-SOP-4 and SAU-SOP-8). An additional serum control using 
FMDV A22 Iraq with the same BVS was included in every new experiment to monitor the 
serum control running mean of the experimental system. In short, HEPES Modified Eagles 
Medium (HMEM) supplemented with 0.2% field antibiotic (penicillin-streptomycin) and 
0.4% NaOH was used as media to dilute the sera and viruses. Viruses were pre-diluted in 
bijou bottles and three virus doses were set-up so that a four-fold dilution fell on either 
side of the estimated 100TCID50 (as described above). A total of 50µl of media were 
dispensed into each well of the plates except wells of top row (A). All sera were tested 
in duplicate wells. A total of 50µl of the tested sera were placed in the first two rows 
(row A and row B). Sera were serially diluted in two-fold down the plate starting from 
row B. A total of 50µl of the three virus doses were dispensed to designated wells 
containing the sera, after which the plates were then incubated at room temperature. 
After approximately 45 minutes, 50µl of IB-RS-2 cell suspension containing 1x106 cells/ml 
were dispensed to all wells. A sticky plastic seal was used to cover each plate, and the 
plates were incubated at 37oC for 72 hours before examined for neutralization (no CPE) 
under a microscope. Serum neutralisation titres at 50% for each virus doses were 
calculated using the Spearman-Kärber method (Kärber, 1931; Spearman, 1908). Finally, 
the TCID50 end point serum neutralization titre at a virus dose of 100TCID50 (2log10) was 
estimated using linear regression line of the three virus doses. The suggested protective 
cut-off used was at log101.4 (Barnett, 2003).  
 
 Liquid phase blocking ELISA (LPBE)  
 
Field FMDV isolate (A/MAY/2/2011) and vaccine virus (A MAY-97) were propagated in 
800ml roller bottles on an IB-RS-2 cell monolayer. The viruses were inactivated with 0.1M 
bromoethlyeneimine (BEI) twice followed by innocuity testing to ensure complete 
inactivation. For the innocuity test, a total of 5 bung tubes were prepared with confluent 
monolayer of primary bovine thyroid (BTy) cells for each virus.  Four bung tubes were 
inoculated with 0.2 ml of the BEI inactivated virus and one with PBS as control. The tubes 
were then examined for CPE daily for 3 days. The absence of CPE of all the 5 bung tubes 
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indicated that the virus was completely inactivated. Each virus was harvested from the 
four bung tubes (excluding the control bung tube) and were pooled and used in an antigen  
detection sandwich ELISA. An antigen detection sandwich ELISA was performed in 
accordance to the method described by Ferris et al. (Ferris and Dawson, 1988) to confirm 
the integrity and determine the titre of the FMDV antigens. The FMDV antigens then 
aliquoted and kept at -80oC until used. The LPBE was performed as described by Hamblin 
et al (C. Hamblin et al., 1986) according to the principle of LPBE illustrated in Figure 3.3. 
 
 
Figure 3.3: The principle of LPBE. In this assay a liquid phase was performed in a 
carrier plate and incubated overnight where the antigen antibody complex ( ) will 
form (between the hyper immune (test) sera and the FMDV antigen). The liquid phase 
was then transferred to the ELISA plate. The well of the ELISA contained trapping 
antibody (rabbit anti FMDV antibody for A/May-97) that trapped the antigen antibody 
complexes ( ) and any free FMDV present in the liquid phase. Subsequently, a guinea 
pig anti-FMDV antibody (capture antibody) is used to detect free FMDV antigen ( ). 
The capture antibody is then bound to the conjugate (Horseradish peroxidase 
conjugated rabbit anti-guinea pig immunoglobulin (DAKO- P0141)) and the chromogen 
substrate solution (O-phenylenediamine dihydrochloride (OPD)) that generates the 
colour in the test. Thus, more free antigens in the liquid-phase will give more colour, 
and hence a higher optical density (OD) will be read, which is inversely proportional 
to the FMDV-specific antibody titre. 
 
 
Briefly, for both the field isolate and the vaccine virus, flat bottom ELISA plates were 
coated with a pre-determined dilution of 100ul of rabbit anti FMDV A/May-97 sera 
[provided by the Serum Assay Unit, The Pirbright Institute (SAU, TPI)] as trapping 
antibody.  
C
s
Liquid phase ELISA plate
C
s Substrate (o-Phenylenediamine dihydrochloride)
Conjugate 
Rabbit Anti-FMDV antibody (A/May-97)
(Trapping antibody)
Antigen
Guinea pig anti FMDV antibody (A/May-97)
(Capture antibody)
Hyper-immune sera: antibody (A/May-97)
C
s C
s
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The coated ELISA plates were incubated overnight at room temperature. The liquid phase 
consisted of serial diluting the test sera using two-fold dilutions in duplicate wells with 
the respective FMD viruses. The volumes used were 50μl of sera and 50μl of pre-diluted 
FMDV virus suspension in U bottom 96 well plates (carrier plate). The plates were 
incubated in 1oC - 8oC overnight on an orbital shaker. The coated ELISA plates were 
washed with phosphate-buffered saline containing 0.05% Tween 80, 0.5M NaCl (PBST) 
three times and dried manually by tapping the plate on non-linen cloth (blue roll). Then, 
50μl of the liquid phase were transferred from the carrier plates onto the ELISA plates 
containing the trapping antibody. The ELISA plates were then incubated at 37oC for an 
hour before being washed again three times with PBST and dried manually. Fifty 
microliters of predetermined dilution guinea pig anti-serum (capture antibody) was added 
to each well of the ELISA plate and the plate was again incubated at 37oC. After one hour, 
the plates were washed three times and dried, after which 50ul of pre-diluted horseradish 
peroxidase conjugated rabbit anti-guinea pig immunoglobulin (DAKO – PO 141) in an equal 
volume of sterile glycerol was added to all the wells. Plates were incubated at 37oC for 
one hour before being washed four times and dried. A total of 50μl of substrate chromogen 
solution, o-phenylenediamine dihydrochloride (OPD) (Sigma, P-8412) mixed with 30% 
hydrogen peroxidase was added to all the wells and left at room temperature for 15 
minutes for colour to develop. A total of 50μl of 1.25M sulphuric acid was added to stop 
the reaction. Finally, the plates were read with an ELISA reader (V-Max model) at 490 
nm. 
 
The percentage of inhibition was calculated using the following formula: 
Percentage of Inhibition (PI%) = 100% – (Optical density (OD) of test serum well) x 100%   
                                                                     (Median OD of antigen control well) 
The antibody titres were expressed as the reciprocal of the final dilution of serum with 
50% percentage of inhibition sera were tested three times per day and at two different 
days and that with these results within and between day was tested.  
 
 Determination of r1 value 
 
The r1 value measures the antigenic cross-reactivity (matching) between a vaccine virus 
(homologous) and a field isolate (heterologous). The r1 value is calculated by dividing the 
neutralisation/total antibody titre against the heterologous with the neutralisation/total 
antibody titre of the homologous virus for VNT and LPBE. The closer the r1 value is to 1 
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the more antigenically similar the field isolate is to the vaccine virus. The OIE 
recommends the minimum suggested antigenic-match cut-off at 0.3 for VNT. Whereas, 
for the LPBE two level of minimum suggested antigenic-match cut-off; r1 = 0.2 – 1.0 and 
r1 = 0.4 – 1.0. With the higher level of r1 values (r1 = 0.4 – 1.0) suggested close relationship 
between field isolate and vaccine strain, where a potent vaccine containing the vaccine 
virus is likely to confer protection. An r1 value between 0.2-0.39 suggests that the field 
isolate is antigenically related to the vaccine virus. Where the vaccine virus might be 
suitable for use if no closer match can be found, provided that a potent vaccine is used 
and booster vaccination applied (OIE, 2017). The r1 value is calculated using the formula 
below. 
reciprocal arithmetic antibody titre of BVS against field virus 
reciprocal arithmetic antibody titre of BVS against vaccine virus 
   
Throughout this study, the r1 values were calculated independently and recorded for each 
test performed. 
 
 Statistical analysis  
 
Independent-t test was used to assess whether VNT performed by two different operators 
produce same or different results. Paired-t tests using Minitab (version 17) were carried 
out to determine whether the antibody titres after primary vaccination were different 
from the antibody titres after booster vaccination.  
In order to assess the within day and between days variability of the two in-vitro vaccine 
matching methods, linear mixed models with backward selection were constructed for 
the individual VNT and LPBE data at 21dpv and 56dpv. This is to determine the sources of 
the variation that may influence the test. Specifically, three models were considered for 
each analysis. These all included whether the sera were tested with homologous or 
heterologous virus (as a fixed effect), but differed in the sources of variation which may 
influence the test (as nested random effects). The first includes all the three parameters 
that may influence the test; different animals, test carried out at different days, and test 
repeats within a day. In the second, the three parameters were reduced to two: different 
animals and test carried out at different days. Finally, the third model only includes one 
parameter; different animals. The models were compared by considering the change in 
residual deviance to determine which of these sources of variation is significant (P<0.05). 
The statistical analysis of the VNT and LPBE data was carried out by Dr Simon Gubbins 
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(The Pirbright Institute) using the lme4 package (Bates, 2015) in R version 3.4.3 
(RCoreTeam, 2017) 
For the pooled sera general linear models were performed on VNT and LPBE data at 56dpv 
to assess within-day and between-days variability using Minitab (version 17). For each VNT 
and LPBE analysis, six different pooled sera as described in section 3.3.3 were included. 
The different pooled sera and virus (homologous or heterologous) factors as fixed effect 
whereas the test carried out on different days and repeats on the same days as random 
effects. The first model includes all the four factors that may influence the test; test 
carried out at different days, all the six different pooled sera, both homologous and 
heterologous virus and test repeated on the same day. In the second model, the four 
factors were reduced to three factors which includes test carried out at different days, 
all the six different pooled sera, both homologous and heterologous virus. Finally, the 
third model includes only two factors namely all the six different pooled sera, and 
homologous vs heterologous virus. The models were compared by considering the change 
in residual deviance to determine which of these sources of variation is significant 
(P<0.05).  
 
3.4 Results 
 
 Effect of booster vaccination on individual animal sera using VNT 
 
Post-vaccination sera from individual cattle collected over a period of 56 days were tested 
at seven-day intervals to assess the effect of primary vaccination and booster vaccination 
on the serological immune responses measured against the homologous (vaccine virus: 
A/May-97) and heterologous (field isolate: A/MAY/2/2011) viruses, as well as the derived 
vaccine-matching (r1) values for each of these measurements.  
The neutralisation titres against the homologous virus were significantly higher (P<0.05) 
than those against the heterologous virus. However, one animal (Animal 281) showed a 
different pattern of homologous virus neutralisation titres compared to other animals 
after primary vaccination (resulting in a higher heterologous titre than homologous titre 
on day seven). In this animal, the neutralisation titres increased in a more gradual manner 
and were lower than for the other animals, and without a marked peak response of the 
booster vaccination (Figure 3.4a and 3.4b). The homologous neutralisation titres of the 
other five individual animals increased after primary vaccination to reach the suggestive 
protective cut-off (1.4 log10) at 21dpv (Barnett et al., 2003). A further increase of the 
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neutralising antibody against the homologous virus was measured after booster to reach 
a peak in all animals at 35dpv. At 42dpv the neutralisation titres started to plateau until 
the last sampling point at 56dpv (Figure 3.4a). On the contrary, the heterologous 
neutralisation titres increased to a value of 1.28 log10 at 7dpv but then a plateau persisted  
until after the booster vaccination. The heterologous neutralisation titres took more than 
two weeks to increase beyond the suggestive protective cut-off (1.4 log10) and peaked at 
42dpv before starting to decrease (Figure 3.4b).  
Despite the increase in neutralisation titres in all animals, calculated r1 values for each 
homologous/heterologous virus pair were variable (Figure 3.5). Analysis on individual sera 
of all the six animals at different sampling times (7, 14, 21, 28, 35, 42, 49 and 56dpv) 
generated highly variable r1 values, both below and above the suggested antigenic-match 
cut-off (0.3). The r1 values for Animal 279 ranged from 0.18 to 0.71, Animal 280 from 
0.13 to 0.41, Animal 281 from 0.16 to 0.74, Animal 282 from 0.20 to 0.96, Animal 283 
from 0.32 to 0.49 and Animal 284 from 0.15 to 0.62. Only one individual sera (Animal 283) 
showed r1 values above the cut-off of 0.3 for all sampling time points, while sera from 
some animals (such as Animal 280) generated r1 values below 0.3 for the majority (five 
of eight) of the time points (Figure 3.5). 
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Figure 3.4: A time course of log10 neutralisation titre of specific antibodies against 
FMD viruses after primary and booster vaccination. The neutralisation titre against 
homologous virus (panel a) and heterologous virus (b) measured by VNT. The dashed 
line highlights 1.4 log10, the suggested protective cut-off for FMDV serotype A 
(Barnett et al., 2003).  
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Figure 3.5: The r1 values generated from neutralisation titres of six individual animals 
at the six sampling time points. The six individual animals represented by coloured 
diamonds. The black dashed line highlights 0.3, the minimum acceptable cut-off 
indicative of an adequate antigenic match (O.I.E, 2018). 
 
 Results for virus neutralisation test versus liquid phase blocking 
ELISA 
 
The serological immune responses and corresponding r1 values measured by VNT and LPBE 
were compared.  
Serological immune responses of sera collected at 21dpv and 56dpv had consistently 
higher antibody titres measured by LPBE compared to VNT (Figure 3.6). Both VNT and 
LPBE showed higher homologous serological responses than the heterologous responses 
for sera collected at 21dpv and 56dpv (Figure 3.6a, b, c and d). At 21dpv, three out of six 
animals had heterologous mean neutralisation titres that were lower than the suggestive 
protective cut-off (Figure 3.6a). By contrast, the total antibody titres measured by LPBE 
of all the six animals at 21 and 56dpv were above the suggestive protective cut-off (Figure 
3.6c and d). The r1 values of neutralisation titres and the total antibody titres were 
calculated for all individual animals (Figure 3.7a and b). For the neutralisation data three 
out of six animals showed similar mean r1 values for both 21dpv and 56dpv. Whereas, the 
other three of the six animals (Animals 279, 281 and 282) showed different mean r1 values 
at 21dpv and 56dpv with values below and above the antigenic-match cut-off for both  
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days. (Figure 3.7a). The r1 values generated using LPBE were less variable than those 
generated by VNT (Figures 3.7b). Nonetheless, different r1 values were observed using 
sera collected at 21dpv and 56dpv with the majority of mean r1 values for the 56dpv sera 
being below the suggested antigenic-match cut-of, while the majority of the r1 values 
using 21dpv sera were above the suggested antigenic-match cut-off (0.2) as in Figure 
3.7b. 
 
Figure 3.6: The mean log10 neutralisation and total antibody titres for six individual 
animals against the homologous and heterologous viruses at 21 and 56dpv. Every 
individual animal serum was tested in duplicate, replicated for three times and 
repeated at three different days; (a) mean neutralisation titres at 21dpv, (b) mean 
neutralisation titres at 56dpv, (c) mean total antibody titre at 21dpv and (d) mean 
total antibody titre at 56dpv. For VNT, the black-dashed line highlights log10 1.4, the 
protective cut-off for minimum neutralisation titres (Barnett et al., 2003), while for 
LPBE, log10 1.9 indicates the protective cut-off for the total antibody titres (Maradei 
et al., 2008).  
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Figure 3.7: The r1 values of individual animals at 21dpv and 56dpv generated from 
VNT titres and LPBE titres. The r1 value were calculated for each three replicate and 
three repeats. Panel (a) shows r1 values generated from VNT titres and panel (b) 
showed r1 values generated from LPBE titres. The cut-off(s) for the r1 value are 
highlighted on the y-axis. The black dashed line highlights 0.3; the minimum 
acceptable cut-off point for r1 values generated by VNT (OIE, 2017). Two back dashed 
line highlight 0.2 the minimum and 0.4 the preferred acceptable cut-off point for r1 
values generated using LPBE (Ferris and Donaldson, 1992). 
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 Influence of pooled sera after vaccination  
 
Pooled sera of multiple different combinations were tested to assess the influence of 
pooling on the variability of the serological immune responses measured by VNT and LPBE 
and corresponding vaccine-matching results (r1-values). 
 
To assess the effect of pooling on serological immune responds, pooled sera were tested 
alongside the sera from the component individual animals. Both pools that comprised sera 
from two animals (Animals 279 + 283 that showed similar neutralisation titres, and 
Animals 282 + 284 that had very different neutralisation titres) showed similar patterns 
with the VNT and LPBE. Both neutralisation and total antibody titre against the 
homologous virus were higher than the titre against the heterologous virus for individual 
and pooled sera of (the individuals and pooled sera of the two). Further investigation on 
the effect of pooled sera and the corresponding calculated r1 values were carried out 
using four different pools constructed using sera from multiple different animals. These 
pooled sera were prepared based on the level of neutralisation titres measured for the 
individual animals (see section 3.3.3 for details). In general, these results had a similar 
pattern to the data generated for individual sera: both the neutralising and the total 
antibody titres of the homologous were higher compared to the heterologous titres 
(Figure 3.8a and b), and the titres measured using LPBE were consistently higher than the 
neutralizing antibody titres measured by VNT (Figure 3.8a and b). The r1 values for the 
pooled sera showed less variability with the LPBE than with the VNT, as was also seen 
with the previous analysis on individual sera. 
The range of the r1 values generated using VNT titres of different the pooled sera were 
varied; pooled of high: 0.22 to 0.36, pooled of low: 0.23 to 0.63, pooled of mix: 0.17 to 
0.56 and pooled of all the six sera: 0.16 to 0.44. On the other hand, a tighter range of r1 
values was observed when using LPBE titres. For these LPBE data the ranges were 0.18 – 
0.25 for pooled of high, for pooled of low 0.13 – 0.25, pooled of mix 0.18 – 0.25 and for 
the pooled of all the six sera 0.18 – 0.25 (Figure 3.9a and b). These analyses indicated 
that the r1 values of the pooled sera generated from VNT titres were more variable than 
the r1 values generated from the LPBE titre. 
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Figure 3.8: Pooled sera at 56dpv neuralisation and total antibody titres measured for 
four different sera pools using VNT and LPBE. Every sera pool was tested using (a) VNT 
and (b) in duplicate, replicated for three times and repeated at three different days 
against the homologous and heterologous. Both the mean neutralisation titres and 
mean total antibody titres were measured in log10 with the mean indicated by the 
bar and the line indicating the standard deviation. The cut-off for the mean 
neutralisation and total antibody titres is highlighted on the y-axis. The black dashed 
line highlights log10 1.4; the protective cut-off for the VNT (3.8a) (Barnett et al., 
2003) and log10 1.9; the suggestive protective cut-off for LPBE (3.8b) (Maradei et al., 
2008). 
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Figure 3.9: The r1 values generated for four different sera pools at 56dpv.  
 
(a) r1 value generated from VNT titres and (b) r1 value generated from LPBE titres. On 
the x-axis are the animal identification numbers. The cut-offs for the r1 value are 
highlighted (as dashed lines) on the y-axis: 0.3, the antigenic match cut-off point for VNT 
(3.9a) (O.I.E, 2018), and 0.2, the minimum cut-off point, or 0.4, the preferred acceptable 
cut-off point for LPBE (3.9b) (Ferris and Donaldson, 1992). 
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 Repeatability of virus neutralisation test and liquid phase blocking 
ELISA results 
 
 Comparison of virus neutralisation test by two different operators 
 
Neutralisation titres of BVS collected at 21dpv and 56dpv against the homologous virus 
were generated by two different operators on two different days. The results are shown 
below (Table 2.1), with Operator 1 producing consistently lower titres compared to 
Operator 2.  Although the results were not identical, these differences were not 
statistically significant. Furthermore, 7/12 of the results were within a two-fold dilution. 
As expected, for both operators, all boosted individual sera (56dpv) showed higher serum 
neutralisation titres compared to sera from cattle receiving only one vaccination. 
 
Table 3.1: The log10 virus neutralisation titres of the homologous virus (A/MAY-97) 
against the same six BVS by two different operators on different days. 
Animal identification (ID) 
(serum) 
OPERATOR 1 OPERATOR 2 
21dpv 56dpv 21dpv 56dpv 
279 1.80 2.85 1.95 3.15 
280 1.95 2.55 1.95 3.15 
281 1.35 2.55 1.95 2.85 
282 1.50 2.70 2.10 3.00 
283 1.35 2.85 1.80 3.00 
284 1.50 2.40 1.80 2.85 
 
 Within day and between day variability  
 
 Individual sera 
 
Post primary and booster vaccination of individual and pooled sera were tested repeatedly 
within the same day and across different days to determine the source of the inherent 
variability of the in-vitro vaccine-matching methods (VNT and LPBE).  
The result for the model built and compared to determine the source of the inherent 
variability are shown in table 3.2. For VNT applied to individual sera at 21dpv and 56dpv, 
there was no significant (21dpv: p=1.0 and 56dpv: p= 1.0) variation in titres within a day, 
but there was significant (21dpv: p=0.004 and 56dpv: p= 0.0007) variation both (i) 
between days and (ii) between animals. However, the contribution of the sources of 
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variation differed between the time points. At 21 dpv, day-to-day variability contributed 
47.4% of the variance, while between animal variability contributed only 0.4% of the 
variance. By contrast, at 56 dpv, day-to-day variability contributed 17.7% of the variance, 
while between animal variability contributed 25.7% of the variance. For LPBE applied to 
individual sera at either 21 dpv or 56 dpv, there was no significant (21dpv: p=0.4 and 
56dpv: p= 0.14) contribution of within day or between-day variability to the variance in 
titre. Only animal-to-animal variability contributing 49.5% and 57.2% of the variance in 
titres for sera collected at 21 dpv and 56 dpv, respectively. The estimated R1 values 
based on VNT were 0.32 (95% confidence interval (CI): 0.27 to 0.38) at 21 dpv and 0.27 
(95% CI: 0.23 to 0.33) at 56 dpv. The estimated R1 values based on LPBE were 0.25 (95% 
confidence interval (CI): 0.23 to 0.28) at 21 dpv and 0.15 (95% CI: 0.13 to 0.17) at 56 dpv 
(Figure 3.10).  
 
Table 3.2: Three models were built namely Model 1: Individual animal/different 
days/replicates in a day, Model 2: Individual animal/different days and Model 3: 
Individual animal. The models were compared for both in-vitro methods (VNT and 
LPBE) and sera collected at 21dpv and 56dpv.” 
Method Sera Models AIC p value 
VNT 21dpv 
 
 
 
 
Model 1: Individual animal/different 
days/replicates in a day 
Model 2: Individual animal/different days 
-27.34 
 
-29.34 
1.0 
Model 2: Individual animal/different days 
Model 3: Individual animal 
-29.34 
-23.00 
0.004** 
56dpv Model 1: Individual animal/different 
days/replicates in a day 
Model 2: Individual animal/different days 
41.80 
 
39.80 
1.0 
Model 2: Individual animal/different days 
Model 3: Individual animal 
39.80 
49.24 
0.0007*** 
LPBE 21dpv Model 1: Individual animal/different 
days/replicates in a day 
Model 2: Individual animal/different days 
-108.45 
 
-110.45 
1.0 
Model 2: Individual animal/different days 
Model 3: Individual animal 
-110.45 
-111.68 
0.4 
56dpv Model 1: Individual animal/different 
days/replicates in a day 
Model 2: Individual animal/different days 
-113.40 
 
-115.40 
1.0 
Model 2: Individual animal/different days 
Model 3: Individual animal 
-115.40 
-115.22 
0.140 
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Individual sera (Individual & 
pooled sera) 
Individual sera (Individual & 
pooled sera) 
( ) (I i i l r ) 
 Pooled sera 
 
Analysis of VNT and LPBE on different combinations of pooled sera collected at 56dpv 
showed no significant differences within and between days test for VNT (p=0.70 and 
p=0.10, respectively) and LPBE (p=0.33 and p=0.44, respectively). These results indicated 
that pooling sera at 56dpv reduces the day-to-day variability of the neutralising antibody 
measured by VNT.  
 
  
 
Figure 3.10: Box plots representing the r1 values of the individual and pooled sera 
tested using LPBE and VNT at 21dpv and 56dpv. On the x-axis are VNT and LPBE 
carried out on sera collected on 21dpv and 56dpv. The dense black line in the box 
indicated the mean while the upper and lower whiskers represented standard 
deviation at 95% confidence interval.  
 
 
3.5 Discussion 
 
The overall aim of this chapter was to determine how the origin of bovine vaccinal sera 
(BVS) impacts upon results generated by in-vitro vaccine matching methods. The 
experiments focused on serotype A which is considered to be the most genetically and 
antigenically diverse among the FMDV serotypes (Knowles and Samuel, 2003). VNT and 
LPBE were performed on the A/May-97 (homologous) and A/MAY/2/2011 (heterologous) 
viruses using individual and pooled BVS. These viruses were selected based on previous 
poor r1 values and the retrospective vaccine matching data collected from 2006 to 2017 
at WRLFMD. In contrast to experiences from the field, these data indicated that the 
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A/May-97 vaccine virus is not likely to confer protection against the serotype A FMDVs 
(from the A/ASIA/Sea-97 lineage) circulating in Malaysia. 
Cattle were vaccinated using a vaccine produced commercially to ensure the quality, 
purity and safety of the vaccine. This particular high-potency vaccine (of at least 6PD50) 
and formulation mirrored the field situation in Malaysia. The BVS was produced from FMD 
naïve cattle to ensure no pre-existing FMDV antibodies could interfere with the results. 
As expected, both VNT and LPBE revealed that the neutralising and total antibody titres 
of the BVS against the homologous virus were consistently higher than antibody titres 
against the heterologous virus (Oh et al., 2012; Pay and Hingley, 1987).  
Neutralising antibodies measured by VNT correlate with protection (Barnett et al., 2003; 
Maradei et al., 2008; Pay and Hingley, 1987; Van Maanen and Terpstra, 1989). 
“Protective” cut-off values have been established to measure post-vaccination responses 
using VNT (Barnett et al., 2003) and LPBE (log10 1.9: (Maradei et al., 2008). In this study, 
all samples tested by LPBE at 21 dpv were above the protective cut-off, while all 
corresponding values for the VNT were below the neutralisation cut-off. Although LPBE 
titres indicated that all animal reached “protective” heterologous titres after a single 
dose of vaccine, these findings indicated that single vaccination did not necessarily elicit 
high enough neutralising antibody titres to protect the cattle against the heterologous 
virus (A/MAY/2/2011). However, conclusions regarding the level of protection of 
individual animals based solely on serological cut-off values are not always reliable. 
Indeed, other researchers claim that the serological immune responses can only be used 
as a guide (McCullough et al., 1992) and that protective humoral responses are dependent 
on other factors such as antibody avidity and spectrum of the antibody response (Siegrist, 
2013). For the purpose of assessing immunity at population level, the FMD Post 
Vaccination Monitoring (PVM) guide suggests that protective cut-offs should be adjusted 
depending on the size and dynamic of the population (Ferrari et al., 2016). It is also 
important to recognise that there are different methods used to determine protective 
responses in animals. In South America, researchers commonly use 75% expected 
percentage of protection (Maradei et al., 2008), while others use titres at which animals 
are protected with probability of 50% (Barnett et al., 2003). Thus, currently there is no 
clear and harmonised approach used to define serological cut-off values that correlate 
with protection. The effect of booster vaccination was measured at 56dpv where both 
VNT and LPBE antibody titres (for the homologous and heterologous viruses) were above 
the suggestive protective cut-off. These findings support importance of a booster dose 
particularly to increase the heterologous neutralisation antibody titres beyond the 
suggested protective cut-off for both VNT and LPBE (Knight-Jones et al., 2016). 
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Sera collected from these vaccinated animals was used for vaccine-matching. The r1 
values generated from VNT titres showed variable results for sera collected at 21 dpv 
(above and below the suggested antigenic match cut-off point of 0.3), whereas LPBE 
generated more consistent r1 values (above the lower level antigenic match cut-off of 
0.2) for 5 out of 6 animals. These conflicting results are representative of the difficulties 
that are often experienced by FMD Reference laboratories (such as WRLFMD, at TPI), 
where variability in vaccine matching data can lead to uncertainty in the selection of an 
appropriate vaccine. Analysis undertaken in this study, indicated that for VNT there were 
two main sources of this inherent variability: one factor was day-to-day variability, and 
the other was differences between sera collected from different individual animals. Based 
on this knowledge, it can be concluded that in order to reduce the inherent variability of 
VNT, both the homologous and heterologous viruses need to be tested simultaneously on 
the same day. It can be expected that repeating the vaccine matching test by VNT on 
different days will provide a range of r1 values for the particular viruses tested. 
Furthermore, VNT method requires personnel to read the CPE by eye using the 
microscope. Therefore, the outcome of the results may vary between personnel 
depending on the personnel’s sensitivity to recognise the CPE, although operator-to-
operator differences measured in this study were not significant.  
The other source of the inherent variability affecting both the VNT and the LPBE was 
identified as the individual animal sera used. Fortunately, this source of inherent 
variability can be reduced by pooling sera irrespective of the number of sera (ranging 
from 2 to 6) and the type of sera (highest, lowest, mix and all). Other researchers have 
reported similar observations about the impact of pooling sera to reduce inter-animal and 
inter-trial variation (Mattion et al., 2009). However, to limit the influence of outliers, 
Brehm et al. advised to make pools comprising of five sera from different individual 
animals (Brehm et al., 2008) which is also an approach recommended in the OIE Manual 
of Diagnostic Test and Vaccine for Terrestrial (OIE, 2017). The reason that pooling 
decreases variability is unknown. However, it might be due to the different quality of the 
antibodies such as the avidity, specificity or neutralising capacity in the serum produced 
by different individual animals. Therefore, pooling serum from different animals lowers 
the variability in the total antigen antibody complexes exhibit by LPBE titre or neutralising 
antibody as in VNT titres.  
Although some sources of inherent variability of VNT and LPBE have been identified in 
this Chapter, and mitigation measures have been laid out to achieve more precise results, 
the issue with the variability of r1 values above and below the cut-off still persist. 
However, since the suggested antigenic-match cut-off is a fixed value for VNT and LPBE, 
regardless of the FMDV serotypes or strains, r1 values for the same viruses may include 
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determination above and below the expected matched threshold. For the VNT, these 
range of r1 values are probably due to the fact that the r1 values were calculated from 
neutralisation titres which allow log10 0.3 (two-fold dilution) more or less than the running 
mean. Since r1 values are derived by dividing the heterologous and homologous titres, 
the differences between repeated values can be widened by the variability of the test. 
This high variability for VNT is not taken into account in the r1 value cut-off. In contrast, 
in-vitro vaccine matching using LPBE method where the day-to-day variability has no 
significant influence on the result the cut-off point for the r1 value is in a range that cater 
for some variability.  
In summary, this work shows that LPBE is a more reproducible in-vitro method to measure 
post FMD vaccination serological immune responses compared to VNT as mentioned by 
other researchers (Robiolo et al., 2010). This finding is also in agreement with other 
reports that LPBE showed less variation than VNT (Tekleghiorghis et al., 2014; Van Maanen 
and Terpstra, 1989). The present study observed precision in LPBE for measuring the total 
antibody titres and r1 values within the group of sera at 21dpv or 56dpv. However, the 
degree to which these r1 matching values relate with protection was not assessed in this 
study since there was no challenge experiment involved. This is an important deficiency 
of the current in-vitro vaccine matching result since they do not take into account 
neutralisation or total antibody titres in determining the antigenic relationship. Hence, 
future work to assess the accuracy of the in-vitro vaccine matching test is suggested. This 
could include in-vivo challenge experiments and humoral antibody measurements 
(including isotyping and avidity ELISAs (Brito et al., 2014; Capozzo et al., 1997; Lavoria 
et al., 2012). 
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: 
 
Influence of viral antigen factors in in-vitro 
vaccine matching: does FMDV capsid integrity 
have an impact upon the reliability of 
serological immune responses? 
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4.1 Abstract  
 
Foot-and-mouth Disease (FMD) virus is sensitive to high temperature and pH < 6.5 resulting 
in dissociation of the virus capsid that contains the determinants that define virus 
antigenicity. Therefore, it is vital to understand the impact of FMD virus integrity on in-
vitro vaccine matching assay particularly virus neutralisation test (VNT), which is 
currently recognised as the gold standard to determine the suitability of vaccine virus. 
Without excipient (glycerol) to stabilise the virus, mild heat treatment at 45°C of FMD 
viruses indicated that the capsid integrity of the field isolate is more heat stable 
compared to vaccine virus as determined by Llama single-domain antibody fragments 12S 
double antibody sandwich ELISA (VHHs DAS ELISA) and virus titration methods. A similar 
result was seen using the particle stability thermal release assay (PaSTRy) that the 
relative stability of FMD vaccine virus (A/May-97 at 53.3°C) was lower compared to two 
field isolates (A/MAY/2/2011 at 56.5°C and A/VIT/13/2015 at 56°C). Subsequently a 
stabilised vaccine virus and field isolate were tested with VNT and liquid phase blocking 
ELISA (LPBE) to assess the impact of dissociated virus particles (DVPs) contained in FMD 
virus preparation upon in-vitro vaccine matching assays. These studies identified that 12S 
capsid particles compete the intact capsid (146S) to bind antibodies that would otherwise 
be available in in-vitro vaccine matching methods resulting in an artificial decrease in 
neutralisation titres (measured by VNT) and FMDV total antibody titres (measured by 
LPBE). Additionally, variable 12S amount were detected in 10 FMD viruses of the same 
lineage (A/ASIA/Sea-97) and eight FMD viruses of the same lineage (A/ASIA/Iran-05). 
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4.2 Introduction 
 
Success of foot-and-mouth disease (FMD) control campaigns by vaccination is influenced 
by multiple factors particularly the quality and stability of the selected vaccine virus 
(antigen). It is well established that antigen integrity is imperative for effective FMD 
vaccine performance (Cartwright et al., 1980; Cartwright et al., 1982; Hingley and Pay, 
1987; Meloen and Briaire, 1980). However, the direct impact of FMD antigen integrity on 
the ability of in-vitro assays to measure specific antibody responses is yet to be fully 
understood.  
FMD virus is a small, non-enveloped, positive-sense single stranded RNA virus that belongs 
to the Picornaviridae family. Similar to other picornaviruses, the protein capsid of FMDV 
is made of 60 copies each of the four structural proteins (VP1, VP2, VP3, and VP4) 
arranged in an icosahedral lattice of 12 pentameric building blocks (Rueckert and 
Wimmer, 1984). Capsid proteins VP1, VP2 and VP3 are positioned externally, whereas VP4 
is concealed within the capsid and is predicted to be in contact with the viral RNA (Mateu, 
2017). The antigenic and immunogenic properties of FMD virus are mainly located in VP1 
of the capsid, complemented by other sites present in VP2 and VP3 structural proteins 
(Reeve et al., 2016; Thomas et al., 1988). However, FMDV capsid are particularly fragile 
compared to other members in the Picornaviridae family such as the enteroviruses.  
The established method to quantify FMD virus capsid particles uses sucrose density 
gradient (SDG) centrifugation developed by Barteling and Meloen (Barteling and Meloen, 
1974). Intact FMD virus capsids have a sedimentation coefficient of 146 in a sucrose 
gradient (146S). It is generally accepted that 146S is the antigenic component which 
stimulates protective antibody responses (Brown and Cartwright, 1961; Doel and Chong, 
1982a; Kotecha et al., 2015; Randrup, 1954). The 146S capsid dissociates under mildly 
acidic conditions at pH below 6.5 (Brown and Cartwright, 1961; Caridi et al., 2015), and 
at temperatures above 56oC (Brown and Crick, 1959). These conditions cause the 
irreversible dissociation of FMD virus capsid into twelve pentameric subunits, each with 
a sedimentation coefficient of 12S (12S capsid particles). It has also been reported that 
at temperatures above 37°C, the commercial inactivated FMDV vaccine can rapidly 
convert into these immunogenically incompetent 12S capsid particles (Doel and Chong, 
1982b). SDG method is laborious, time consuming and highly operator dependent. As 
alternatives to SDG centrifugation, the proportion of 12S can also be determined based 
on size-exclusion using high performance chromatography (HPLC) (Spitteler et al., 2011; 
Yang et al., 2015) although this method requires expensive specialized equipment. The 
12S can also be detected using a lateral flow immunoassay (Yang et al., 2015). An 
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alternative ELISA method has been developed and was used in this study. This method 
uses llama single-domain antibody fragments (VHHs) specific for 12S capsid components 
in a double antibody sandwich (DAS) ELISA to specifically quantify the 12S capsid particles 
present in a sample (Harmsen et al., 2011). The VHHs, also called Nanobodies®, are single-
domain functional antibody fragments that are fully capable of antigen binding without 
requiring domain pairing (Harmsen and De Haard, 2007). The word “double antibody” in 
DAS ELISA means that the same llama single-domain antibody (M3ggsVI-4Q6E) is used for 
both trapping and detection of 12S capsid particles. The advantages of VHHs DAS ELISA is 
that it is easier to perform, has higher sensitivity as well as higher sample throughput 
than SDG and HPLC (Harmsen et al., 2017).  
During FMD virus replication, in addition to 146S, there are empty capsid particles that 
are naturally produced. These empty capsid particles are the complete form of the FMDV 
capsid without the viral RNA inside. These are often referred to as “natural” empties or 
75S since they sediment at coefficient of 75 sucrose gradient. Although the 75S particles 
resemble the 146S in structure and antigenicity, they are inherently less stable 
(Basavappa et al., 1994). However, it has been demonstrated that 75S particles of FMD 
virus serotype A Cruzeiro are able to produce useful level of immunity but less effective 
than the intact capsid (146S) (Doel and Chong, 1982b). These different FMD virus capsid 
protein particles (146S, 75S and 12S) are present in FMD virus stocks and more so in FMD 
vaccine due to the production process (Rowlands et al., 1975). Moreover, the seven FMD 
virus serotypes are markedly different in their capsid stability. For instance, serotype A 
is reported to be relatively more stable than serotype O to heat and decreases in pH (Doel 
and Baccarini, 1981). However, since serotype A are reported to have high antigenic 
diversity (Knowles and Samuel, 2003); it is possible that there will be differences in the 
capsid stability between the serotype A virus lineages.  
Although protective antibody responses usually target epitopes expressed on the FMD 
virus capsid, serological immune responses of infected hosts recognise epitopes that are 
present both on the intact and dissociated capsid components (Cartwright et al., 1980). 
However, the 12S capsid particle of FMDV do not stimulate significant levels of 
neutralizing antibody (Cartwright et al., 1980; Randrup, 1954). The hypotheses of this 
chapter are that dissociated virus particles (DPVs) are present in virus and stocks used for 
the VNT and LBPE; that the presence of these DPVs compete with the ability of FMDV 
antibodies present in hyper-immune serum to bind to intact capsids (146S particles); and 
this will in turn influence the results of the in-vitro vaccine matching methods as 
illustrated in Figure 4.1 and 4.2, causing a reduction in antibody titres measured by both 
VNT and LBPE methods. This chapter explores these hypotheses through a series of 
experiments and also investigates the related question of whether viral capsid integrity 
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is the same for the antigenically diverse serotype A viruses of FMDV, which would cause 
any effect detected to be different for different viruses.  
 
 
Figure 4.1: The hypothesised impact of dissociated FMD virus particles (12S) on VNT.  
In this model, the dissociated capsid particles interact with the FMDV-specific 
antibodies available resulting in more free-infectious virus that can infect cells and 
cause cytopathic effect. Consequently, the presence of FMD virus dissociated capsid 
particles reduce the neutralization titre. 
 
Virus model 1 (more stable) Virus model 2 (less stable)
At same virus dose (e.g.: at 2 log)  
Higher neutralisation titre
Same virus dose (e.g.: at 2 log)  
Lower neutralisation titre
ANTIBODY
12S
INFECTIOUS 
VIRUS
75S
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Figure 4.2: The hypothesised impact of dissociated FMD virus capsid particles (12S) 
on LPBE. In this model, the dissociated FMD virus capsid particles bind to the 
antibodies available in the sera of the liquid phase. Infectious free virus can then bind 
to the guinea pig anti-FMDV, which capture the chromogen-substrate. Consequently, 
the presence of dissociated capsid particles increases the colour density that 
correlates to a reduction in the total antibody titres. 
 
4.3 Materials and methods 
 
 Study design 
 
The study design of this chapter involved four main experiments as described in Table 
4.1. In this study two different preparation of FMD virus that are non-glycerinated and 
glycerinated were used. Glycerol is routinely added as excipient to FMD virus stocks in 
order to increase their stability for future diagnostic serological assays such as VNT and 
LPBE. In Experiment 4.1, non-glycerinated A/May-97 (vaccine virus) and A/MAY/2/2011 
(field isolate) were heat-treated at 45°C to assess the effect of mild heat treatment on 
the production of 12S capsid particles measured using VHHs DAS ELISA and the impact of 
these dissociated viral particles (DPVs) on FMD virus titres. Experiment 4.2 was performed 
with thermostability assay using the particle stability thermal release assay (PaSTRy) to 
12S Infectious Virus75S
Rabbit Anti-FMDV sera (A/May-97)
Guinea pig anti FMDV sera (A/May-97)
Hyper-immune sera (A/May-97)
Carrier plate
50µl
Carrier plate
50µl
Virus model 1 (more stable) Virus model 2 (less stable)
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determine the capsid dissociation point of the vaccine virus (A/May-97) and two field 
isolates from the same region (A/MAY/2/2011 and A/VIT/13/2015). The findings from 
Experiment 4.1 and 4.2 were used to select the applicable temperature for Experiment 
4.3. Experiment 4.3 then tested whether the VHHs DAS ELISA generated different results 
when glycerinated FMD viruses (vaccine virus: A/May-97 and field isolates: A/MAY/2/2011 
and A/VIT/13/2015) were subjected to three temperatures (51°C, 56°C and 61°C). This 
experiment optimised the temperature and conditions required to fully dissociate the 
FMD viruses to produce Dissociated Virus Particles (DVPs) (described in detail in section 
4.3.7). Next, the optimal conditions were used to investigate the impact of glycerinated 
DVPs on FMD virus titres, and antibody responses using VNT and LPBE methods. For 
Experiment 4.3 three different individual sera collected at 21st and 56th day post 
vaccination (dpv) (Animal IDs: 281, 283 and 284; described in Chapter 3 section 3.3.2) 
were tested.  Finally, the fourth experiment (Experiment 4.4) was performed to assess 
whether there is variability in 12S particle produced by different FMD viruses of serotype 
A.   
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Table 4.1: The series of experiments carried out for chapter 4. 
  Experiment 4.1 Experiment 4.2 Experiment 4.3 Experiment 4.4 
Viruses: 
Vaccine virus 
Field virus 
A/May-97 
A/MAY/2/2011 
A/May-97 
A/MAY/2/2011 
A/VIT/13/2015 
A/May-97 
A/MAY/2/2011 
A/VIT/13/2015 
FMDV isolates 
from 2 different 
lineages: 
A/ASIA/Sea-97 
and 
A/ASIA/Iran-05 
Temperature 
for heat-
treatment 
45°C 
Range of 
temperatures: 
25°C to 94°C* 
51°C 
56°C 
61°C 
51°C 
56°C 
61°C 
Excipient**  No glycerol  No glycerol 50% glycerol 50% glycerol 
Detection 
method used 
to determine 
FMDV capsid 
degradation 
and FMDV 
specific 
antibody 
responses 
VHHs DAS ELISA 
Virus titration 
 
PaSTRy 
VHHs DAS ELISA 
Virus titration 
VNT 
LPBE 
VHHs DAS ELISA 
 
 
* N.B.: PaSTRy analyses were performed using a real-time PCR machine 
** Glycerol can be added at the ratio 1:1 to stabilise FMD viruses prior to storage. 
Therefore, adding glycerol to the viruses mimics the current VNT and LPBE methods used 
within the WRLFMD at Pirbright (where glycerol is added to FMD virus stocks for long-term 
storage). In this study, no glycerol was added to the viruses in experiments 4.1 and 4.2, 
whereas the other two experiments 4.3 and 4.4 glycerol was added to the untreated and 
the heat-treated viruses (Table 4.1). 
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 FMDV isolates 
 
Two FMD vaccine viruses and sixteen field isolates representing two serotype A lineages 
(A/ASIA/Sea-97 and A/ASIA/Iran-05) were selected from the repository held at the FAO 
World Reference Laboratory for FMD (WRLFMD) at The Pirbright Institute (TPI). For detail 
of the viruses see Appendix ii). All field isolates were treated with stabilised di-ethyl 
ether to destroy any adventitious lipid-containing organisms before propagation. These 
viruses were previously characterized by phylogenetic analyses (Figure 4.3) based on VP1 
coding sequences (Knowles NJ, 2016).  
 
 Virus propagation 
 
All viruses were propagated in 175ml flasks (Greiner Bio-One) on a 100% confluent 
monolayer of IB-RS-2 cells (De Castro, 1964). The media used for propagation of the 
viruses comprised HEPES Modified Eagles Medium supplemented with 0.2% field antibiotic 
containing mixture of penicillin (10MU), neomycin (25,000µg/ml), polymyxin B 
(100,000U/ml) and amphotericin B (field antibiotic from central services unit [CSU, TPI]) 
and 0.4% sodium hydroxide solution (NaOH from Sigma-Aldrich). Sterile glycerol 
(bidistilled analar from VWR International) was added to the FMDV at ratio of 1:1 after 
the viruses were harvested except for the viruses propagated in experiment 4.1. For this 
experiment A/May-97 (vaccine virus), and A/MAY/2/2011 (field isolate), were titrated 
and tested straight after harvesting; no glycerol was added (Table 4.1). For each 
experiment, all viruses were passaged to the same passage number. 
For the preparation of material for PaSTRy analysis in experiment 4.2, three FMD viruses 
were selected: A/May-97 (vaccine virus), A/MAY/2/2012 and A/VIT/13/2015 (field 
isolates). These three viruses were propagated in 175ml flasks (Greiner Bio-One) on a 
100% confluent monolayer of foetal goat epithelium cell lines (ZZR cells, (Brehm et al., 
2009) and passaged twice to propagate high amounts of virus required for purification 
prior to testing.  These viruses were not glycerinated before testing. 
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Figure 4.3: Phylogenetic analyses of field virus isolates used in this study. Midpoint-
rooted Neighbour-joining phylogenetic trees were constructed based on RNA 
sequences and visualised using MEGA 6.06. Bootstrap values above 70 are displayed 
next to branches. The phylogenetic tree was constructed by Dr Katarzyna Bachanek-
Bankowska. 
A/ASIA/Sea-97
A/ASIA/Iran-05
N.B.: All viruses were passaged in IB-RS-2 cells to the same 
passage no: 3 (RS 3) before use 
0.01 
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 Viral capsid dissociation 
 
Heat treatment, by placing the sample in a water bath for 30 minutes, was used to 
dissociate the FMDV capsid. For experiment 4.1, the temperature used was 45°C. For the 
other two subsequent experiments; experiment 4.3 and experiment 4.4, the viruses were 
heat-treated for 30 minutes in a water bath at 51°C, 56°C or 61°C (Table 4.1).  
 
 Llama single-domain antibody fragments, 12S double antibody 
sandwich ELISA  
 
The VHHs DAS ELISA to detect the FMDV capsid particle (12S) was carried out following 
the method described by Harmsen et.al (Harmsen et al., 2011) (Figure 4.4). All samples 
were tested in duplicate. Briefly, ELISA plates were coated with 100µl of M3ggsVI-4Q6E 
antibody (kindly provided by Dr Eva Perez, TPI) at a concentration of 0.5 mg/l in 
carbonate-bicarbonate buffer to capture FMDV antigen. The plate was then incubated at 
4°C overnight. After washing three times using phosphate buffer solution with Tween 
(0.05% Tween 20) (PBST):), 50µl of each sample was added in the designated wells. The 
plates were sealed and incubated at 37°C on a shaker for one hour. After washing three 
times, the ELISA plates were incubated again for one hour with 100µl per well of 
biotinylated version of the same M3ggsVI-4Q6E antibody (diluted to 0.1 ml/l in VHHs ELISA 
buffer) for detection of the captured 12S. The bound biotinylated M3ggsVI-4Q6E antibody 
was detected with 100 µl per well of streptavidin-HRP (SIGMA-ALDRICH) at a 1:1,000 
dilution in VHHs ELISA buffer before adding 50µl of O-phenylenediamine dihydrochloride 
(OPD; Sigma, P-8412) mixed with 30% hydrogen peroxidase per well. The VHHs ELISA 
buffer contained 1% skimmed milk; 0.05% Tween; 0.5M NaCl; 2.7mM KCl; 2.8mM KH2PO4; 
8.1mM Na2HPO4 at pH4.4. Finally, after 50ul per well of 1.25M sulphuric acid stopping 
solution was added, absorbance measurements were read at 490nm. Unlike the LPBE, the 
higher the OD reading, the higher amount of 12S FMDV capsid particle was present in the 
sample. 
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Figure 4.4: The principle of the VHHs 12S DAS ELISA. The M3ggsVI-4Q6E antibody are 
bound to the surface of an ELISA plate well to capture the 12S capsid particle (denoted 
as ). The same M3ggsVI-4Q6E antibody (biotinylated) is then used to detect the 
captured 12S capsid particle. Peroxidase-conjugated streptavidin-HRP ( ) is added, 
which will bind to the M3ggsVI-4Q6E antibody. The presence of enzyme is detected 
by substrate reaction (S).   
 
 Virus titration 
 
In order to assess the impact of 12S capsid particles on the FMDV titre, a titration series 
of the non-treated and heat-treated viruses were performed simultaneously using IB-RS-
2 cells for experiments 4.1 and 4.3 (Table 4.1). Prior to the virus titration of experiment 
4.3, the non-specific cytopathic effect (CPE) of glycerol (routinely added as excipient to 
virus stocks) was assessed. Glycerol was added to media at ratio of 1:1 with cell 
supernatants for each of the three viruses (A/May-97, A/MAY/2/2011 and A/VIT13/2015) 
and heat-treated at 61°C for 30 minutes, after which the viruses were tested in duplicate 
on the same plate titrated using a two-fold dilution series. The virus titration for 
experiment 4.1 and 4.3 were performed on the three viruses of the untreated and heat-
treated at three different temperatures 51°C, 56°C or 61°C for 30 minutes. These 
experiments consisted of a four-fold titration, in duplicate carried out in flat-bottom 96 
well micro-titration plates (Fisher Scientific) using a pre-diluted virus, which has an 
expected virus dose of 100TCID50. The plates were sealed and incubated at 37°C for three 
days before being examined by microscope for CPE. The 50% endpoint titre was calculated 
following the Spearman-Kärber method (Kärber, 1931; Spearman, 1908).  
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 Virus neutralisation test (VNT) 
 
The method for the VNT was described in Chapter 3, material and method section 3.3.5. 
Both the vaccine and field viruses were tested simultaneously under the same condition 
with modification (as described in (i) and (ii) below) to capture the effect of 12S capsid 
particle on VNT. Two preparations ((i) and (ii)) were made for both the vaccine viruses 
and field viruses: 
(i). Untreated - The viruses were prepared as standard with media (HMEM, field antibiotics 
and NaOH) as diluent to dilute the untreated and sera.  
(ii). “Dissociated Virus Particles” (DVPs) - Heat-treated viruses (detail in section 4.3.4) 
were used as diluent (to replace the media) to dilute the untreated and sera tested.  
For experiment 4.3, three virus doses were used. Dilutions were used so that a four-fold 
dilution fell on either side of the estimated 100TCID50. The r1 values of both the untreated 
and DVPs were calculated from neutralization titres at a virus dose of 100TCID50. 
Comparison of the neutralisation titres of the untreated and DVPs were carried out using 
a paired T test using Minitab version 17.  
 
Note: 
When one of the three virus doses showed no CPE (neutralization) in all designated wells 
the maximum, titre (3.15 log10) was accepted to draw the linear regression line in order 
to estimate the neutralisation titre.  
 
 Liquid phase blocking ELISA (LPBE)  
 
The liquid phase blocking ELISA (LPBE) was carried out for experiment 4.3 to assess the 
impact of 12S capsid particles on FMDV-specific antibody titres. Unlike the LPBE method 
used in Chapter 3, (described in material and method section 3.3.6), both the vaccine 
and field viruses were infectious (live viruses) used in the test. The untreated virus and 
DVPs preparations for LPBE were made the same way as VNT (detailed in 4.3.7). Both the 
untreated and DVPs of the vaccine virus and field virus were tested simultaneously as 
described in chapter 3, materials and methods section 3.3.6 (described by Hamblin et al. 
1986 (Hamblin et al., 1986)). In these experiments, post-vaccination sera collected at 21 
and 56dpv from three different cattle (Animal IDs 281, 283 and 284) were used. For the 
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field isolate, LPBE was performed using only the sera from one individual Animal ID 284 
at 21 and 56dpv. For this chapter, only optical density (OD) values were recorded and the 
total antibody titres were not calculated.  
 
 FMDV purification and capsid integrity assessment of homologous and 
heterologous viruses using PaSTRy method 
 
Three FMD viruses (vaccine virus: A/May-97, field isolates: A/MAY/2/2011 and 
A/VIT/13/2015) were tested using the PaSTRy method. Purification was carried out using 
a sucrose cushion method (Brown and Cartwright, 1963). Briefly, the cell lysates from 
infected monolayers of ZZR cells (in 175ml flasks) were clarified by centrifugation at 
2,060 g at 4 °C for 20 min to remove debris and 7.5% (w:v) PEG 6,000 was used to 
precipitate the virus in the supernatant. Precipitated viruses were resuspended in PBS, 
clarified and then pelleted over a 30% sucrose cushion by centrifugation at 104,000 g at 
12 °C for 2.5 h. Pellets were resuspended in PBS, overlaid onto a 15–30% sucrose gradient 
and then fractionated by centrifugation at 104,000 g at 12 °C for 3 h. The concentration 
of virus was determined by spectrophotometric quantification using the following 
formula: (OD260 × Total volume)/7.6) = mg of virus. 
The PaSTRy method that measures viral RNA when the capsid is dissociated was performed 
in accordance to Kotecha et al (Kotecha et al., 2016) using an Agilent MX3005 PCR 
machine (Walter et al., 2012). A total of 0.4 µg of virus and SYBR green-II dye (Molecular 
Probes, Invitrogen; final dilution 1:1000) was used to quantify the RNA released. 
Reactions were set up in 96-well PCR plate. Temperature was ramped from 25°C to 94°C 
in 0.5°C increments with 10 seconds intervals between temperatures. Fluorescence was 
read with the excitation and emission spectra at wavelengths of 490nm and 516nm to 
detect the release of viral RNA. Virus purification and PaSTRy method was carried out in 
collaboration with Dr. Julian Seago, from TPI.  
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4.4  Results 
 
 Experiment 4.1 
 
In this experiment, the VHHs DAS ELISA was conducted to assess the effect of mild heat 
treatment on non-stabilised (not glycerinated) FMD viruses for the production of 12S 
capsid particles. Using this assay, the OD value measured were an indicator of the 
presence of 12S capsid particles. The increase in the OD value after the mild heat 
treatment at 45°C of the A/May-97 (vaccine virus) was obvious (Figure 4.5a), but for 
A/MAY/2/2011 (field isolate) the increase in OD was very small (0.049, Figure 4.5b). 
Consistent with these results, the baseline OD values for these two viruses were also very 
different, with A/May-97 (vaccine virus) a higher OD (by a factor of 2.8 times) was 
measured which was indicative of more 12S capsid particles being present in the non-
heat-treated samples. Although the amount of 12S was not directly quantified in the 
assay, these observations suggest that the capsid integrity of the field isolate was more 
stable compared to the vaccine virus under storage conditions and after mild heat 
treatment. The virus titration performed in this experiment showed that the vaccine virus 
which was heat-treated at 45°C had a lower virus titre (5.43 log10) compared to the 
untreated vaccine virus (5.84 log10). However, for the field isolate, the untreated virus 
has a virus titre of 6.63 log10 which was only slightly lower than the heat-treated field 
virus (6.78 log10). These findings indicted that mild heat-treatment at 45°C was not 
sufficient to completely dissociate both the FMD viruses. Therefore, higher temperatures 
were used for the subsequent experiments 4.2, 4.3 and 4.4. 
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Figure 4.5: The amount of 12S capsid particle in FMDV measured using VHH DAS ELISA. 
Panel (a) A/May-97 (vaccine virus) and panel (b) A/MAY/2/2011 (field isolate). The 
amount of 12S capsid particles are measured by mean optical density (OD) on the y-
axis. On the x-axis are the treatment given to the viruses. The higher the OD value 
the more 12S capsid particles are present. 
 
 Experiment 4.2 
 
Viral capsid integrity assessment using the PaSTRy method  
 
The relative stability of the FMDV vaccine virus (A/May-97) and two field isolates 
(A/MAY/2/2011 and A/VIT/13/2015) were determined using PaSTRy analysis. First 
negative derivative plots of the respective dissociation curves are shown in Figure 4.6. 
The results show that A/May-97 (vaccine virus) was the most unstable, exhibiting peak 
RNA release (Tr), monitored as an indicator of capsid dissociation, at 53.5˚C. In 
comparison, the field isolates exhibited Tr values of 56.5˚C (A/MAY/2/2011) and 56.0˚C 
(A/VIT/13/2015).  
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Figure 4.6: FMDV capsid integrity monitored by PaSTRy method which detects the 
release of the viral genome over a temperature gradient as an indicator of capsid 
dissociation. Dissociation curves (negative first-derivative plot) obtained for A/May-
97 (blue), A/MAY/2/2011 (red) and A/VIT/13/2015 (green). Arrows indicate the 
temperature of viral RNA release (Tr) and hence capsid dissociation for each virus.  
These results are representative of three independent assays. 
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 Experiment 4.3 
 
This experiment assessed the effect of heat treatment on glycerinated (stabilised) FMD 
viruses and the impact of DPVs upon the results generated by VNT and LPBE methods. 
 
 VHHs DAS ELISA  
 
The effect of heat treatment of glycerinated viruses on the production of 12S capsid 
particles was assessed in a vaccine virus (A/May-97) and two field viruses (A/MAY/2/2011 
and A/VIT/13/2015). The three viruses were heat-treated at 51°C, 56°C and 61°C. All 
three glycerinated viruses tested showed different (in the range 0.1 to 0.2) initial OD 
values without any heat treatment, less variable and lower than the two non-glycerinated 
viruses from Experiment 4.1. With the heat treatment, the mean OD values for all three 
viruses increased with the increment of the temperatures (Figure 4.7a, b and c), and all 
three viruses showed the highest mean OD values after heat-treatment at 61°C (Figure 
4.7a, b and c), but still did not achieve the OD values of the non-glycerinated viruses 
(from Experiment 4.1).   
Preliminary experiments showed that when glycerol was added to media at a ratio of 1:1, 
a non-specific cell toxicity was generated similar in appearance to the viral cytopathic 
effect, and this response could also be detected when the glycerol was diluted further to 
1/2, 1/4 and 1/8, although this non-specific effect disappeared when glycerol was diluted 
at 1/16. Virus titrations were carried out on the three different FMD viruses for both the 
untreated and heat-treated at the three different temperatures simultaneously using the 
same IB-RS-2 cell suspension to determine whether the viruses had completely dissociated 
(i.e. no “live” FMD virus that indicates that 146S were absent). All of the three undiluted 
virus stocks [A/May-97 (vaccine virus) and A/MAY/2/2011 and A/VIT/13/2015 (field 
isolates)] contained glycerol at 1:1 ratio but this effect was reduced through dilution in 
media from the left to the right in the plate. 
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Figure 4.7: Effect of heating on the production of 12S capsid particles for the vaccine 
virus and field isolates of FMDV measured using the VHHs DAS ELISA. The three 
different colour panels represent (a) vaccine virus: A/May-97 (blue), (b) field isolate: 
A/MAY/2/2011 (red) and (c) field isolate: A/VIT/13/2015 (olive). The relative amount 
of 12S capsid particles are measured by mean optical density (OD) on the y-axis. On 
the x-axis are the treatment given to each of the viruses. 
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 Virus titration 
 
As expected, the virus titre of all the three viruses decreased with the heat treatment at 
51oC and further decreased with heat treatment at 56oC. Finally, with heat treatment at 
61oC, all three viruses failed to generate CPE in the cell cultures (no titre) (Figure 4.8). 
Results from this experiment indicated that heat-treated of glycerinated FMDV at 61oC 
for 30 minutes completely dissociated the viral capsid.  
 
 Virus neutralisation titre 
 
The effect of dissociated capsid particles on VNT and LPBE were investigated using 
individual cattle sera collected at 21 and 56dpv. The neutralisation titres determined 
using the A/May-97 (vaccine virus) and A/MAY/2/2011 (field isolate) of FMDV containing 
the DVPs material were consistently lower than the neutralisation titres generated with 
the control viruses (Figure 4.9a to 4.9f and 4.10a to 4.10f) for all three virus doses. 
However, variation was observed for sera of animal ID 284 at 21dpv and sera of animal ID 
283 at 56dpv against the A/May/2/2011 (field isolate) at virus dose 1.43 log10 (Figure 4.8f 
and 4.9d). Subsequently, when adjusted to 100TCID50 the neutralization titres of both 
viruses containing DPVs were always lower than the untreated controls viruses for all 
individual sera of animal ID at 21 and 56dpv (Table 4.2). However, all neutralisation titres 
of all sera tested were above the log10 1.4 cut-off. The paired T-test indicated that the 
neutralisation titres of the untreated virus were significantly higher compared to the 
neutralization titres of DVPs (p<0.05). The r1 values for the neutralization titres showed 
variable, values above and below the suggested vaccine-match cut-off (0.3) as in Table 
4.3. 
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Figure 4.8: Virus titres of three untreated FMD viruses compared to the heat-
treatment at 51oC, 56oC and 61oC. Individual CPE data (indicated by a +) for vaccine 
virus A/May-97 (blue), field viruses A/MAY/2/2011 (red) and A/VIT/13/2015 (olive) is 
shown where the top row shows the dilution of the virus from 1.2 log10 to 6.6 log10 
with a 0.6 log10 (4x) interval (in duplicate). 
 
Virus dilution 1.2 1.8 2.4 3.0 3.6 4.2 4.8 5.4 6.0 6.6
A/May-97
(Untreated)
+ + + + + + - - - -
+ + + + + + - - - -
A/May-97
(Heated at 51oC)
+ + + + + - - - - -
+ + + + - - - - - -
A/May-97
(Heated at 56oC)
+ + + + - - - - - -
+ + + + - - - - - -
A/May-97
(Heated at 61oC)
- - - - - - - - - -
- - - - - - - - - -
Virus dilution 1.2 1.8 2.4 3.0 3.6 4.2 4.8 5.4 6.0 6.6
A/MAY/2/2011
(Untreated)
+ + + + + + + - - -
+ + + + + + + - - -
A/MAY/2/2011
(Heated at 51oC)
+ + + + + + - - - -
+ + + + + + - - - -
A/MAY/2/2011
(Heated at 56oC)
+ + + + + - - - - -
+ + + + - - - - - -
A/MAY/2/2011
(Heated at 61oC)
- - - - - - - - - -
- - - - - - - - - -
Virus dilution 1.2 1.8 2.4 3.0 3.6 4.2 4.8 5.4 6.0 6.6
A/VIT/13/2015
(Untreated)
+ + + + + + + + + -
+ + + + + + + + - -
A/VIT/13/2015
(Heated at 51oC)
+ + + + + + - - - -
+ + + + + - - - - -
A/VIT/13/2015
(Heated at 56oC)
+ + + + + - - - - -
+ + + + - - - - - -
A/VIT/13/2015
(Heated at 61oC)
- - - - - - - - - -
- - - - - - - - - -
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Figure 4.9: Neutralisation titres of individual sera for animal ID 281, 283 and 284 
collected at 21dpv. The three different panels where (+) and (-) represents wells with 
and without CPE, respectively are (a) and (b) for animal ID 281 against vaccine virus 
and field isolate, (c) and (d) for animal ID 283 against vaccine virus and field isolate 
and (e) and (f) for animal ID 284 against vaccine virus and field isolate. Boxes with the 
shades of navy blue and light blue represent the neutralization titres against vaccine 
virus at three virus doses (3.0, 2.4 and 1.8 log10). Boxes with shades of red and pink 
represent the neutralization titres against field isolate at three virus doses (2.63, 2.03 
and 1.43 log10). The maximum titre (3.15 log10) was accepted for DVPs of the 
heterologous virus for individual sera of animal ID 281 collected at 21dpv (b).  
A/May-97 dilution in media
281 at 21dpv
A/May-97 dilution in 
dissociated virus particles 
281 at 21dpv
3.0 2.4 1.8 3.0 2.4 1.8
- - - - - - - - - - - -
- - - - - - + - - - - -
+ + - - - - + + + - - -
+ + + + - - + + + + + +
+ + + + + - + + + + + +
+ + + + + + + + + + + +
+ + + + + + + + + + + +
+ + + + + + + + + + + +
A/MAY/2/2011 dilution in 
media
281 at 21dpv
A/MAY/2/2011 dilution in 
dissociated virus particles 
281 at 21dpv
2.63 2.03 1.43 2.63 2.03 1.43
- - - - - - - - - - - -
- - - - - - + + - - - -
+ + - - - - + + + + - -
+ + - - - - + + + + - -
+ + - - - - + + + + + +
+ + + - - - + + + + + +
+ + + + - - + + + + + +
+ + + + - - + + + + + +
A/May-97 dilution in media
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Figure 4.10: Neutralisation titres of individual sera for animal ID 281, 283 and 284 
collected at 56dpv. The three different panels where (+) and (-) represents wells with 
and without CPE, respectively are (a) and (b) for animal ID 281 against vaccine virus 
and field isolate, (c) and (d) for animal ID 283 against vaccine and field isolate and (e) 
and (f) for animal ID 284 against vaccine virus and field isolate. Boxes with the shades 
of navy blue and light blue represent the neutralization titres against vaccine virus at 
three virus doses (3.0, 2.4 and 1.8 log10). Boxes with shades of red and pink represent 
the neutralization titres against field isolate at three virus doses (2.63, 2.03 and 1.43 
log10). The maximum titre (3.15 log10) was accepted for DVPs of the field isolate for 
individual sera of animal ID 281, 283 and 284 (a, c and e respectively) of sera at 
collected 56dpv against the untreated vaccine virus.  
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Table 4.2: The neutralisation titres at 100TCID50 for A/May-97 (vaccine virus) and 
A/MAY/2/2011 (field isolate) including DVP compared to the untreated controls. Three 
sera of different individual animals were used for these studies was collected at 21 
and 56dpv. Neutralisation titre of >log101.4 is indicative of protective cut-off. 
Animal 
Id 
Sampling 
time 
Viruses 
 
Neutralisation titres 
(Untreated) 
Neutralisation titres 
(DVP) 
281 21dpv Vaccine virus 1.96 1.60 
283 21dpv Vaccine virus 2.40 1.85 
284 21dpv Vaccine virus 2.10 1.76 
281 56dpv Vaccine virus 3.21 2.80 
283 56dpv Vaccine virus 3.46 2.91 
284 56dpv Vaccine virus 3.26 2.76 
281 21dpv Field isolate 2.46 1.47 
283 21dpv Field isolate 1.82 1.58 
284 21dpv Field isolate 1.98 1.85 
281 56dpv Field isolate 2.52 2.18 
283 56dpv Field isolate 2.57 2.48 
284 56dpv Field isolate 2.72 2.22 
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Table 4.3: The corresponding r1 values of the untreated and DVPs of the homologous 
and heterologous viruses for three different sera at 21 and 56dpv. 
Animal 
Id 
Sampling 
time 
r1 value (Untreated) 
 
r1 values (DVP) 
 
281 21dpv 3.16 0.73 
283 21dpv 0.26 0.53 
284 21dpv 0.75 1.25 
281 56dpv 0.20 0.24 
283 56dpv 0.13 0.37 
284 56dpv 0.29 0.29 
 
N.B.: In red are r1 values below the antigenic-match value (0.3) recommended by the 
OIE  
 
 Liquid phase blocking ELISA (LPBE) 
 
The effect of the DVPs on FMDV-specific antibody titres (for three individual sera, 
collected at 21dpv and 56dpv) measured with LPBE were assessed. The total antibody 
titres against the A/May-97 (vaccine virus) for all three sera with animal IDs 281,283 and 
284 at 21dpv and 56dpv showed that the mean optical density (OD) of the DVPs were 
consistently higher than the OD of the untreated virus (Figure 4.11a to 4.11d and 4.12a 
and 4.12b). In LPBE, higher ODs related to lower total antibodies titres. The LPBE was 
extended to determine the total antibodies titre of sera with animal ID 284 at 21 and 
56dpv against the A/MAY/2/2011 (field isolate) to determine the impact of 12S capsid 
particle. Similarly, the total antibodies titres against the field isolate using the same sera 
of animal ID at 21dpv and 56dpv showed higher mean optical density (OD) of the DVPs 
compared to the untreated field isolate of FMDV (4.12c and 4.12d). 
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Figure 4.11: Mean OD values generated with LPBE for two individual sera of animal ID 
281 and 283 against A/May-97 (vaccine virus). The four panels are (a) animal ID 281 
at 21dpv, (b) animal ID 281 at 56dpv, (c) animal ID 283 at 21dpv and (d) 2 animal ID 
283 at 56dpv. On the x-axis are the 2-fold serial dilutions of the sera. Line and 
markers with blue and green represent the mean OD values for the homologous virus.  
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Figure 4.12: Mean OD values generated with LPBE for individual sera of animal ID 284 
against A/May-97 (vaccine virus: blue and green plots) and A/MAY/2/2011 (field 
isolate: red and pink plots). The four panels are (a) animal ID 284 at 21dpv against 
vaccine virus, (b) animal ID 284 at 56dpv against vaccine virus, (c) animal ID 284 at 
21dpv against field isolate and (d) animal ID 284 at 56dpv against field isolate. On the 
x-axis are the 2-fold serial dilutions of the sera. 
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 Experiment 4.4 
 
Impact of heat treatment on capsid integrity; comparison of FMDV field isolates from two 
different serotype A lineages (A/ASIA/Sea 97 and A/ASIA/Iran 05) 
 
The impact of heat treatment on the capsid integrity by the production of 12S capsid 
particles for representative FMD viruses within two different lineages of FMDV serotype A 
were compared using the VHHs DAS ELISA. Viruses from both lineages showed a similar 
pattern with an increase in 12S capsid particles generated by heat-treatment as indicated 
by an increase in the OD values (Figure 4.13a and b). Without any heat treatment, all FMD 
viruses from both lineages contained 12S capsid particles corresponding within range of 
OD values between 0.175 to 0.277 for lineage A/ASIA/Sea-97 and 0.188 to 0.336 for 
lineage A/ASIA/Iran-05, respectively. Analysis of variance on the OD values of viruses of 
the same lineage after heat treatments indicated that there was a significant difference 
between the heat treatment groups of the lineages for both A/ASIA/Sea-97 (P<0.05) and 
A/ASIA/Iran-05 (p<0.05). However, comparison of the mean OD values between the two 
lineages receiving the same heat treatments showed no significant different between the 
two lineages p>0.05.  
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Figure 4.13: The effect of heating on the 12S capsid particle production of two 
different lineages of FMDV serotype A  viruses measured using VHH DAS ELISA. Panel 
(a) A/Sea-97 and (b) A/Iran-05. The relative amount of 12S capsid particles are 
measured by mean optical density (OD) on the y-axis. On the x-axis are the treatment 
given to the viruses. 
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4.5 Discussion 
 
The work in this chapter investigated the impact of viral capsid integrity of FMDV serotype 
A in order to understand whether dissociated viral particles (DVPs) can influence the 
results of in-vitro vaccine matching methods. 
Heat-treatment was used to mimic long-term storage of FMDV; to break down FMDV 146S 
capsid into component fragments such as 12S which were measured using a specific ELISA. 
Different temperatures were used to assess the relative stability of two different serotype 
A field viruses to heat treatment, where a greater increase in ELISA signal was observed 
for A/VIT/13/2015 at lower temperatures as compared to A/MAY/2/2011. These results 
provide a first indication that the production rate of the 12S capsid particles are not the 
same for each virus; findings that were further supported by the results from the PaSTRy 
method, where A/MAY/2/2011 had the most stable capsid followed by the A/VIT/13/2015 
and finally A/May-97 (vaccine virus). Unexpectedly the vaccine virus capsid integrity was 
found to be more sensitive to heat treatment as compared to the capsid integrity of the 
field isolates. The reason for vaccine virus capsid being less stable than the capsid of the 
field isolates is not known. However, it may be because the vaccine virus has been 
adapted in cell culture systems over many passages.  
When added back into the FMDV test samples, the 12S capsid particles appeared to reduce 
the FMDV titres that were measured by CPE on the IB-RS-2 cells. For post-vaccination 
sera, the serum neutralization titres were consistently (and significantly) higher in the 
untreated sera than the paired samples containing DVPs. These differences between the 
measured neutralization titres were usually greater than a two-fold dilution (0.3 log10). 
Similar observations were made when the same individual sera were tested using LPBE, 
where the mean ODs for the FMD viruses containing DVPs were consistently higher than 
the OD of the untreated viruses. In other words, the added DVPs influenced the LPBE to 
lower the FMDV-specific antibodies that were detected. These findings are in agreement 
with the other reports that indicate 12S capsid particles can reduce the virus 
neutralization titres of guinea pigs and mice (Cartwright et al., 1980; Meloen et al., 1979; 
Rowlands et al., 1975).  
The results from this study demonstrate that DVPs can influence the serum antibody titres 
measures by VNT and LPBE. When considering vaccine-matching studies, these effects 
may be particularly important in cases where the ratio between 146S (live FMDV) and the 
DVPs varies between the vaccine virus and field virus. There is evidence from this study 
that different FMD virus preparations have different levels of DVPs. For instance, while 
A/VIT/13/2015 (field isolate) virus had the highest virus titre (measured by VNT) 
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compared to A/May-97 (vaccine virus) and A/MAY/2/2011 (field isolate), the untreated 
sample for this virus generated the lowest OD values in the VHHs DAS ELISA. This may 
indicate that the A/VIT/13/2015 virus had proportionally more intact virus compared to 
the other two viruses. To further compare the differences in capsid stability between 
viruses, a pilot study (Experiment 4) was performed to examine the effect of heat-
treatment on different field viruses, and although the changes were not significant across 
two FMDV lineages, small differences between isolates were observed (particularly at 
51°C and 56C); findings which further support the idea that the impact of heat on 
different viruses is not necessarily the same.  
In addition to heat-treatment, it is also reported that long-term storage of inactivated 
FMD virus at -70oC does not prevent 146S degradation, and storing FMD virus for long-term 
in liquid nitrogen is recommended since these conditions do not significantly affect the 
immunogenic properties of the virus (Ferris et al., 1984). Consideration of storage 
conditions is especially important since the in-vitro vaccine matching methods employed 
in FMD Reference Laboratories frequently use long-term stored FMD virus stocks. The act 
of freezing and thawing the viruses may also increase the dissociation of FMDV capsid 
particles present in a sample. Therefore, it is suggested to store FMD viruses in aliquot 
for single use in order to prevent the formation of additional dissociated capsid particles. 
The current in-vitro vaccine matching methods use glycerol as excipient to stabilise the 
viruses used in the tests. Other study suggests that glycerol stabilises the virus and hinders 
the production of capsid intermediates (Yang et al., 2017). Therefore, adding glycerol 
may reduce variability of in-vitro vaccine matching. Furthermore, inactivated virus using 
BEI has also been shown to reduce the dissociation of 146S particles. Moreover, the use 
of inactivated virus is much easier and safer to use for the LPBE that does not require live 
virus. 
Previous studies using other methods such as SDG and HPLC only reported 12S capsid 
particles in heated or acid treated FMD viruses (Spitteler et al., 2011; Yang et al., 2013). 
Data from this study suggests that the VHHs DAS ELISA is more sensitive compared to the 
other methods, and may provide a simple method to assess FMDV capsid stability. In 
summary, the results presented in this chapter suggest that the hypothesis can be 
accepted: i.e., that 12S capsid particles can mop up antibodies that would otherwise be 
available for detection by in-vitro vaccine matching methods. This results in an artificial 
decrease in neutralisation titres (measured by VNT) and FMDV-specific antibody titres 
(measured by LPBE), and may play a central role as a factor that influences the variability 
of vaccine-matching tests. 
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Foot-and-mouth disease virus-specific serological 
immune responses of cattle in Peninsular 
Malaysia following vaccination 
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5.1 Abstract  
 
FMD vaccination together with other control measures has contributed to the success of 
eradication campaigns in countries such as those in Western Europe and most parts of 
South America. However, at present there are still many countries in Asia and African 
regions that are endemic for FMD despite the use of prophylactic and responsive 
vaccination. These FMD endemic countries are facing detrimental losses to livestock 
production and cost to control FMD, in addition to losing opportunities to access lucrative 
markets for livestock trade. In this chapter, a field experiment was carried out in a dairy 
cattle farm located in area with lower risk of FMD in Peninsular Malaysia to assess the 
post-vaccination antibody responses generated in after primary and booster vaccination 
in calves and adult cows. In this farm, serum samples were collected from young calves 
at different ages, with different levels of maternally derived antibody after primary and 
booster vaccination, while for cow serum samples were only collected after booster 
vaccination. Additionally, dairy cattle farms located in areas with lower and higher risk 
of FMD that received multiple FMD vaccinations were assessed for antibody against the 
non-structural protein of FMD virus. No NSP positive detected from all 48 cows and 51 
calves at all sampling points of the selected dairy farm located in lower FMD risk area. In 
contrast, 32% of cattle were NSP positive in the high risk FMD area. For dairy farm located 
in lower risk area, all cows showed neutralisation antibody titre against the vaccine 
strains higher than the suggested protective cut-off points of both serotypes A (2.84 log10 
 0.27 log10) and O (2.54 log10  0.49 log10). Moreover, >90% of cows that received multiple 
FMD vaccinations showed neutralisation antibody titre against the field strains of serotype 
A (A/MAY/2/2011) and serotype O (O/MAY/10/2016) above the suggestive protective cut-
off point. The calves showed that maternally derived antibody titre is higher in younger 
calves and reduces with age. Maternally derived antibody also interfered negatively with 
primary neutralisation titre but does not affect neutralisation antibody titre after booster 
vaccination. These findings indicate that the vaccine tested was suitable for use against 
the serotype A field viruses tested, despite that fact that r1-values generated from 
neutralisation titres in all groups (either after primary, booster or multiple booster 
vaccination) had a high degree of variability. 
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5.2 Introduction 
 
Countries with FMD endemic status face annual losses due to impacts on livestock 
production and vaccination that alone is estimated at a value of US$ 6.5 to 21 billion 
(Knight-Jones and Rushton, 2013; Knight-Jones et al., 2017). Vaccination is an important 
tool that has contributed to the successful control and eradication of FMD in Western 
Europe and parts of South America (Clavijo et al., 2017; Leforban and Gerbier, 2002; 
Saraiva, 2004). In addition, “vaccination-to-kill” policies have been adopted in the 
Netherlands during 2001 FMD outbreak in Europe (Pluimers et al., 2002) and in Japan 
during the 2010 FMD outbreak in Miyazaki (Muroga et al., 2012). These policies shown to 
have contained the FMD outbreaks rapidly in FMD free countries and have helped to lift 
international trade restrictions. However, currently there are still many countries in Asia 
and African region that are endemic to FMD and are therefore without an official OIE 
status (O.I.E, 2018).  
The country of Malaysia comprises Peninsular (P) Malaysia and the States of Sabah and 
Sarawak on the Island of Borneo (see Figure 5.1). P. Malaysia is connected to mainland 
Southeast Asia through Isthmus of Kra in the north. Malaysia has a multiracial population 
with unique cultural, social and livestock husbandry practices. The livestock industry only 
makes a small contribution to the country’s economy mostly through export of poultry 
and processed livestock products (D.V.S., 2018). Pig production sustains the domestic 
consumption with exports of product to Asian countries. On the other hand, most (57%) 
of the ruminant livestock production is from a traditional husbandry system, while cattle 
that are reared integrated into oil palm plantations account for a smaller proportion (23%) 
of the industry. In both systems, livestock are free to feed in an open area and chances 
for animals to co-mingle with other herds are high particularly in the traditional system 
where risks for disease transmission are very high. These systems currently produce far 
less ruminant meat and milk than is required by the population in the country. As a result, 
Malaysia is dependent on imports of live ruminants, meat, milk and other dairy products 
from neighbouring countries, to cater for the need of the people (D.V.S., 2018). These 
factors emphasise the importance of regional programmes with strong cooperation 
between neighbouring countries and effective control at borders to successfully control 
FMD in Malaysia (Adullah, 2014).  
In Malaysia, FMD has never been reported in Malaysian Borneo (Sabah and Sarawak) 
(Figure 5.1). In contrast, there has been a long history of FMD in P. Malaysia. According 
to Wallace, (Wallace, 1936), the first reports of a disease that resembled FMD in P. 
Malaysia was recorded in 1860 followed by another episode that occurred in 1909. In 1936, 
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a clinically similar disease was reported in the states of Perak and Selangor, Malaysia 
affecting 551 animals (Wallace, 1939). The first confirmed case of FMD in P. Malaysia was 
in 1973, when FMD virus subtype A22 was detected by the WRLFMD (Pirbright, UK) in 
samples sent to the UK (Chong, 1979). In December 1982, a disease control policy to 
vaccinate all susceptible livestock on P. Malaysia was implemented after an FMD 
eradication policy was strongly objected by the people (Babjee, 1994; Chong, 1979; 
Department of Veterinary Services Malaysia, 1995; Thuraisingham, 1977). However, the 
effectiveness of this vaccination policy was questioned in view of FMD outbreaks that 
occurred; initially in Pahang in 2001 (Senawi, 2012), which led to FMD outbreaks not only 
in the northern states of P. Malaysia, but also in all other states in P. Malaysia (Ramanoon 
et al., 2013). Despite continuous efforts to control FMD in P. Malaysia, the disease has 
expanded and there have been more FMD outbreaks recorded with more FMDV serotypes 
and strains over time. The range of different FMDV serotypes (and lineages) shown to be 
present in the country include FMDV A/ASIA/Sea-97, O/SEA/Mya-98, O/SEA/Cam-94 
(2001-2003), O/ME-SA/PanAsia (2000-2001), O/ME-SA/PanAsia-2 (2003-2009), O/CATHAY 
(2005) and Asia 1 (Abdul-Hamid et al., 2011) as well as the FMDV O/ME-SA/Ind-2001e sub 
lineage that has also been recently detected (WRLFMD, 2018).   
The use of prophylactic vaccination as part of FMD control measures in an endemic area 
has to be continuously assessed to ensure the effectiveness of the vaccine that is used 
(Ferrari et al., 2016a). FMDV-specific antibody responses in vaccinated animals can be 
measured using structural protein-specific tests such as VNT or SP-ELISAs (Anna Ludi, 
2017). However, interpretation of post-vaccination serological results is not always 
straight-forward due to the lack of clearly defined protective cut-offs for these tests 
(especially for heterologous protective responses). Furthermore, post-vaccination 
serological patterns in endemic countries are often complicated by the presence of FMDV-
specific antibodies resulting from natural infection. In addition, maternally derived 
neutralisation titres have been documented to have negative influence in eliciting 
protective immune response induced by vaccination in young calves (Nicholls et al., 
1984a). In cases where it is important to distinguish vaccinated animals from those that 
are naturally infected, an NSP-ELISA that detects antibodies against the FMDV non-
structural protein can be used (Sorensen et al., 1998). This approach works as long as the 
vaccine used has been purified to remove non-structural proteins. However, antibodies 
against non-structural proteins take a minimum of about 8 days post infection to be 
detected (Sorensen et al., 1998) compared to the antibodies against the structural 
proteins which are generated much more quickly.  
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Figure 5.1: Map of Malaysia; in relation to countries in mainland Southeast Asia where 
FMD is endemic (pink). FMDV free areas are indicated in green. The proposed FMD 
free zone for Malaysia as part of the OIE SEAFMD campaign is indicated with yellow, 
and the states where the farms are located for this study are identified.  
 
 
The previous chapters in this thesis have tested the antigenic relationship between a 
commonly used FMD vaccine (A/May-97) and a representative field virus from the 
A/ASIA/Sea-97 lineage. The results from these studies highlight (i) the variability of the 
in-vitro vaccine-matching tests and (ii) the uncertainty that can sometimes arise when 
using these tests to define heterologous protection. The objectives of this chapter were 
(i) to investigate whether the in-vitro vaccine matching using VNT method may provide 
similar picture to the field situation in a herd of cattle in Malaysia, (ii) to describe and 
evaluate the neutralisation titre following primary and booster vaccination in a herd of 
cattle in Malaysia, (iii) to assess the impact of maternally derived neutralisation antibody 
on the calves’ neutralisation titre in a herd of cattle in Malaysia.   
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5.3 Materials and methods 
 
  
Figure 5.2: Schematic diagram showing the outline of serum samples collected from 
farms in P. Malaysia and the tests carried out. 
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 Background information about the study farms and sera collection 
 
For this study, dairy cattle herds located in two areas (states) in P. Malaysia were selected 
based on the risk of FMDV infection in the areas. One area was considered a lower-risk 
for FMD while the second area was a higher-risk area for FMD (Figure 5.2). The lower-risk 
farm was selected for its location, good biosecurity and zoo-sanitary control measures 
and husbandry practices. The farm, Pusat Ternakan Haiwan (PTH) Ayer Hitam, Kluang, 
Johor was located in the southern P. Malaysia (Figure 5.1) where FMD occurrence was 
lower than other states. This cow and calf unit is government owned and has Mafriwal 
dairy cattle (about 400 heads) and Friesian Shahiwal (about 100 heads). All cattle on this 
farm are vaccinated for FMD twice a year starting at six months of age and there have 
never been any clinical cases of FMD reported. All eligible cattle receive FMD vaccination 
during the first week of January and June every year. However, no regular post-
vaccination monitoring program has been carried out on this farm to assess the 
performance of the FMD vaccine. For this study, a group of 51 calves, aged two to seven 
months were selected which had not previously received an FMD vaccine. Forty-eight out 
of 51 mothers (cows) of the selected calves were also included in the study. Sera were 
collected from all 48 cows at 56dpv and from all 51 calves at 0dpv. At 21dpv, serum 
samples were collected from all 51 calves after which the calves were divided into two 
groups. One group of 26 calves were given a booster vaccination at 21dpv, and the other 
group that contained 25 calves were not boosted. Finally, serum samples were collected 
from all calves at 49dpv.  
For the second area that has a higher risk of FMD, serum samples from dairy cattle were 
collected to assess whether there was evidence for subclinical infection in an FMD 
vaccinated population. This part of the study measured NSP-specific antibody responses 
to recognise FMDV-infected animals in the vaccinated herds. The state of Melaka was 
chosen for this purpose because it has dairy cattle herds that are well monitored by the 
State Department of Veterinary Services (DVS). Melaka is a small state divided into three 
districts located in the mid-west P. Malaysia with total area of 1615.92 square kilometres. 
Melaka has total dairy cattle population of 2256 heads (D.V.S., 2018). No cases of clinical 
FMD have been recorded in dairy cattle farms in Melaka since early 2013 to November 
2016. A total of 60 cows from nine private dairy cattle farms located in three different 
districts of Melaka were selected. Thirty of these cows were selected from herds with no 
history of clinical FMD, whereas the other 30 cows were selected from herds where the 
last clinical cases due to FMD were recorded in January 2013. Cows were aged between 
2 to 4 years at the start of the study (0dpv) and were examined for FMD lesions (both old 
and new) during sera collection at 0, 21 and 49dpv (Figure 5.2). 
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 Vaccine and Vaccination 
 
All FMD vaccines used in P. Malaysia are produced by MERIAL/Boehringer Ingelheim and 
therefore this vaccine was tested on all the study farms recruited for this study. This is 
an aqueous vaccine with a potency of at least 6PD50 purchased by the Government of 
Malaysia for farmers that keep ruminants in P. Malaysia. The adult cows in the herds had 
received FMD vaccination on multiple occasions ranging from seven times in three years 
to 22 times in 10 years with the last FMD vaccination on 7th June 2016. The calves were 
vaccinated on 2nd August 2016 which was designated as 0 days post vaccination (dpv). At 
0dpv, 2 ml of inactivated polyvalent (quadrivalent) FMD vaccine containing A/May-97, O1 
Manisa, O-3039 and Asia 1 Shamir (Aftovaxpur® Merial Animal Health Ltd) was 
administrated subcutaneously in the front of the shoulder of the vaccinated calves. 
Booster vaccination was carried out using the same dose and route at 21dpv to 26 selected 
calves (as described above). On the days of vaccination and sampling, every cow and calf 
selected for the study were physically examined to ensure no clinical signs of FMD were 
present. 
The same vaccine and route of administration was used for the cows selected from the 
higher risk area; where cattle received multiple vaccination following the manufacturer 
recommendation starting from January 2013. These cows received booster vaccination at 
the start of the study ((0dpv): not first vaccination). (Figure 5.2).   
 
 Collection and processing of blood samples. 
 
Sera were collected from coccygeal vein of each cow and calf using 10ml red top 
vacutainers without any anticoagulant (BD Franklin Lakes USA). After collection, the tubes 
were transported in a cool box to a regional veterinary laboratory in P. Malaysia (Makmal 
Veterinar Kawasan Salak Tinggi) and placed in a refrigerator at 4°C overnight. The tubes 
were then centrifuged at 2000g for 5 minutes using a stand-alone centrifuge (Kubota 
5800). Collected sera were placed in water-bath at 56°C for 30 minutes to inactivate any 
viruses and complement factors that might have been present (according to Pirbright 
Institute biosecurity regulations) before being aliquoted into 1.8 ml cryo-vials. Aliquots 
of sera were stored at -20°C until transported to The Pirbright Institute for testing. 
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 Non-structural protein ELISA 
 
Sera collected at all the sampling points were tested using a commercially available kit 
(PrioCHECK® FMDV-NS) produced by Prionics Lelystad B.V. (Catalogue no 7610440). NSP 
ELISA results were used for two purposes: firstly, to ensure that all cows and calves 
selected for this study in PTH Ayer Hitam (lower-risk herd) were not infected with FMDV 
prior to, or during the study, and secondly, to test all 60 sera from the cows from Melaka 
(higher-risk herds) to assess whether the animals might have been infected with FMDV. 
Briefly, on the first day of the test, 80µl of prepared ELISA buffer was dispensed into all 
wells. A total of 20µl of the negative control, the weak positive control, positive control 
and test serum samples were dispensed into the designated wells in duplicates. The plates 
were sealed and left at room temperature (+19°C to +25°C) overnight. The plates were 
washed with washing buffer (provided in the kit) six times. The plates were dried by 
tapping them onto a lint-free absorbent towel. A total of 100µl of prepared conjugate 
was dispensed into all wells before the plates were sealed and incubated at room 
temperature for an hour (+19C to +25C). The plates were emptied and washed again. 
After drying the wells, 100µl of chromogen/substrate solution (provided in the kit) was 
added. The plates were then sealed and incubated at room temperature (+19C to +25C) 
for 20 minutes. A total of 100µl stop solution (provided in the kit) was dispense to all 
wells and the side of the plates were tapped to ensure even mixing before the plates 
were read ELISA reader machine (V-MAX model) at 450nm filter to measure the optical 
density (OD). The mean OD values were calculated for percentage of inhibition (PI) using 
the formula: 
PI = 100 – (OD of test or control samples) X 100 
                                OD max 
According to kit guidelines, samples ≥ 50% PI were considered as positive for FMDV NSP-
specific antibodies. 
 
 Virus neutralisation test 
 
The method for the VNT used the protocol described in Chapter 2 (Material and methods 
section; neutralisation titres). All serum collected from PTH Ayer Hitam (a total of 210 
sera: 48 cow’s and 51 calves sera at 0, 21 and 49dpv) were tested for antibodies against 
A/May-97 (homologous virus) and A/MAY/2/2011 (heterologous virus), representing the 
FMD vaccine virus and a representative A/ASIA/Sea-97 field isolate, respectively. 
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A subset of sera collected from cows and calves from PTH Ayer Hitam were also tested 
with VNT for FMDV serotype O-specific antibody responses. For these analyses, a total of 
25 sera from mother cows and sera from paired 25 calves were selected. For the 25 sera 
from calves, 17 calves received the booster vaccination in comparison to 8 calves that 
received only a single dose of vaccine. A total of 100 sera: 25 cows and 25 calves’ sera at 
0, 21 and 49dpv) were tested for 0-3039 (vaccine virus) and O/MAY/10/2016 (field 
isolate). 
For both serotype A and O viruses, selected cows’ sera at 56dpv and selected calves’ sera 
at 0, 21 and 49dpv were tested with VNT. All sera were tested in batches where the same 
individual sera tested against the homologous/vaccine virus and heterologous/field 
isolate were performed simultaneously at the same time with the same cell (CSFV positive 
IB-RS-2) suspension. 
 
 Determination of the r1 value  
 
In order to measure the antigenic cross-reactivity between the vaccine viruses and field 
isolates, r1 values were calculated from the neutralisation titres generated from the VNT 
of individual sera as described in Chapter 2 (Determination of r1 value section). The r1 
values were calculated for individual sera of the cows and sera of the individual calves 
aged between six and seven months of age (for both 21dpv and 49dpv) against both FMDV 
serotype A and O. The cut-off values at 0.3 used were according to those recommended 
by the OIE (OIE, 2017).  
 
 Statistical analysis 
Analysis of variance using a general linear model were carried out on the data gathered 
for FMDV serotype A and serotype O. The linear model was built independently for 
serotype A and serotype O to assess the mean difference and interaction between factors. 
The factors were (i) viruses: homologous/vaccine virus and heterologous/field isolate, (ii) 
vaccination: primary and booster, (iii) day post vaccination (dpv): 0, 21 and 49dpv. 
Tukey’s pairwise comparison tests were also performed independently for serotype A and 
serotype O to identify interaction between factors. All statistical analyses were 
performed using Minitab (version 18). One-way ANOVA was also performed on the net 
antibody produced (neutralisation antibody titre) after the primary vaccination of the 
homologous virus for all age groups as well as for the net antibody produced after booster 
vaccination for all age groups.  
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5.4 Results 
 
 Detection of antibodies against FMDV non-structural proteins 
 
In order to detect FMDV infection in the lower-risk area study herd, NSP ELISAs were 
performed for all 48 cow sera at 56dpv as well as for all 51 calf sera at 0dpv, 21dpv and 
49dpv. All these serum samples generated negative results (PI < 50%) using the NSP ELISA 
(at all sampling times). 
To investigate the occurrence of NSP-specific antibodies within the higher-risk area of 
FMD, sera collected from 60 animals at three different sampling time points ((0dpv), 
(21dpv) and (49dpv)) were tested with NSP ELISA. As a result, NPS-specific antibodies 
were detected in nine out of the 60 cows (15%) (≥ 50% PI for NSP ELISA) at all three 
sampling points. In addition, four animals (6.7%) were found to be NSP positive at two 
sampling points ((0dpv) and (21dpv)) and six animals (10%) generated positive NSP results 
at just one sampling point, either at (0dpv) (four animals) or at (49dpv) (two animals). 
The detection of NPS-specific antibodies depended on the history of clinical FMD in the 
herds held within the higher-risk area of FMD. Thus, in herds with no clinical history of 
FMD, four out of 30 animals (13%) involving three out of four (75%) herds were positive 
for NSP-specific antibodies at any time point of the experiment (Figure 5.3a), while NSP-
specific antibodies were detected in 15 out of 30 animals (50%) involving all five (100%) 
in herds with history of clinical FMD in January 2013 (Figure 5.3b). 
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Figure 5.3: NSP positive and negative sera from cattle herds located in an area with 
higher-risk of FMD. Panel (a) herds without any clinical history of FMD and (b) herds 
with history of clinical FMD in January 2013. The black error bars represent the 
standard deviation from the mean NSP percentage of inhibition (PI). The black dotted 
lines represent the test cut-off value for NSP positive samples (PI ≥ 50% was 
considered positive NSP). 
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 FMDV-specific neutralising antibody responses in cows 
 
All VNT experiments described in this chapter were carried out using sera collected 
from cows held in the farm located in an area with lower-risk of FMD.  
 
 FMDV-serotype A-specific responses measured in adult cow sera  
 
As can be seen in Figure 5.4, all 48 adult cows had homologous neutralisation titres against 
the A/May-97 vaccine virus, a component of the Aftovaxpur® used in Malaysia (see 5.3.2 
section), that were found to be above the suggested protective cut-off of 1.4 log10 for 
FMDV serotype A (Barnett et al., 2003). For these samples, the neutralisation range 
observed was 2.17 log10 to 3.53 log10, with a mean neutralisation titre  standard deviation 
of 2.84 log10  0.27 log10. When these sera were tested using the heterologous virus 
(A/MAY/2/2011; field isolate), the overall level of heterologous neutralisation antibody 
titres was lower compared to homologous titres (Figure 5.4).  Only three out of the 48 
adult cow sera had neutralisation titres that were below the suggestive protective cut-
off level (Barnett et al., 2003) (Figure 5.4) suggesting a heterologous percentage 
protection of 93.8%. These three sera were from the cows that showed the lowest 
neutralisation titre for the homologous virus. These heterologous log10 neutralisation 
antibody titres ranged from 0.82 to 2.70, with a mean log10 neutralisation titre  standard 
deviation of 2.11  0.43.  
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Figure 5.4: Homologous and heterologous FMDV-serotype A-specific neutralisation 
antibody titres. Neutralisation antibody titres (log10) of individual adult cows is 
projected against homologous (A/May-97) and heterologous (A/MAY/2/2011) viruses. 
The sera were collected after multiple vaccination with Aftovaxpur®, a quadrivalent 
vaccine containing FMDV A/ASIA/Sea-97 (A/May-97), O1 Manisa, O-3039, and Asia 1 
Shamir. The suggestive protective cut-off point for serotype A is indicated by the black 
dashed line at 1.4 log10 (Barnett, 2003). The black error bar indicates the standard 
deviation from the mean neutralisation titre.  
 
 FMDV-serotype O-specific responses measured in adult cow sera 
 
For serotype O, VNT was only performed on a reduced subset of the antisera and for only 
one (O-3039) of the two (O-3039 & O1 Manisa) vaccine virus components that were present 
in the of the Aftovaxpur® quadrivalent vaccine (see section 5.3.2). All 25 (100%) adult 
cow sera generated neutralization titres against this vaccine virus that were above the 
suggestive protective cut-off point for FMDV serotype O of 1.6 log10 (Barnett et al., 2003) 
as shown in Figure 5.5. The highest neutralization antibody titre against this vaccine virus 
was 3.3 log10, whereas the lowest neutralization titre against the vaccine strain was 1.67 
log10. The mean neutralisation antibody tires against the vaccine virus was 2.54  0.49 
log10.  
The neutralisation antibody titres against the heterologous virus (O/MAY/10/2016: field 
isolate) had a range of 2.88 log10 to 1.21 log10. The mean neutralisation antibody titre was 
1.94 log10. Four out of 25 (estimated 16%) individual sera tested showed neutralization 
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antibody titres against the field isolate below the suggestive protective cut-off 1.6 log10 
(Figure 5.5). 
 
Figure 5.5: Homologous and heterologous FMDV-serotype O-specific neutralisation 
antibody titres. Neutralisation antibody titres (log10) of individual adult cows is 
projected against vaccine strain (O-3039) and field strain (O/MAY/10/2016) viruses. 
The sera were collected after multiple vaccination with Aftovaxpur®, a quadrivalent 
vaccine containing FMDV A/ASIA/Sea-97 (A/May-97), O1 Manisa, O-3039, and Asia 1 
Shamir antigens. The suggestive protective cut-off point for serotype O is indicated 
by the black dashed line at 1.6 log10 (Barnett, 2003) and the black error bars indicate 
the standard deviation from the mean neutralisation titre.  
 
 Neutralising antibody response in calves 
 
FMDV-specific immune responses after primary and booster vaccination were investigated 
using sera collected from calves, aged two to seven months, held in farms located in an 
area of lower-frisk of FMD. 
 
 Maternally derived neutralisation titres at 0dpv for serotype A and O 
 
For the first component of this study, maternally-derived neutralisation antibody titres 
against serotype A homologous (A/May-97) and heterologous (A/MAY/2/2011) viruses 
were measured in 51 unvaccinated calves (at 0dpv). Maternally-derived neutralisation 
titres against the homologous virus were highest in the calves aged two, and four-months 
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(which were above the suggested protective cut-off), but at three months old, only four 
out of nine individual sera had measurable maternally-derived neutralisation titres 
(Figure 5.6). At the age of 5 months, the maternally derived neutralisation titres were 
lower and all individual sera of calves in age groups six and seven months generated 
negative maternally-derived neutralisation titres. Similar patterns were observed 
between homologous and heterologous antibody responses of the individual titres were 
measured using the heterologous VNT assay.  However, overall, the heterologous 
maternally-derived neutralisation titres were lower than the homologous, and below the 
suggested protective cut-off point (Figure 5.7). 
 
 
Figure 5.6: Maternally-derived neutralisation titres against the A/May-97 
(homologous) vaccine virus in unvaccinated calves.  The suggestive protective cut-off 
point for serotype A is represented by the black dashed line at 1.4 log10 (Barnett, 
2003). The error bars indicate standard deviation from the mean; number of calves 
in an age group is indicated by n.  
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Figure 5.7: Maternally-derived neutralisation titres against the A/MAY/2/2011 
(heterologous) field virus in unvaccinated calves.  The suggestive protective cut-off 
point for serotype A is represented by the black dashed line at 1.4 log10 (Barnett, 
2003). The error bars indicate standard deviation from the mean; number of calves 
in an age group is indicated by n. 
 
 
As for FMDV serotype O, maternally-derived neutralisation titres were measured in 25 
unvaccinated calves (at 0dpv). Maternally-derived neutralisation titres against the O-3039 
vaccine virus were measurable in five out of eight calves aged between two to five months 
at 0dpv (Figure 5.9a) All individual sera of the calves aged five to seven months showed 
comparably lower maternally-derived neutralisation titres to the younger age groups. The 
same sera were also tested for heterologous maternally-derived neutralisation titres 
(against the O/MAY/10/2016 field isolate) with the highest maternally-derived 
neutralisation titre being 1.43 log10.  (Figure 5.8b).   
2 3 4 5 6 7
0 .0
0 .3
0 .6
0 .9
1 .2
1 .5
1 .8
A /M A Y /2 /2 0 1 1 ; m a te rn a l a n tib o d y  d e c a y
C a lv e s  a g e  in  m o n th s
N
e
u
tr
a
li
s
a
ti
o
n
 t
it
re
 (
L
o
g
1
0
)
( n = 6 )
(n = 9 )
(n = 5 ) (n = 6 ) (n = 1 4 )
(n = 1 1 )
Chapter 5 
 
131 
 
 
Figure 5.8: Serotype O FMDV-specific antibody responses after vaccination. 
Maternally-derived neutralisation titres (0dpv), neutralisation antibody titres after 
primary (21dpv) and booster vaccination (49dpv) for homologous (panel a) and 
heterologous (panel b) viruses are shown in calves aged 2, 3 and 4 months at the start 
of the study. Solid lines represent antibody responses in calves that did not receive 
booster vaccination, while dashed lines represent antibody responses in calves that 
received booster vaccination at 21dpv. Blue lines trace neutralisation titres of 
homologous virus while red of heterologous virus. Open and closed circles with 
different colours indicate individual calves, while age groups are noted in brackets 
following the calves’ identification number. The suggestive protective cut-off point is 
represented by the black dashed line at 1.6 log10 (Barnett, 2003).  
0.0
1.0
2.0
3.0
0dpv 21dpv 49dpv
N
e
u
tr
a
lis
a
ti
o
n
 t
it
re
 (
lo
g
1
0
)
Sampling points at days post vaccination (dpv)
Vaccine virus: calves age 2, 3 and 4 months at 0dpv
I865036 (2)
I865042 (2)
I665030 (3)
I665032 (3)
I665035 (3)
I765028 (3)
I865033 (3)
I765022 (4)
Primary 
vaccination
Booster 
vaccination
0.0
1.0
2.0
3.0
0dpv 21dpv 49dpv
N
e
u
tr
a
lis
a
ti
o
n
 t
it
re
 (
lo
g
1
0
)
Sampling points at days post vaccination (dpv)
Field isolate: calves age 2,3 and 4 months at 0dpv 
I865036 (2)
I865042 (2)
I665030 (3)
I665032 (3)
I665035 (3)
I765028 (3)
I865033 (3)
I765022 (4)
Primary 
vaccination
Booster 
vaccination
a.
b.
Chapter 5 
 
132 
 
 Effect of primary vaccination on FMDV-specific antibody responses 
for serotypes A and O  
 
The individual neutralisation antibody titres against vaccine viruses (A/May-97 and O-
3039) and field isolates (A/MAY/2/2011 and O//MAY/10/2016) were measured at 21dpv 
in order to access the impact of primary vaccination upon the FMDV-specific immune 
response of calves with varying levels of maternally-derived neutralisation titre.  
For serotype A, the primary vaccination neutralisation titre against the vaccine virus 
(A/May-97) of all individual calves’ sera were negatively correlated with the maternally 
derived neutralisation titre (p<0.0001) (Figure 5.9).  
 
 
Figure 5.9: Negative effect of maternally derived neutralisation titre on primary 
neutralisation titre for serotype A (vaccine virus). The red-dotted line indicates the 
regression trend. 
 
More specifically, animals with the highest (above the 1.4 log10 protective cut-off point) 
maternally-derived neutralisation titres produced lower FMDV-specific neutralisation 
antibody titres after primary vaccination as compared to calves with maternally-derived 
neutralisation titres measured below the protective cut-off point (Figures 5.10 a, c, e and 
5.11 a, c, e). For instance, calves aged two and four months showed lower mean log10 
neutralisation titre against A/May-97 after primary vaccination dropping from 2.03 to 
1.65, and 1.78 to 1.32, respectively. Analysis of variance indicated there were significant 
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differences (p<0.05) in the net antibody titres produced after primary vaccination 
between animals with the highest maternally derived neutralisation titres in groups age 
two- and four-months as compared to calves’ sera in the older age groups (at six and 
seven months of age). In all four calves with low maternally-derived neutralisation titres 
against the homologues A/May-97 virus in the three-month old group, an increase in the 
neutralisation antibody titre after the primary vaccination was observed (Figure 5.10c). 
A similar trend of an increase of maternally-derived neutralisation titres after primary 
vaccination response were observed for the individual sera of calves in the older age 
groups of five, six and seven months (Figure 5.11a, c, e).  
At 95% confidence interval the mean net antibody titres against vaccine virus produced 
after the primary vaccination for two-month age group was -0.34 (95% CI -0.74, 0.06), for 
the three-month age group was 0.11 (95% CI -0.22, 0.44), for the four-month age group 
was -0.46 (0.90, -0.24), for the five-month age group was log10 0.03 (95% CI -0.37, 0.43), 
for the six-month age group log10 0.67 (95% CI 0.41, 0.94) and finally for age group of 
seven-month was 0.74 (95% CI 0.44, 1.04). No difference between the mean neutralisation 
titres produced after booster vaccination for calves in all age groups was observed. The 
same sera were also tested against serotype A heterologous virus (A/MAY/2/2016: field 
isolate) showed in principle similar pattern in response to primary vaccination compared 
to response against the homologous virus (A/May-97: vaccine virus) as in Figure 5.10b, d, 
f and 5.11b, d, f. However only two out of the 51 calves had maternally-derived 
neutralisation titre above the suggested protective cut-off of 1.4 log10 at 0dpv. Both calves 
were two months old (Figure 5.10b, d, f and 5.11b, d, f).   
For serotype O, a similar pattern of neutralisation antibody titres was observed when 
measured against the vaccine virus (O-3039) and the field isolate (O/MAY/10/2016) after 
the primary vaccination at 21dpv. All 5 calves that initially had maternally-derived 
neutralisation titres against vaccine virus above the suggested protective cut-off, 
produced lower neutralisation antibody titres after primary vaccination (Figure 5.8a). 
Only two calves that belonged to age groups of five, six and seven months, produced 
neutralisation antibody titres above the suggested protective cut-off after the primary 
vaccination against the vaccine virus (O-3039) (Figure 5.12c). In contrast, calves that had 
maternally-derived neutralisation antibody titres against the field isolate 
(O/MAY/10/2016) showed reduction or no difference after the primary vaccination was 
given (Figure 5.8b). No sera in any age group showed neutralisation antibody titres against 
the field isolate (O/MAY/10/2016) above the suggested protective cut-off point after the 
primary vaccination (Figure 5.12b, d, f).  
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 Effect of booster vaccination on calves at 49dpv on FMDV-specific 
serotype A and O antibody responses 
 
The effect of booster vaccination on calves with different levels of maternally-derived 
neutralisation titres against vaccine viruses (A/May-97 and O-3039) and field viruses 
(A/MAY/2/2011 and O//MAY/10/2016) were measured in sera collected at 49dpv.  
For serotype A, all individual sera from calves that received booster vaccination at 21dpv 
showed an increase in neutralisation antibody titres against the vaccine virus (A/May-97) 
virus at 49dpv, irrespective of their age when they were first vaccinated (Figure 5.10 and 
Figure 5.11). Only one individual serum had a neutralisation antibody titre against the 
A/May-97 virus below the suggested protected cut-off point despite an increase after the 
booster vaccination (Figure 5.11a). On the other hand, the majority (76%) of individual 
calves that were not given booster vaccination at 21dpv demonstrated a reduction in their 
serum neutralisation antibody titres against vaccine virus (A/May-97) at 49dpv. However, 
there were two individual calves that did not show a reduction in their serum 
neutralisation antibody titres against the A/May-97 virus which remained above the 
suggested protective cut-off despite no booster vaccination being given (Figure 5.10 c 
and Figure 5.11 c). The effect of booster vaccination on the neutralisation antibody titre 
against the field isolate (A/MAY/2/2011) differed in some individuals, in the young calves 
age two, three and four months old, to the effect observed for vaccine virus (A/May-97). 
There were individual sera that showed a reduction in their neutralisation antibody titres 
against field isolate (A/MAY/2/2011) despite of the booster vaccination given at 21dpv 
(Figure 5.10 d, b and e). There were also individual sera that showed an increase in their 
neutralisation antibody titre against field isolate (A/MAY/2/2011) measured at 49dpv 
even without booster vaccination (Figure 5.10 d, b and e). For serotype O, the booster 
vaccination resulted in an increase in neutralisation antibody titres against vaccine virus 
(O-3039) above the suggested protective cut-off point in most animal tested except for 5 
individual calves aged two, six and seven months (Figure 5.8a, 5.12c and 5.12e). All calves 
that did not receive booster vaccination showed a reduction in specific neutralisation 
antibody titres against vaccine virus (O-3039). Booster vaccination also increased the 
neutralisation antibody titres against field isolate (O/MAY/10/2016), except in four 
individual calves that belonged to the six and seven-month age groups (Figure 5.12d and 
f). However, booster vaccination was not able to increase the neutralisation antibody 
titre against field isolate above the suggested protective cut-off point except for all 
calves aged two, three and four-months old (Figure 12b) and five individual sera in the 
five, six, and seven-month old groups (Figure 5.12b and 5.12d). 
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Figure 5.10: Generation of serotype A FMDV-specific antibody responses after 
vaccination in calves aged two, three, and four months at the start of the study. Data 
presented shows maternally-derived neutralisation titres (0dpv), primary vaccination 
(21dpv) and booster vaccination (49dpv) neutralisation antibody titres against vaccine 
virus (5.9a, c and e) and against field isolate (5.9b, d and f) of the serotype A. Solid 
lines represent calves that did not receive booster vaccination (in blue for vaccine 
virus, in red for field isolate), while dashed lines represent calves that received 
booster vaccination at 21dpv. The suggestive protective cut-off point is represented 
by the black dashed line at 1.4 log10 (Barnett et al., 2003). 
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Figure 5.11: Generation of serotype A FMDV-specific antibody responses after 
vaccination in calves aged five, six, and seven months at the start of the study. Data 
presented shows maternally-derived neutralisation titres (0dpv), primary vaccination 
(21dpv) and booster vaccination (49dpv) neutralisation antibody titres against vaccine 
virus (a, c and e) and against field isolate (b, d and f) of the serotype A. Solid lines 
represent calves that did not receive booster vaccination (in blue for vaccine virus, 
in red for field isolate), while dashed lines represent calves that received booster 
vaccination at 21dpv. The suggestive protective cut-off point is represented by the 
black dashed line at 1.4 log10 (Barnett et al., 2003). 
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Figure 5.12: Generation of serotype O FMDV-specific antibody responses after 
vaccination in calves aged five, six, and seven months at the start of the study. Data 
presented shows maternally-derived neutralisation titres (0dpv), primary vaccination 
(21dpv) and booster vaccination (49dpv) neutralisation antibody titres against vaccine 
virus (a, c and e) and against field isolate (b, d and f) of the serotype O. Solid lines 
represent calves that did not receive booster vaccination (in blue for vaccine virus, 
in red for field isolate), while dashed lines represent calves that received booster 
vaccination at 21dpv. The suggestive protective cut-off point is represented by the 
black dashed line at 1.6 log10 (Barnett et al., 2003). 
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 Calculated r1 values 
 
The antigenic relationship (r1 values) between the vaccine viruses and field viruses were 
calculated for all individual 48 cows, 51 calves after primary vaccination (serum collected 
at 21dpv) and 26 calves that were boosted (serum collected at 49dpv). 
The antigenic relationship between the A/May-97 vaccine virus (homologous virus) and 
the A/MAY/2/2011 field isolate (heterologous virus) for the individual sera of the cows 
ranged from 0.01 to 0.59 (with the mean r1 value of 0.24). The majority (31 of 48 sera) 
generated an r1 value less than the suggested vaccine-match cut-off value of 0.3 (OIE, 
2017) (Figure 5.13a). Interestingly, two sera with the lowest neutralisation titres 
generated r1 values above the suggested vaccine-match cut-off (sera ID 17Y4481: r1 value 
0.37 and sera ID 1724626: r1 value 0.38). 
For sera of the calves’ sera after primary vaccination at 21dpv against the serotype A the 
r1 value generated from VNT titres showed wider range from 0.10 to 22.71. Majority of 
the calves (57%) showed r1 value more than 1.0, 35% calves showed r1 value above the 
suggested vaccine-match cut-off (0.3) and below 1.0 and only 9% showed r1 value below 
the suggested vaccine-match cut-off (Figure 5.13b). Calves that received booster 
vaccination showed different distribution of r1 value compared to calves after the primary 
vaccination. There were 46% of the calves that received booster vaccination show r1 value 
above the suggested vaccine-match cut-off (0.3) and below the 1.0. Only about 7.7% of 
the calves that received booster vaccination showed r1 value less than the suggested 
vaccine-match cut-off, whereas the rest of the calves that received booster vaccination 
(42%) showed r1 value more than 1.0 (Figure 5.13c).  
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Figure 5.13: The r1 values generated from neutralisation titres of adult cows and 
calves against the vaccine virus and field isolate of A/ASIA/Sea-97. Panel (a) cows at 
56dpv after multiple vaccination, (b) of calves after primary vaccination and (c) of 
calves after booster vaccination. Bars in pink represent sera that have r1 value below 
the protective cut-off and bars in green represent sera with r1 value above the 
suggested protected cut-off (0.3) (OIE 2018). The grey bars represent sera with r1 
values that were more than 1.0. 
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 Statistical analysis for FMDV serotype A and O specific antibody 
responses 
 
Analysis using a general linear model built on the antibody responses indicated that there 
was significant difference between the mean neutralisation antibody titres of the 
homologous and the heterologous virus of serotype A (p=0.004). There was also a 
significant difference (p=0.0001) in the mean neutralisation antibody titres at different 
sampling points (0dpv, 21 and 49dpv). Tukey pairwise comparison indicated significant 
increase in the mean neutralisation titres between 21dpv and 49dpv in sera that was 
boosted, but for the non-boosted sera there was no significant difference in the mean 
neutralisation antibody titre for the same time points. Tukey pairwise comparison also 
indicated significant higher maternally derived neutralisation titre against the 
homologous virus than heterologous viruses. Analysis of variance for the FMDV serotype 
O: O-3039 and O/SEA/Mya-98 showed there was a significantly higher in the mean 
neutralisation titre against the vaccine virus and the field isolate (p=0.001). The 
difference in the mean neutralisation titre against the vaccine virus and the field isolate 
was also significant at 0, 21 and 49dpv with the (p=0.002).  
 
5.5 Discussion 
 
Post-vaccination monitoring (PVM) is very important in FMD endemic areas that use 
vaccination as part of their FMD control program (Ferrari et al., 2016a). PVM ensures that 
the vaccination carried out is beneficial and that the control program is working 
effectively. However, in endemic areas it can be challenging particularly in countries 
where resources and access to data are limited. Therefore, the PVM guide describes the 
general key elements in how to perform post vaccination evaluation to meet the country’s 
specific objectives which most of the time are related to the stage of PCP that the country 
has achieved. There are four main elements in the PVM guide. The first is the selection 
and purchase of a suitable vaccine that includes the use of r1 values (for all the vaccine 
components) as an indication of adequate antigenic matching. This element also includes 
ensuring that the vaccine used is of suitable quality (dependent upon potency and purity 
of the vaccine). The second part of the PVM guide covers the importance of defining the 
objectives of the vaccination program that are specific to the country’s needs. The third 
and fourth elements describe how to measure and evaluate antibody response in the 
vaccinated herds and how to undertake vaccine effectiveness studies. In addition, the 
PVM guide highlights the importance of ensuring an intact cold chain during the 
distribution and delivery of the vaccine.  
Chapter 5 
 
141 
 
The OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals (OIE, 2017) 
provides guidelines on production of good quality vaccines in a chapter describing the 
principles of veterinary vaccine production. Good quality vaccines contain FMDV strains 
that match field isolates causing FMDV infection in a given area. It is essential to ensure 
the antibodies elicited by the vaccine virus are most likely to confer protection. At the 
same time, it also crucial to ensure that the vaccine is safe for use and free from a 
possible contamination with other organisms. Furthermore, good quality vaccine should 
be purified from FMD virus NSPs so that naturally infected animals can be discriminated 
from vaccinated animals. Vaccine potency also is very important. It is usually determined 
by establishing the percentage of protection either in in-vivo challenge or in-vitro 
conditions and serological antibody response of the vaccinated population are measured 
either by VNT or ELISA. Studies shown that high potency FMD vaccines (of at least 6PD50) 
were more likely to confer protection even when r1 values generated were low (Brehm 
et al., 2008).  
In this study, all sera collected from cows and calves, located in an area with lower risk 
of FMD, were negative for NSPs. Adult cows that had been vaccinated multiple times over 
the years showed similar neutralisation antibody titre levels for homologous and 
heterologous viruses against the A/ASIA/Sea-97 lineage as well as against the O-3039 (a 
serotype O component in the vaccine) vaccine virus and O/MAY/10/2016 field virus. It 
has been suggested that for herd immunity at least 80% vaccination coverage in the herds 
is needed (Leforban and Gerbier, 2002; Lombard and Schermbrucker, 1994; Lubroth et 
al., 2007). In this study, all sera of the cows showed this level of neutralisation antibody 
titres against the homologous virus and only small proportion (6.25%) did not achieve the 
suggested protective cut-off point (1.4 log10) against the heterologous virus for the 
A/ASIA/Sea-97 virus (Barnett et al., 2003). As for the FMDV O-3039 vaccine virus, all 25 
sera of the cows tested showed neutralisation antibody titre above the suggested 
protective cut-off point (1.6 log10) (Barnett et al., 2003). A total of 21 out of 25 (84%) 
sera of the cows showed neutralisation antibody titre against the heterologous virus above 
the suggested protective cut-off (1.6 log10). In this study, the protective cut-offs point 
was based on challenge experiments by Barnett, et al (Barnett et al., 2003). Ideally, the 
protective cut-off point should be made to match the disease and population dynamic of 
the herds studied (Ferrari et al., 2016a). Other researchers have also suggested to 
determine more suitable field-based correlates for vaccine assessment (Lyons et al., 
2017). Based on the neutralisation antibody titres against homologous (vaccine virus) and 
heterologous (field isolate) of the adults as well as the NSP result, for this field study the 
suggested protective cut-off point suggested by Barnett 2003 can probably be considered 
appropriate. Furthermore, the suggested protected cut-off by Barnett were based on the 
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same FMDV linage (A/May-97). Although there are other researchers that have suggested 
different protected cut-off to be used based on different FMDV lineages (Goris et al., 
2008; Maradei et al., 2008). Maternally derived antibodies are of IgG isotype transferred 
from cow to their new-born calf through colostrum that is absorbed by the gut (intestines) 
within the first 24 hours after birth. Therefore, IgG will be present in the bloodstream of 
calves and naturally declines over time. The results from this study measured higher and 
longer maternally-derived neutralisation titres against the homologous (vaccine) virus as 
compared to the heterologous virus (field isolate). This study also showed that maternally 
derived neutralisation titres against the homologous virus (vaccine: A/May-97) as well as 
the heterologous (A/MAY/2/2011: field isolate) decreased with calves’ age (R2 = 0.5 and 
P<0.0001). This study is in agreement with other reports (Cokcaliskan et al., 2017; 
Nicholls et al., 1984b) showing that maternally derived neutralisation titres in young 
calves can reach levels above the protective cut-off point, and for this study 16/20 of the 
individual sera tested at age two to four months reached this threshold for the 
homologous virus.  
The negative effect of the maternally derived antibody on the generation of neutralising 
antibodies after primary vaccination in calves is in agreement with published reports 
(Elnekave et al., 2016, Bucafusco et al., 2014). However, in this study maternally derived 
antibodies did not directly impact upon booster vaccination responses; calves with 
maternally derived neutralisation titre against the homologous (vaccine) virus increased 
their neutralisation antibody titre after booster vaccination. Therefore, it can be 
concluded that booster vaccination can overcome the negative effect of maternally 
derived antibodies observed after primary vaccination. This finding is also in agreement 
with another report showing that booster vaccination increased FMDV-specific antibody 
responses (Cokcaliskan et al., 2017). It has been previously shown that B cells still 
differentiate and produce memory cells even when maternally-derived antibodies are 
present (Foote et al., 2007). This could explain the booster vaccination responses 
regardless of the maternally derived neutralisation titre at primary vaccination. In 
addition to the results for serotype A, similar data was generated for FMDV serotype O 
although in this case, the vaccine contains two components (O-3039 and O1 Manisa) which 
were heterologous (from different lineage to the field isolates in P. Malaysia). The results 
presented here are different findings to a report which indicated that prophylactic 
vaccination using a different lineage than the challenge virus can overcome the problem 
of the negative influence of maternally derived antibodies (Dekker et al., 2014). Based 
on the negative effects of maternally derived antibodies on the neutralisation titre 
induced after primary vaccination against the serotype A virus, the result from this study 
reinforce the importance of vaccinating calves later than the recommendation at 2.5 
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months of age or 2 months in severe epidemiological circumstances (Doel, 2003), 
particularly when considering heterologous titres.  
The r1 values generated for individual animals in this field study were very variable and 
similar to the r1 values calculated in the in-vitro vaccine matching in the other chapters 
in this thesis (particularly Chapter 3). Issues with the r1 value were also emphasised here 
in this chapter when the heterologous neutralisation titre were higher than the 
homologous virus to produce an r1 values greater than 1. Furthermore, some of the 
heterologous neutralisation antibody titres that were below the protective cut-off, 
produced r1 values above the suggested vaccine-match cut-off (0.3). As indicated in 
Chapter 3, pooling sera should be used for post vaccination monitoring to reduce 
variability of the antibody neutralisation titre of a herd. However, vaccine effectiveness 
evaluation studies in an endemic area should focus on the neutralisation antibody titre 
after vaccination being above the suggested protective cut-off point before r1 values are 
calculated, for example above 1.4 log10 for A/May-97 and above 1.6 log10 for the O-3039 
vaccine components. Another important way to assess vaccine effectiveness in endemic 
counties is by monitoring FMDV infections in young adult animals in vaccinated herds 
(between 1 to two years of age) using NSP ELISA. This method can also be used as an 
indicator whether the vaccine used is effective or not. The fact that P. Malaysia is 
endemic for FMD makes the NSP ELISA test crucial to ensure that the neutralisation titre 
measured in this study were due to the vaccination and not natural FMDV infection. It can 
be concluded that FMD vaccination coupled with good zoo sanitary and husbandry 
practiced at PTH Ayer Hitam dairy cattle herd has shown to be effective to control FMD 
in the lower risk area.  NSP ELISA testing was also performed on all serum samples 
collected from dairy cows that were reared in an area of higher-risk for FMD. This area 
experienced FMD outbreaks in January 2013 and sera collected from affected farms 
showed a higher proportion (50%) of NSP positive cows than sera collected from the same 
risk area but without any clinical history of FMD (13%). It may not possible to discriminate 
whether the NSP detected in sera collected from herds with history of clinical FMD in 
January 2013 were due the clinical FMD episode in January 2013 or more recent infection 
(or persistent infection). This is considering the fact that NSPs antibodies may be 
detectable for a longer period than antibodies against structural proteins (SPs), and can 
be detected after 6 months post infection (Sorensen et al., 1998). Furthermore, the NSP 
ELISA cannot discriminate subclinical infection from the persistently infected animals 
(Paton et al., 2006). However, the fact that 13% NSP positive serum samples were 
collected from cows with no history of clinical FMD indicated that there is a potential for 
subclinical or persistent infection in these vaccinated animals. These herds were 
vaccinated regularly following the manufacturer recommendation to vaccinate animals 
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at 2.5 months of age and achieving the minimum 80% coverage of protective immune 
response in the herd so FMDV infection and spread should be prevented. However, sub-
clinical (and unapparent) circulation of FMDV in previously vaccinated herds has been 
recently recognised to be problem (Farooq et al., 2018; Hayer et al., 2018; Lyons et al., 
2017; Ranjan et al., 2018; Stenfeldt et al., 2016). Further studies are required to 
understand this problem, work that could be supported by probang sampling and testing 
from NSP positive vaccinated animals in an endemic area. Currently, NSP ELISA is the only 
serological tool available to discriminate FMDV infection and a response against 
vaccination. There are reports which indicate that repeated vaccination over several 
years can produce NSP positive results (Mackay et al., 1998) even when a purified vaccine 
has been used, although other studies have reported that multiple vaccination does not 
induce NSP antibodies (Niedbalski and Haas, 2003). More recent reports suggested that 
regularly vaccinated, NSP positive, young animals (between 1 to 2 years of age) with no 
clinical FMD may be used as indicators for subclinical disease (Lyons et al., 2017). Taken 
together with the results from the lower-risk herd (where all the samples were NSP 
negative), this study provides a framework for implementing FMD surveillance (and an 
assessment of vaccine performance) in P. Malaysia. In these future studies, it will be 
important that only young animals, aged between six to twelve months, are selected for 
surveillance purpose in order to increase confidence in the surveillance data (Ferrari et 
al., 2016b). This is because calves six to twelve month of age are known to be free of 
NSP, unless they are infected and their maternally derived antibodies have waned. 
This study focused on the impact of maternally derived neutralisation titre on primary 
and booster vaccination and the effect of booster vaccination on the host’s immune 
responses in an endemic area. It is important to consider the negative effect of maternally 
derived neutralisation titre when considering vaccination schedules, to identify the 
optimal age of vaccine delivery in calves. The results of this study also highlight the 
importance of using booster vaccination to protect the most susceptible, young animals 
against clinical FMDV infection. In this situation, the vaccine used elicited the immune 
response suggestive of protection despite inconclusive and variable r1 values. In general, 
this study emphasises the importance and priority that should be given to PVM in FMD 
endemic areas to ensure the vaccination programme to control FMD is effective. In 
conclusion, this study indicated that the current vaccine strains of A/May-97 used in 
Malaysia is suitable and most likely to confer protection against the contemporary field 
virus belonging to serotype A. Moreover, this serotype A vaccine strain will also be suitable 
for use in mainland SEA as FMD viruses in this endemic region share genetic and antigenic 
properties. 
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General discussion, conclusions and suggestions  
 
This discussion chapter focuses on three main areas (i) review of the conclusions from the 
experimental studies, (ii) discussion of the main findings of the thesis in context with 
recent data from the Malaysian national surveillance programme for FMD, and (iii) a 
discussion of options for FMD control programme in Peninsular Malaysia. 
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6.1  Background and context 
 
Vaccination plays major role as part of the control measures used in countries where FMD 
is endemic, as well as in “vaccinate–to-kill” or “vaccinate-to-live” policies used in 
previously FMD free countries in response to disease incursions to regain free status. In 
both situations, the vaccine is used to reduce the impact of FMD clinical disease and 
suppress the potential spread of FMD virus to susceptible animals. Therefore, it is vital 
that a suitable vaccine is selected, and that the performance of the vaccine is evaluated 
in order to achieve the purpose of vaccination. This thesis focuses on laboratory-based 
serological methods that are widely used for FMD vaccine matching with the main 
objective to understand the factors that influence test variability and limitations of these 
tests. The project focussed on viruses classified within the A/ASIA/Sea-97 lineage, as a 
model system representing an important FMD virus lineage that is currently circulating in 
the field in Peninsular (P.) Malaysia and other countries in Southeast Asia (SEA), and poses 
an on-going threat to Malaysia via land borders with Thailand and Myanmar.  
It has been previously documented that the in-vitro vaccine matching tests used to 
generate r1 values using both VNT and LPBE methods, suffers from a high degree of test-
to-test variability (Tekleghiorghis et al., 2014). This thesis investigated different factors 
that underpin the variability of these tests. As shown in Chapter 2, the replication cycle 
of cells used to propagate FMDV for VNT has a significant impact on variability of virus 
and neutralisation titres, leading to variability of vaccine matching test results. This 
suggests that laboratories should adopt a protocol in which they always use the cells at 
the same point of the cell replication cycle. In this context, it is easier to standardise the 
use of cells at 100% confluence. In Chapter 3, r1 values generated by VNT and LPBE using 
bovine vaccinal sera (BVS) produced after primary and booster vaccination highlighted 
the variability of these tests, especially with respect to the suggested antigenic-match 
cut-off, with some results above, and others below the suggested antigenic-match cut-
off point for the same samples. Comparison between these two methods showed that less 
variation was observed in r1 values generated from the LPBE titres compared to r1 values 
generated by VNT. Subsequently, Chapter 4 emphasised the importance of the irreversible 
dissociation of FMD virus capsid proteins in in-vitro vaccine matching methods. This work 
showed that different FMD viruses have different dissociation temperature points and 
contained different amount of dissociated FMD virus capsid particles (12S), that leads to 
further variability of the in-vitro vaccine matching results.  
The high degree of variability seen in these studies, helps us to understand the different 
factors that may underlie the range of r1 values that have been observed for closely 
related field samples. Retrospective data for field isolates from the A/ASIA/Sea-97 
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lineage against the A/May-97 vaccine is highly variable (data for samples tested during 
2006 to 2017 is presented in Chapter 1; section 1.4.1), although there is no evidence from 
the field that the antigenic nature of these viruses has changed. Much of the difficulties 
that arise from the use of a strict and universal cut-off (at 0.3 for VNT and 0.2 - 0.4 for 
LPBE) to define whether a vaccine is antigenically related to a field virus. The use of such 
a cut-off is unrealistic since these in-vitro methods suffer inherent variability as 
evidenced in this thesis. Furthermore, the r1 values do not necessarily provide any 
indication about “protection” that might be afforded by the vaccines since the values are 
not usually connected to the results from challenge studies.  The inherent limitations of 
the vaccine-matching tests are important since these assays are widely used to define 
antigenic relationships and make important decisions about the selection of FMDV 
vaccines for control programmes. For instance, the widespread use of A22 Iraq as a 
serotype A component in FMD vaccine in SEA (Horsington et al., 2018), even when A22 Iraq 
is not closely genetically related to A/ASIA/Sea-97. 
Results in this thesis lead to the conclusion that relationship coefficient (r1 values) that 
are currently recommended by the OIE need attention and improvement. These data are 
often vital for international agencies that oversee FMD control (such as the OIE and FAO) 
as well as for endemic countries. However, these assays can only be performed by 
specialised laboratories equipped with high-containment facilities and access to the 
vaccine strains (that are sometimes subject to the property rights of the vaccine 
manufacturer). A simple suggestion to improve the current vaccine matching reports 
provided by reference laboratories is to include the neutralisation titres against the 
homologous and heterologous viruses and to link these titres to heterologous protective 
values (described later in this discussion).  
 
6.2 Use of serological assays to define protection 
 
This study showed LPBE is more repeatable than VNT as described in Chapter 3. However, 
LPBE method uses polyclonal antibodies and therefore measures the binding of all 
antibodies to FMDV, while VNT measures the neutralising antibody titre which are 
reported to correlate better to protection (Robiolo et al., 2010). In contrast to in-vivo 
challenge studies which are also criticised as they have issues of low precision unless large 
number of animals are used (Goris et al.), the current in-vitro methods (using VNT and 
LPBE) are simple and affordable. However, there are a few points that need consideration 
when using these in-vitro methods. At present, defined cut-offs for different serotypes 
and lineages have not been systematically approached outside of viruses that circulate in 
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South America. Additionally, the current protective cut-off values available in references 
are mostly derived from experimental conditions which is not related to field situation 
(due to un-natural route and very high dose (10,000 BID) of virus challenge used in these 
studies). This results in the need for of the neutralisation or total antibody titres cut-off 
for other parts of FMD endemic world which have different FMD virus pools and host 
population dynamics. Longitudinal observation surveillance data such as clinical or 
serological prevalence of vaccinated herds in combination with systematic vaccine 
evaluation is therefore suggested. This effort is vital for FMD endemic countries as part 
of regular post vaccination monitoring (Ferrari et al., 2016). However, it is currently not 
carried out in many FMD endemic countries probably due to the challenges and resources 
required. Activities related to evaluation of vaccine performance in the field within FMD 
endemic area include detailed planning, suitability of the herds and animal selected, 
follow up, sample processing and testing as well as data organisation and analysis. 
Furthermore, these activities are directly related and therefore involve a chain of well-
planned procedures usually undertaken by local veterinary services. Animals and herds 
selected for the purpose of vaccine evaluation have to be tested with a reliable and 
accurate test to ensure that there is no FMDV infection at any stage (both apparent and 
unapparent). With the potential for sub-clinically and persistently infected animals, NSP 
ELISA needs to be performed to discriminate herds with these FMD before selection can 
be made. It is important to note that the use of NSP ELISA is useful for evaluating the 
status of a herd but not so for individual animals (Clavijo et al., 2004) which leads to high 
number of farms to be tested in order to find suitable herds that can be selected for PVM. 
An example of this situation is shown in Chapter 5 where even in herds with no clinical 
history of FMD, NSP positives were detected in 13% of 30 serum samples involving three 
out of four (75%) herds while farms with FMD history (three years before sampling) showed 
all five (100%) herds sampled are not fit for PVM. Furthermore, repeated vaccination may 
also result in NSP positive cattle particularly due to impurities in the FMD vaccine use 
(Lee et al., 2006). Also, the selected animals have to be old enough to ensure that no 
maternally derived antibodies present for these may interfere with the immune response 
induced by vaccination. Considering factors that influence the NSP ELISA it is advised to 
include only calves aged between six months to one year for FMD vaccine evaluation. The 
use of serological assays to define protection in an endemic country is studied in Chapter 
5. 
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6.3 What do r1 values mean in the context of FMD 
vaccination in P. Malaysia? 
 
Chapter 5 emphasised the similarity in antigenic relationship of the in-vitro findings with 
the field situation in a herd of dairy cattle in Malaysia. This field experiment provided 
evidence that the current vaccine used in the field elicited neutralisation titres after 
primary vaccination and the number of neutralising antibodies increased after booster 
vaccination to achieve the suggested protective cut-off point. These findings indicate 
that the serotype A component in the vaccine used in Malaysia is appropriate for the field 
strains of FMDV that are circulating (even though the r1-values are variable). 
This study also showed the negative impact of the maternally derived antibody on 
neutralisation titre after primary vaccination. It is therefore recommended that first 
vaccination is administered in calves after the level of maternally derived antibodies had 
waned to a level that that will not interfere with the primary vaccination and booster 
vaccination are given after the primary vaccination following the manufacturer 
recommendations.  
 
6.4 Other factors define FMDV vaccine performance 
 
We have seen that vaccine-matching is one of the key elements in the selection of an 
appropriate FMDV vaccine. However, it is crucial that an assessment of a vaccine 
performance includes other elements in addition to antigen matching. The major 
elements that influence FMD vaccine performance can be classified into three main 
groups comprising host, vaccine and human factors (Figure 6.1). Human factors include 
ensuring that the cold-chain integrity from the manufacturer to the farm, time to 
vaccinate and vaccine delivery to individual animals are done correctly. The elements 
under indirect host factors are more commonly encountered in farm animals’ particularly 
the negative effects of maternally derived antibodies which are essential to determine 
the optimum time for the first FMD vaccination, in order to reduce the “immunological 
gap” between the waning of maternal protection and the first vaccination where animals 
may be infected by the virus. The second vaccine factor is subdivided into virus-related 
and manufacturer-related components which include matching as indicated by the 
antigenic relationship of the vaccine strain (virus in the vaccine preparation) and the field 
isolate (virus isolated from diseased animal in the field).   
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Figure 6.1: Schematic representation of the three main factors that influence the 
performance of FMD vaccines. Adapted from (Heininger et al., 2012; Lyons et al., 
2016). 
 
 Future challenges for FMD control in Malaysia: continued threats 
posed by FMD incursions form neighbouring countries 
 
The Malaysian national surveillance program for FMD for the year 2017 revealed that 
approximately 50% animals imported from Thailand and Myanmar and held at Quarantine 
stations in Malaysia, were found to have NSP antibodies against FMD virus.  
Studies show that FMD cases in P. Malaysia are linked predominantly to the importation 
of live animals from neighbouring countries (Abila and Foreman, 2006; Adullah, 2014; 
Host factors
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– maternally derived
antibodies
- Pre-existing infection
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Gleeson, 2002; Maswati et al., 2000; Ramanoon, 2016). These findings were supported 
further by data from 2017 FMD national surveillance which showed that the estimated 
point prevalence for FMD (based on NSP ELISA tested in n = 9044 cattle sera) was highest 
in states bordering Thailand and Myanmar and progressively lower towards the south 
(Figure 6.2). More specifically, the overall point estimate for FMDV NSP positivity for 
cattle at individual level for the country was relatively low (32%) but significantly higher 
in the border states of Kelantan (53%; n = 816 serum samples), Perlis (49%; n = 728 serum 
samples) and Kedah (47%; n = 957 serum samples). Although the state of Perak is also 
neighbouring Thailand, the border terrain consists mainly of dense tropical jungle and 
mountainous terrain with the top of Mountain Inas as the highest point is difficult to 
penetrate. Therefore, importation of animals into this state is indirect, mostly via the 
states of Perlis, Kedah or the state of Kelantan. This shows that the existence of barriers 
(e.g. geographical) can reduce FMD incidence in the region.    
The 2017 FMD national surveillance also revealed that estimated point prevalence for FMD 
in cattle at the farm level (71%) was higher than at the level of individual animals (32%) 
(Figure 6.3). This low level of NSP positive in multiple premises is most likely an effect of 
in-country livestock movement. Moreover, this observation is in agreement with a study 
on animal traceability in P. Malaysia which shows high movement with no specific pattern 
in cattle within and between districts/states in P. Malaysia (Bugis, 2018). 
As evidenced following the 2017 FMD national surveillance program, water buffalo was 
shown to have the highest percentage of individual FMD NSP positive (43%), followed by 
cattle (32%), goat (19%), sheep (12%) and pigs (3%). However, the 3% serological 
prevalence in pigs is debatable since none of the 2647 pigs, from which sera samples were 
taken, showed any clinical sign of FMD. In P. Malaysia, pigs are reared in commercial pig 
farms with stringent rules after eradication of Nipah virus in 1999 (Mohd Nor et al., 2000). 
Clinical signs of FMD in commercial pig farms are relatively easy to identify since pigs are 
reared on concrete flooring, an environmental condition which often enhances severity 
of feet lesions in pigs. Possible explanation for the 3% NSP positive could be due to false 
positive since in reality there is no serology test that have 100% sensitivity and specificity 
at once even though pigs can also be sub-clinically infected with FMDV. 
The 2017 FMD national surveillance program revealed 32% prevalence of NSP antibody 
positive cattle, however, without further specification into dairy and beef production. 
The distinction is important since, due to animal accessibility, vaccination is undertaken 
regularly only in dairy cattle. Interestingly, analysis of suspected FMD cases in cattle in 
Melaka (a state in the mid-west P. Malaysia) between 2016 and 2017 showed that, of 34 
FMD suspected cases, 32 were beef cattle while only 2 dairy cattle. Further investigation 
on the two dairy farms revealed that the FMD clinical sign occurred in young animals and 
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no FMD incidence was noted in older animals which received booster vaccinations. On the 
other hand, only nine among the 32 suspected beef herds had history of FMD vaccination; 
six received FMD vaccine more than two years ago while in 17 herds last vaccination was 
administered more than one year ago. Higher serological positivity for FMD in water 
buffalo compared to cattle was also reported in Lao People's Democratic Republic and 
Vietnam (Blacksell et al., 2008; de Carvalho Ferreira et al., 2017).  
The relatively low prevalence of the disease in pigs and dairy cattle provides the evidence 
that the current vaccine used to control FMD in P. Malaysia and the regime by which it is 
applied is effective. Currently, in Malaysia, vaccination against FMD in pigs and dairy 
cattle is compulsory and animals are vaccinated regularly following the manufacturer’s 
recommendation.  
 
Figure 6.2: Results of the 2017 national FMD serological surveillance in P. Malaysia. 
Percentages point estimates of FMD prevalence in individual animals in each state as 
displayed; numbers in brackets () relate to percentages point estimates at the farm 
level in each state. 
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Figure 6.3: Percentages point estimates for FMD prevalence in livestock species in P. 
Malaysia in 2017. The percentages point estimates were established based on testing 
NSP positive animals.  
 
 Suggestion: control versus eradication of FMD  
 
In addition to technical challenges, in endemic countries political decisions regarding FMD 
control vs eradicate need to be made and followed rigorously in form of implementation 
of polices. The extent to which these policies are adopted and implemented is dependent 
upon the economic status of the endemic country as well as local resources and priorities. 
The impact of FMD in relation to food security and livelihood of the nation play major 
role in the decision-making process. 
As an example, the policy to control rather than eradicate FMD currently adopted in P. 
Malaysia was based on two main factors: (i) the high dependency on red meat and dairy 
products which need to be imported from other countries and (ii) the geographical 
location of P. Malaysia with common international borders with countries in SEA that are 
endemic for FMD. However, the policy used in P. Malaysia is different to that used in East 
Malaysia (Sabah and Sarawak) on the Island of Borneo, where FMD free zones (without 
vaccination) have been established (and recognised by the OIE). Maintenance of the FMD-
free status in East Malaysia requires that stringent FMD control measures are applied such 
as strict controls on the movement of animals and animal products into this part of the 
country.  
However, in P. Malaysia where FMD is endemic, FMD control policy demands compulsory 
vaccination but focusses mainly on pigs, dairy farms and beef cattle in defined FMD 
hotspots. The vaccine is provided free of charge to smallholders. Additionally, restrictions 
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on importation of live animals (pigs and dairy cattle breeds) into P. Malaysia from FMD 
free countries only are applied. However, the restrictions on importation do not apply to 
beef cattle and small ruminants. This is considered a major obstacle for successful disease 
control in the country. This is evident since nearly half (48%) of live cattle imported from 
Thailand and Myanmar were tested NSP positive at quarantine stations in the northern 
states of P. Malaysia in 2017. Therefore, it can be concluded that the FMD control policy 
in terms of importation of live animals into P. Malaysia needs improvements in order for 
the country to eradicate FMD.  
Furthermore, most FMD incidences in P. Malaysia are recorded in beef cattle and small 
ruminants kept mainly in traditional and integration husbandry practice systems where 
vaccination is difficult. With the current FMD control measures in P. Malaysia, FMDV is 
likely to continue circulating within the small ruminant and beef cattle populations and 
pose a constant threat to the other susceptible livestock species. Therefore, to tighten 
the disease control a regular FMD vaccination program needs to be extended to include 
the small ruminant and beef cattle populations outside the areas considered as the 
disease hotspots. 
Based on current knowledge, only when the above recommendations are fully 
implemented and practiced, eradication program for FMD that may include culling of 
clinically infected animals can be implemented in P. Malaysia. However, the biggest 
challenge that the country has to face in order to achieve FMD eradication is how to 
maintain the supply of live cattle and red meat with affordable prices in order to cater 
to the basic needs of the people. For instance, in 2017 about 24,517 live beef cattle were 
legally imported into P. Malaysia from Thailand for slaughter. There are also 20,556 live 
cattle imported into Malaysia from Australia for the same purpose. The value of ruminant 
meat and product imported into P. Malaysia is valued at US$1.7 billion in 2017.  
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6.5 Concluding remarks 
 
i. The relationship coefficient (r1 values) that are currently recommended by the OIE 
need attention and improvement. Much of the difficulties that arise from the use 
of a strict and universal cut-off (especially the single cut-off of 0.3 for VNT, but 
also the lack of flexibility in the 0.2-0.4 cut-off for LPBE for different vaccines) to 
define whether a vaccine is antigenically related to a field virus. The use of such a 
cut-off is unrealistic since these in-vitro methods suffer inherent variability as seen 
in this PhD.  
 
ii. Variability of in-vitro vaccine matching was in part due to the cellular cycle of the 
cells being used, the BVS and the stability of the antigen. By decreasing the 
variability of each of these three elements the in-vitro vaccine matching can 
produce more reliable and reproducible results. 
 
iii. The host immune protective cut-off needs to be defined (using a range of available 
laboratory tests) for FMD viruses in different regions taking into consideration the 
epidemiological triad of FMD that has dynamic agent, host and environment 
factors.  
 
iv. FMD is a transboundary animal disease. Therefore, it is recommended for field 
studies to be carried to determine suitability of a vaccine virus before decisions 
are made to change vaccine components (at the regional level). 
 
v. Post Vaccination Monitoring for FMD has to be performed as part of surveillance 
program in FMD endemic countries that use vaccination as part of their FMD control 
measures to ensure their FMD control program is working (Ferrari et al., 2016). 
 
vi. In general, field observations in P. Malaysia indicated that the vaccine used is 
beneficial and able to confer protection against the contemporary field virus. Since 
there is no significant antigenic variation in FMDV within Pool 1 it is predicted that 
same vaccine can be used in other countries in mainland SEA. 
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Appendix i 
Phylogenetic tree for lineage A/ASIA/Sea-97 viruses isolated in P. Malaysia. 
Midpoint-rooted Neighbour-joining phylogenetic tree were constructed based on 
RNA sequences and visualised using MEGA 6.06. Bootstrap values are displayed 
next to branches.  
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Appendix ii 
 
List of FMDV isolates selected 
Virus Lineage Country of Origin Passage history 
A/May-97 A/ASIA/Sea-97 Boehringer 
Ingelheim* 
BHK1 
A/Iran-05 A/ASIA/Iran-05 Boehringer 
Ingelheim* 
BHK1 
MAY/2/2011 A/ASIA/Sea-97 Malaysia BTy1 
VIT/10/2015 A/ASIA/Sea-97 Vietnam BTy1 
VIT/13/2015 A/ASIA/Sea-97 Vietnam BTy1 
TAI/4/2017 A/ASIA/Sea-97 Thailand BTy1 
VIT/14/2014 A/ASIA/Sea-97 Vietnam BTy1 
MAY/15/2014 A/ASIA/Sea-97 Malaysia BTy1 
MAY/20/2011 A/ASIA/Sea-97 Malaysia BTy1 
MAY/7/2012 A/ASIA/Sea-97 Malaysia BTy1 
CAM/2/2015 A/ASIA/Sea-97 Cambodia BTy1 
TUR/3/2012 A/ASIA/Iran-05 Turkey BTy1 
IRN/55/2011 A/ASIA/Iran-05 Iran BTy1 
AFG/140/2010 A/ASIA/Iran-05 Afghanistan BTy1 
IRN/24/2012 A/ASIA/Iran-05 Iran BTy1 
IRN/33/2012 A/ASIA/Iran-05 Iran BTy1 
AFG/69/2011 A/ASIA/Iran-05 Iran BTy1 
IRN/36/2011 A/ASIA/Iran-05 Iran BTy1 
BHK: Baby hamster kidney cell BTy: Bovine thyroid cells 
 
*These are vaccine viruses and the full passage histories are not known; however, prior 
to use in these experiments the virus was passaged in BHK. Their origin is marked as 
Boehringer Ingelheim to indicate the commercial source from which the virus was derived. 
